[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 253
1. Mainio A, Hakko H, Niemelä A, Koivukangas J, Räsänen P: Gender difference in relation to depression and quality of life among patients with a primary brain tumor. Eur Psychiatry; 2006 Apr;21(3):194-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gender difference in relation to depression and quality of life among patients with a primary brain tumor.
  • OBJECTIVE: We studied the relationship between depressive symptoms and quality of life (QOL) as well as functional status in primary brain tumor patients at recurrent measurements.
  • Differences in QOL between depressive and non-depressive samples by gender were controlled for tumor characteristics and patients' psychosocial factors.
  • MATERIALS AND METHODS: The data consisted of 77 patients with a primary brain tumor, 30 males and 47 females.
  • Depression of the patients was assessed by Beck Depression Inventory (BDI) and Crown-Crisp Experiential Index (CCEI), functional status by Karnofsky Performance scale (KPS) and QOL by Sintonen's 15D before tumor operation as well as at 3 months and at 1 year from surgical operation of the tumor.
  • Depressive patients with a benign brain tumor had significantly worse QOL versus non-depressive ones.
  • DISCUSSION AND CONCLUSION: Decreased QOL was strongly related to depression, especially among patients with a benign brain tumor.
  • [MeSH-major] Brain Neoplasms / psychology. Depressive Disorder / psychology. Glioma / psychology. Patients / psychology. Quality of Life / psychology
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Psychiatric Status Rating Scales / statistics & numerical data. Severity of Illness Index. Sex Factors. Time Factors


2. Ramina R, Maniglia JJ, Fernandes YB, Paschoal JR, Pfeilsticker LN, Coelho Neto M: Tumors of the jugular foramen: diagnosis and management. Neurosurgery; 2005 Jul;57(1 Suppl):59-68; discussion 59-68
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Complete excision was possible in 89% of benign tumors and 80% of paragangliomas.
  • CONCLUSION: Radical removal of benign jugular foramen tumors is the treatment of choice and may be curative.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / surgery. Embolization, Therapeutic / methods. Glomus Jugulare Tumor / diagnosis. Glomus Jugulare Tumor / surgery. Neurosurgical Procedures / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Female. Glomus Jugulare / pathology. Glomus Jugulare / surgery. Humans. Male. Middle Aged. Retrospective Studies. Skull Base Neoplasms. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15987570.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


3. Al-Khalaf HH, Lach B, Allam A, Hassounah M, Alkhani A, Elkum N, Alrokayan SA, Aboussekhra A: Expression of survivin and p16(INK4a)/Cdk6/pRB proteins and induction of apoptosis in response to radiation and cisplatin in meningioma cells. Brain Res; 2008 Jan 10;1188:25-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In addition, we present evidence that the level of the anti-apoptosis survivin protein is high in these benign tumors.
  • [MeSH-major] Apoptosis / physiology. Cyclin-Dependent Kinase 6 / metabolism. Cyclin-Dependent Kinase Inhibitor p16 / metabolism. Meningeal Neoplasms / metabolism. Meningioma / metabolism. Microtubule-Associated Proteins / metabolism. Neoplasm Proteins / metabolism. Retinoblastoma Protein / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / pharmacology. Cell Line, Tumor. Cisplatin / pharmacology. Female. Flow Cytometry. Humans. Hydroxyurea / pharmacology. Immunoblotting. Inhibitor of Apoptosis Proteins. Male. Middle Aged. Proto-Oncogene Proteins c-bcl-2 / drug effects. Proto-Oncogene Proteins c-bcl-2 / metabolism. Proto-Oncogene Proteins c-bcl-2 / radiation effects. Radiotherapy. Signal Transduction / drug effects. Signal Transduction / physiology. Up-Regulation / drug effects. Up-Regulation / physiology. Up-Regulation / radiation effects. bcl-2-Associated X Protein / drug effects. bcl-2-Associated X Protein / metabolism. bcl-2-Associated X Protein / radiation effects

  • Genetic Alliance. consumer health - Meningioma.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18048012.001).
  • [ISSN] 0006-8993
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / BIRC5 protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Retinoblastoma Protein; 0 / bcl-2-Associated X Protein; EC 2.7.11.22 / CDK6 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 6; Q20Q21Q62J / Cisplatin; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


Advertisement
4. Schneider AB, Ron E, Lubin J, Stovall M, Shore-Freedman E, Tolentino J, Collins BJ: Acoustic neuromas following childhood radiation treatment for benign conditions of the head and neck. Neuro Oncol; 2008 Feb;10(1):73-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acoustic neuromas following childhood radiation treatment for benign conditions of the head and neck.
  • Childhood radiation exposure has been associated with an increased risk for developing several neoplasms, particularly benign and malignant thyroid tumors, but little is known about the risk of developing acoustic neuromas.
  • Forty-three patients developed benign acoustic neuromas, forty of them surgically resected, far in excess of what might be expected from data derived from brain tumor registries.
  • Although acoustic neuromas are usually benign and often asymptomatic, many cause significant morbidity.

  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2001 Apr 18;93(8):618-29 [11309438.001]
  • [Cites] Pediatr Blood Cancer. 2007 Apr;48(4):453-9 [16767718.001]
  • [Cites] J Natl Cancer Inst. 2002 Oct 16;94(20):1555-63 [12381708.001]
  • [Cites] J Neurosurg Sci. 2003 Jun;47(2):113-6; discussion 116 [14618141.001]
  • [Cites] Cancer. 2004 Oct 1;101(7):1644-54 [15378499.001]
  • [Cites] Arch Environ Health. 1976 Jan-Feb;31(1):21-8 [1244805.001]
  • [Cites] N Engl J Med. 1976 May 6;294(19):1019-25 [1256510.001]
  • [Cites] JAMA. 1977 May 9;237(19):2098-100 [576893.001]
  • [Cites] Mayo Clin Proc. 1980 Oct;55(10):648-50 [7412405.001]
  • [Cites] Cancer. 1983 Jun 15;51(12):2159-63 [6850504.001]
  • [Cites] J Clin Endocrinol Metab. 1986 Jul;63(1):107-12 [3711256.001]
  • [Cites] N Engl J Med. 1988 Oct 20;319(16):1033-9 [3173432.001]
  • [Cites] N Engl J Med. 1989 Mar 30;320(13):835-40 [2927450.001]
  • [Cites] Br J Cancer. 1989 May;59(5):783-6 [2736213.001]
  • [Cites] Neurosurgery. 1989 Jun;24(6):929-32 [2747873.001]
  • [Cites] J Clin Endocrinol Metab. 1993 Aug;77(2):362-9 [8345040.001]
  • [Cites] J Clin Endocrinol Metab. 1995 Jan;80(1):254-7 [7829622.001]
  • [Cites] Arch Intern Med. 1996 Sep 9;156(16):1873-8 [8790083.001]
  • [Cites] Am J Epidemiol. 1996 Oct 15;144(8):728-33 [8857821.001]
  • [Cites] Radiat Res. 1998 Jun;149(6):625-30 [9611101.001]
  • [Cites] J Natl Cancer Inst. 1963 Dec;31:1379-405 [14087657.001]
  • [Cites] J Clin Endocrinol Metab. 2005 Oct;90(10):5747-53 [16030170.001]
  • [Cites] Am J Clin Oncol. 2005 Dec;28(6):640-1 [16317282.001]
  • [Cites] JAMA. 2006 Jan 25;295(4):416-28 [16434632.001]
  • [Cites] Neuro Oncol. 2006 Jan;8(1):1-11 [16443943.001]
  • [Cites] Am J Epidemiol. 2006 Feb 15;163(4):327-33 [16357108.001]
  • [Cites] J Natl Cancer Inst. 2006 Nov 1;98(21):1528-37 [17077355.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Jul;87(7):3236-41 [12107231.001]
  • (PMID = 18079359.001).
  • [ISSN] 1522-8517
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-21518; United States / NCI NIH HHS / CP / N01-CP-85604; United States / NCI NIH HHS / CP / N01-CP-95614; United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2600840
  •  go-up   go-down


5. Xu XL, Ma JR, Xiang Q, Jiang HB, Yi WS, Wang CY: [Transcranial operation for cranio-orbital communicating tumors and its complications]. Zhonghua Yan Ke Za Zhi; 2008 Aug;44(8):696-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The head of condenser was used to freeze the tumor, and the tissue around the tumor was separated until the tumor was extirpated.
  • In cases where the tumor penetrated the dura mater and invaded the brain, surgery was performed by neurosurgeons.
  • RESULTS: In 37 cases, 32 cases undertook total resection of tumors and palliative resection was performed in 5 cases due to severe tumor invasion of the cavernous sinus or sphenoid sinus.
  • Of the 37 cases, 28 cases were benign tumors and accounted for 75.67% of total cases (28/37); 9 were malignant tumors and accounted for 24.32% (9/37).
  • Pathological examination showed that 11 cases were meningioma which was the most common type of tumor and accounted for 29.73% of total cases(11/37).
  • [MeSH-major] Neurosurgical Procedures / adverse effects. Ophthalmologic Surgical Procedures / adverse effects. Orbital Neoplasms / surgery. Postoperative Complications
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Humans. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - After Surgery.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19115631.001).
  • [ISSN] 0412-4081
  • [Journal-full-title] [Zhonghua yan ke za zhi] Chinese journal of ophthalmology
  • [ISO-abbreviation] Zhonghua Yan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


6. Pérez-Magán E, Rodríguez de Lope A, Ribalta T, Ruano Y, Campos-Martín Y, Pérez-Bautista G, García JF, García-Claver A, Fiaño C, Hernández-Moneo JL, Mollejo M, Meléndez B: Differential expression profiling analyses identifies downregulation of 1p, 6q, and 14q genes and overexpression of 6p histone cluster 1 genes as markers of recurrence in meningiomas. Neuro Oncol; 2010 Dec;12(12):1278-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The majority of meningiomas are probably benign but a number of tumors display considerable histological and/or clinical aggressivity, sometimes with unexpectedly high recurrence rates after radical removal.
  • [MeSH-major] Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 14 / genetics. Chromosomes, Human, Pair 6 / genetics. Histones / genetics. Meningeal Neoplasms / genetics. Meningioma / genetics. Neoplasm Recurrence, Local / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Female. Gene Expression Profiling. Humans. Immunoenzyme Techniques. In Situ Hybridization, Fluorescence. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Prognosis. Survival Rate. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Feb;18(3):636-45 [10653879.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Jul 1;120(1):30-6 [10913674.001]
  • [Cites] J Neurosurg. 2001 Feb;94(2):293-300 [11213968.001]
  • [Cites] Am J Pathol. 2002 Aug;161(2):665-72 [12163391.001]
  • [Cites] Mod Pathol. 2003 Jul;16(7):708-15 [12861068.001]
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 1):3606-14 [14506147.001]
  • [Cites] Cancer Res. 2004 Feb 1;64(3):883-8 [14871816.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):9-16 [15015765.001]
  • [Cites] Oncol Rep. 2004 Oct;12(4):939-43 [15375526.001]
  • [Cites] J Neurosurg. 1985 Jan;62(1):18-24 [3964853.001]
  • [Cites] J Neurosurg. 1989 Nov;71(5 Pt 1):665-72 [2809720.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14719-24 [9405679.001]
  • [Cites] Am J Surg Pathol. 1997 Dec;21(12):1455-65 [9414189.001]
  • [Cites] Cancer. 1998 Jul 15;83(2):360-6 [9669820.001]
  • [Cites] Mayo Clin Proc. 1998 Oct;73(10):936-42 [9787740.001]
  • [Cites] J Neurooncol. 1999 Jan;41(2):167-74 [10222437.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] Curr Opin Neurol. 2004 Dec;17(6):687-92 [15542977.001]
  • [Cites] Int J Cancer. 2005 Mar 20;114(2):249-56 [15540215.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2653-61 [15805262.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 May 24;102(21):7659-64 [15897450.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5070-5 [15958550.001]
  • [Cites] Am J Clin Pathol. 2005 May;123(5):744-51 [15981814.001]
  • [Cites] Neurosurgery. 2005 Sep;57(3):538-50; discussion 538-50 [16145534.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 [16199517.001]
  • [Cites] Cell. 2005 Dec 29;123(7):1199-212 [16377562.001]
  • [Cites] Clin Cancer Res. 2006 Feb 1;12(3 Pt 1):772-80 [16467088.001]
  • [Cites] Oncogene. 2006 May 11;25(20):2920-30 [16331278.001]
  • [Cites] Lancet Neurol. 2006 Dec;5(12):1045-54 [17110285.001]
  • [Cites] Neuro Oncol. 2007 Oct;9(4):438-46 [17704362.001]
  • [Cites] Mol Cancer. 2007;6:64 [17937814.001]
  • [Cites] J Biol Chem. 2008 Apr 4;283(14):9113-26 [18258596.001]
  • [Cites] Neoplasia. 2008 Jun;10(6):604-12 [18516297.001]
  • [Cites] Int J Cancer. 2009 Jan 15;124(2):346-51 [19003955.001]
  • [Cites] Mol Cancer. 2008;7:93 [19099607.001]
  • [Cites] Gynecol Oncol. 2009 Mar;112(3):646-53 [19095296.001]
  • [Cites] Biofactors. 2009 Mar-Apr;35(2):200-8 [19449449.001]
  • [Cites] Brain Pathol. 2009 Jul;19(3):409-20 [18637901.001]
  • [Cites] Int J Oncol. 2009 Dec;35(6):1395-407 [19885562.001]
  • [Cites] Int J Cancer. 2010 Jun 1;126(11):2584-93 [19847810.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Oct 1;162(1):63-7 [16157202.001]
  • (PMID = 20685720.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Histones
  • [Other-IDs] NLM/ PMC3018937
  •  go-up   go-down


7. Lamkin DM, Lutgendorf SK, McGinn S, Dao M, Maiseri H, DeGeest K, Sood AK, Lubaroff DM: Positive psychosocial factors and NKT cells in ovarian cancer patients. Brain Behav Immun; 2008 Jan;22(1):65-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Less is known about the relationship between psychosocial factors and NKT cells, a rare group of lymphocytes that have known relevance for tumor control.
  • We examined four psychosocial factors and percentage and number of CD3+CD56+ NKT cells, CD3-CD56+ NK cells, and CD3+CD56- T cells in peripheral blood lymphocytes (PBL), ascites, and tumor of 35 ovarian cancer patients and 28 patients with benign pelvic masses.
  • Ascites and tumor were taken during surgery.
  • Benign and cancer patients did not differ on PBL subpopulations.
  • Among cancer patients, NKT cell percentage was significantly higher in tumor and ascites than in PBL; T cell percentage was significantly higher in PBL than tumor.
  • Social support was related to significantly higher NKT cell percentage in tumor.
  • Given the anti-tumor activity of CD3+CD56+ cells, these relationships may have relevance for cancer control.

  • Genetic Alliance. consumer health - Ovarian cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Abnorm Psychol. 1984 Nov;93(4):378-90 [6512084.001]
  • [Cites] Brain Behav Immun. 2005 Mar;19(2):153-64 [15664788.001]
  • [Cites] Brain Behav Immun. 2005 May;19(3):185-94 [15797305.001]
  • [Cites] J Clin Oncol. 2005 Oct 1;23(28):7105-13 [16192594.001]
  • [Cites] Cancer Immunol Immunother. 2005 Dec;54(12):1162-71 [15889254.001]
  • [Cites] Cancer Immunol Immunother. 2006 Jun;55(6):734-43 [16283306.001]
  • [Cites] Brain Behav Immun. 2003 Feb;17 Suppl 1:S27-36 [12615183.001]
  • [Cites] J Neuroimmunol. 2003 May;138(1-2):17-24 [12742648.001]
  • [Cites] Psychosom Med. 2003 Jul-Aug;65(4):571-81 [12883107.001]
  • [Cites] World J Gastroenterol. 2004 Jan 15;10(2):268-72 [14716837.001]
  • [Cites] J Neuroimmunol. 2004 Mar;148(1-2):106-15 [14975591.001]
  • [Cites] J Psychosom Res. 2004 Jan;56(1):1-8 [14987957.001]
  • [Cites] Nat Rev Immunol. 2004 Mar;4(3):231-7 [15039760.001]
  • [Cites] Psychiatry Res. 2004 Jul 15;127(3):237-45 [15296823.001]
  • [Cites] Cancer Immunol Immunother. 2004 Oct;53(10):911-24 [15127235.001]
  • [Cites] J Neuroimmunol. 2004 Nov;156(1-2):153-62 [15465606.001]
  • [Cites] Hum Immunol. 2000 Jan;61(1):44-50 [10658977.001]
  • [Cites] J Exp Med. 2000 Feb 21;191(4):661-8 [10684858.001]
  • [Cites] J Invest Dermatol. 2000 May;114(5):941-7 [10771475.001]
  • [Cites] Nat Immunol. 2000 Dec;1(6):515-20 [11101874.001]
  • [Cites] Nat Immunol. 2000 Dec;1(6):521-5 [11101875.001]
  • [Cites] Cancer. 2002 Jan 1;94(1):131-40 [11815969.001]
  • [Cites] Clin Cancer Res. 2002 Mar;8(3):745-51 [11895904.001]
  • [Cites] J Pers Soc Psychol. 1984 Jun;46(6):1313-21 [6737214.001]
  • [Cites] J Immunol. 1986 Jun 15;136(12):4480-6 [3086432.001]
  • [Cites] J Exp Med. 1986 Jul 1;164(1):351-6 [3088199.001]
  • [Cites] JAMA. 1987 Dec 4;258(21):3125-30 [3669259.001]
  • [Cites] Psychosom Med. 1990 Jan-Feb;52(1):73-85 [2305024.001]
  • [Cites] Behav Med. 1990 Fall;16(3):101-10 [2224168.001]
  • [Cites] Soc Sci Med. 1991;33(2):177-83 [1887281.001]
  • [Cites] Fukuoka Igaku Zasshi. 1991 Oct;82(10):499-507 [1748365.001]
  • [Cites] Circulation. 1994 Feb;89(2):762-9 [7508828.001]
  • [Cites] Clin Diagn Lab Immunol. 1994 Mar;1(2):125-33 [7496932.001]
  • [Cites] Cancer. 1995 Aug 15;76(4):631-7 [8625157.001]
  • [Cites] Brain Behav Immun. 1996 Jun;10(2):77-91 [8811932.001]
  • [Cites] J Psychosom Res. 1997 May;42(5):453-66 [9194018.001]
  • [Cites] J Natl Cancer Inst. 1998 Jan 7;90(1):30-6 [9428780.001]
  • [Cites] J Immunol. 1998 Jun 1;160(11):5239-45 [9605119.001]
  • [Cites] Clin Cancer Res. 1996 Jan;2(1):161-73 [9816103.001]
  • [Cites] J Pers Assess. 1983 Jun;47(3):305-6 [6886962.001]
  • [Cites] Cancer Immunol Immunother. 2002 Oct;51(8):440-8 [12202905.001]
  • (PMID = 17643954.001).
  • [ISSN] 1090-2139
  • [Journal-full-title] Brain, behavior, and immunity
  • [ISO-abbreviation] Brain Behav. Immun.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA104825; United States / NCI NIH HHS / CA / R01 CA104825-05; United States / NCI NIH HHS / CA / R21 CA088293-01; United States / NCI NIH HHS / CA / CA088293-01; United States / NCI NIH HHS / CA / R21 CA088293; United States / NCI NIH HHS / CA / CA104825-05
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antigens, CD3; 0 / Antigens, CD56
  • [Other-IDs] NLM/ NIHMS232786; NLM/ PMC2964139
  •  go-up   go-down


8. Liu J, Zheng S, Yu JK, Yu XB, Liu WG, Zhang JM, Hu X: [Establishment of diagnostic model of cerebrospinal protein fingerprint pattern for glioma and its clinical application]. Zhejiang Da Xue Xue Bao Yi Xue Ban; 2005 Mar;34(2):141-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Seventy-five samples of cerebrospinal fluid from patients with gliomas, benign brain tumors and mild brain traumas were collected.
  • A total of 50 samples from gliomas and non-brain-tumors were divided into training sets (33 cases including 17 gliomas and 16 non-brain-tumors) and testing sets (17 cases including 5 gliomas and 12 non-brain-tumors).
  • The cerebrospinal proteins bound to H4 chip were detected by SELDI-TOF MS, the profiles of cerebrospinal protein were gained and then analyzed with artificial neural network algorithm (ANN); and the diagnostic model of cerebrospinal protein profiles for differentiating gliomas from non-brain-tumors was established.
  • Forty-seven of cerebrospinal samples of gliomas and benign brain tumors were divided into training sets (31 cases including 13 gliomas and 18 benign brain tumors) and testing sets (16 cases including 9 gliomas and 7 benign brain tumors), the diagnostic model of cerebrospinal protein profiles for differentiating gliomas from benign brain tumors was established based on the same method.
  • RESULT: The diagnostic model of cerebrospinal protein profiles for differentiating gliomas from non-brain-tumors was established and was challenged with the test set randomly, the sensitivity and specificity were 100% and 91.7%, respectively.
  • The cerebrospinal protein profiling model for differentiating gliomas from benign brain tumors was also developed and was challenged with the test set randomly, the sensitivity and specificity were 88.9%, and 100%, respectively.
  • CONCLUSION: The technology of SELDI-TOF MS which combined with analysis tools of bioinformatics is a novel effective method for screening and identifying tumor biomarkers of gliomas and it may provide a new approach for the clinical diagnosis of glioma.
  • [MeSH-major] Brain Neoplasms / cerebrospinal fluid. Cerebrospinal Fluid Proteins / genetics. Glioma / cerebrospinal fluid. Peptide Mapping / standards
  • [MeSH-minor] Adult. Aged. Algorithms. Biomarkers, Tumor. Diagnosis, Differential. Female. Humans. Male. Meningioma / cerebrospinal fluid. Meningioma / diagnosis. Middle Aged. Neural Networks (Computer). Sensitivity and Specificity. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15812888.001).
  • [ISSN] 1008-9292
  • [Journal-full-title] Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences
  • [ISO-abbreviation] Zhejiang Da Xue Xue Bao Yi Xue Ban
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cerebrospinal Fluid Proteins
  •  go-up   go-down


9. Temprano T, Fernández-de León R, Rial JC, Fernández JM, Mateos V: [Cystic bulbar hemangioblastoma]. Rev Neurol; 2008 Aug 1-15;47(3):134-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Hemangioblastomas are neoplasm of vascular type having benign characteristics.
  • They represent between 2-3% of brain tumors and 7-12% of neoformative processes in the posterior fossa.
  • Brain tumor was diagnosed by neuroimage techniques.
  • [MeSH-major] Brain Stem Neoplasms / diagnosis. Hemangioblastoma / diagnosis
  • [MeSH-minor] Adult. Humans. Male

  • Genetic Alliance. consumer health - Hemangioblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18654967.001).
  • [ISSN] 1576-6578
  • [Journal-full-title] Revista de neurologia
  • [ISO-abbreviation] Rev Neurol
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


10. Matsumura A, Isobe T, Anno I, Takano S, Kawamura H: Correlation between choline and MIB-1 index in human gliomas. A quantitative in proton MR spectroscopy study. J Clin Neurosci; 2005 May;12(4):416-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: There were seven benign and seven malignant gliomas.
  • RESULT: A positive correlation was observed between Cho and MIB-1 in benign gliomas, whereas there was a trend to an inverse correlation in malignant gliomas.
  • This inverse correlation became a positive correlation when the necrotic area of the tumor (on the T1-weighted gadolinium enhanced images) was excluded from the voxel of interest (VOI) for MRS, but this correlation did not reach statistical significance.
  • [MeSH-major] Brain Neoplasms / metabolism. Choline / metabolism. Glioma / metabolism. Ki-67 Antigen / metabolism. Magnetic Resonance Spectroscopy / methods. Protons
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Statistics as Topic

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CHOLINE CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15925772.001).
  • [ISSN] 0967-5868
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Protons; N91BDP6H0X / Choline
  •  go-up   go-down


11. Mainio A, Hakko H, Timonen M, Niemelä A, Koivukangas J, Räsänen P: Depression in relation to survival among neurosurgical patients with a primary brain tumor: a 5-year follow-up study. Neurosurgery; 2005 Jun;56(6):1234-41; discussion 1241-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Depression in relation to survival among neurosurgical patients with a primary brain tumor: a 5-year follow-up study.
  • In a 5-year follow-up study, we investigated the association of depression with survival of patients with a primary brain tumor.
  • METHODS: The study population consisted of 75 patients with a solitary primary brain tumor treated surgically at the Oulu Clinic for Neurosurgery, Oulu University Hospital, in Northern Finland.
  • The patients were interviewed during admission to the hospital for the tumor surgery.
  • Information on all deaths within 60 months after tumor operation was collected from the Cause of Death Register, provided by Statistics Finland.
  • RESULTS: The patients with a high-grade glioma had a survival time of 22.5 months (standard deviation, 21.4 mo), whereas the corresponding time was 50.2 months (standard deviation, 19.9 mo) for patients with a low-grade glioma and 58.2 months (standard deviation, 9.4 mo) for the patients with a histologically benign tumor (P < 0.001, difference between groups, Kruskal-Wallis test).
  • A corresponding difference was not found in patients with high-grade gliomas or benign tumors.
  • Tumor location in one hemisphere compared with bilateral location and wider extent of tumor surgery was associated with better survival in patients with low-grade gliomas and benign tumors but not in patients with high-grade gliomas.
  • In clinical practice, an evaluation of depression among brain tumor patients by structured and standardized diagnostic methods is needed to distinguish the patients whose depression actually needs treatment.
  • The effective treatment of clinical depression among brain tumor patients and the impact of treatment on the patients' chances of survival should be a focus of future research.
  • [MeSH-major] Brain Neoplasms / mortality. Brain Neoplasms / surgery. Depression / etiology. Depression / mortality. Neurosurgery / methods. Postoperative Complications
  • [MeSH-minor] Adult. Age Factors. Demography. Evaluation Studies as Topic. Female. Humans. Longitudinal Studies. Male. Middle Aged. Severity of Illness Index. Sex Factors. Survival Analysis. Survival Rate


12. Broggi M, Darbar A, Teo C: The value of endoscopy in the total resection of pineocytomas. Neurosurgery; 2010 Sep;67(3 Suppl Operative):ons159-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The endoscope was used at various times throughout the case and consistently at the end to evaluate any possible residual tumor.
  • In 6 cases (40%), the endoscope was able to detect residual tumor located either behind the Vein of Galen or attached to the undersurface of the corpus callosum.
  • Residual tumor was then resected using a 30 degrees endoscope and dedicated angled endoscopic instruments.
  • With total removal of these histologically benign tumors patients may enjoy extended progression-free survival without adjuvant radiotherapy.
  • [MeSH-major] Brain Neoplasms / surgery. Endoscopy / methods. Neurosurgery / methods. Pineal Gland / surgery. Pinealoma / surgery. Ventriculostomy / methods
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Longitudinal Studies. Magnetic Resonance Imaging / methods. Male. Middle Aged. Retrospective Studies. Third Ventricle / surgery

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Endoscopy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20679933.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Delgado-López PD, Martín-Velasco V, Castilla-Díez JM, Fernández-Arconada O, Corrales-García EM, Galacho-Harnero A, Rodríguez-Salazar A, Pérez-Mies B: Metastatic meningioma to the eleventh dorsal vertebral body: total en bloc spondylectomy. Case report and review of the literature. Neurocirugia (Astur); 2006 Jun;17(3):240-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE REPORT: In March 1996, a 37 year-old male underwent surgical resection for a left occipital intraventricular benign meningioma (WHO I).
  • Workup studies failed to reveal any primary tumor.
  • Definite pathology: benign meningioma (WHO I).
  • DISCUSSION: Distant metastases from intracranial meningiomas are rare entities, arising from benign lesions in, at least, 60% of cases.
  • Enam et al proposed a specific pathological score to differentiate benign, atypic and malignant meningiomas.
  • Such score correlates with the chance of metastatizing: more than 40% in malignant meningiomas compared to 3.8% of brain tumors overall.
  • Hematogenous (especially venous; Batson's perivertebral plexus), linfatic and cerebrospinal fluid are the main routes involved in the spreading of the tumor.
  • [MeSH-major] Meningioma / pathology. Orthopedic Procedures / methods. Spinal Neoplasms / secondary. Spinal Neoplasms / surgery. Thoracic Vertebrae
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Review Literature as Topic

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16855782.001).
  • [ISSN] 1130-1473
  • [Journal-full-title] Neurocirugía (Asturias, Spain)
  • [ISO-abbreviation] Neurocirugia (Astur)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


14. Shuto T, Inomori S, Fujino H, Nagano H, Hasegawa N, Kakuta Y: Cyst formation following gamma knife surgery for intracranial meningioma. J Neurosurg; 2005 Jan;102 Suppl:134-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECT: The authors conducted a study to evaluate the clinical significance of cyst formation or enlargement after gamma knife surgery (GKS) for intracranial benign meningiomas.
  • The tumor location was the sphenoid ridge in one case, petroclival in two, tentorium in one, and parasagittal region in one.
  • The mean tumor volume was 10.5 cm3, the mean margin dose was 13.4 Gy (median 14 Gy), and the mean maximum dose was 27.5 Gy (median 24.1 Gy).
  • Histological examination demonstrated various findings such as tumor necrosis, proliferation of small vessels, vascular obliteration, and hemosiderin deposits.
  • CONCLUSIONS: New cyst formation following GKS for benign intracranial meningioma is relatively rare; however, both preexisting and newly developed cysts tend to enlarge after GKS and often require surgery.
  • [MeSH-major] Brain Diseases / etiology. Brain Diseases / surgery. Cysts / etiology. Cysts / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery. Postoperative Complications. Radiosurgery / instrumentation
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Radiation Dosage

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Brain Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15662796.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Panagopoulos AT, Lancellotti CL, Veiga JC, de Aguiar PH, Colquhoun A: Expression of cell adhesion proteins and proteins related to angiogenesis and fatty acid metabolism in benign, atypical, and anaplastic meningiomas. J Neurooncol; 2008 Aug;89(1):73-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of cell adhesion proteins and proteins related to angiogenesis and fatty acid metabolism in benign, atypical, and anaplastic meningiomas.
  • Most meningiomas are benign tumours of arachnoidal origin, although a small number have high proliferative rates and invasive properties which complicate complete surgical resection and are associated with increased recurrence rates.
  • Paraffin sections from 25 intracranial meningiomas were analysed for expression of the proteins vascular endothelial growth factor (VEGF), VEGF receptors Flt1 and Flk1, E-cadherin, metalloproteinases 2 and 9 (MMP2, MMP9), CD44, receptor for hyaluronic acid-mediated motility (RHAMM), hyaluronic acid (HA), CD45, cyclooxygenase 2 (COX2), brain fatty acid binding protein (BFABP), Ki67, and proliferating cell nuclear antigen (PCNA).
  • [MeSH-major] Biomarkers, Tumor / metabolism. Cell Adhesion Molecules / biosynthesis. Fatty Acids / metabolism. Meningeal Neoplasms / metabolism. Meningioma / metabolism. Neoplasm Proteins / biosynthesis. Neovascularization, Pathologic / metabolism
  • [MeSH-minor] Adult. Aged. Cell Proliferation. Child. Cyclooxygenase 2 / analysis. Cyclooxygenase 2 / metabolism. Eicosanoids / metabolism. Female. Humans. Ki-67 Antigen / analysis. Ki-67 Antigen / metabolism. Male. Microcirculation / metabolism. Middle Aged. Proliferating Cell Nuclear Antigen / analysis. Proliferating Cell Nuclear Antigen / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1997 Jan;86(1):113-20 [8988089.001]
  • [Cites] Acta Neuropathol. 1999 Sep;98(3):240-4 [10483780.001]
  • [Cites] Cancer. 2007 Feb 1;109(3):588-97 [17177201.001]
  • [Cites] Virchows Arch. 2006 Nov;449(5):529-38 [17016718.001]
  • [Cites] Neurosurg Focus. 2005 Nov 15;19(5):E9 [16398473.001]
  • [Cites] Neurosurgery. 2002 Jul;51(1):183-92; discussion 192-3 [12182416.001]
  • [Cites] J Neurosurg. 2005 Sep;103(3):508-17 [16235684.001]
  • [Cites] J Biol Chem. 2002 Feb 15;277(7):4589-92 [11717317.001]
  • [Cites] Br J Neurosurg. 1998 Oct;12(5):414-8 [10070443.001]
  • [Cites] J Neurosurg. 1997 May;86(5):793-800 [9126894.001]
  • [Cites] J Clin Pathol. 2004 Jan;57(1):6-13 [14693827.001]
  • [Cites] Histopathology. 2003 Sep;43(3):280-90 [12940781.001]
  • [Cites] J Neurooncol. 2002 Dec;60(3):235-45 [12510775.001]
  • [Cites] Neuropathol Appl Neurobiol. 2006 Dec;32(6):674-8 [17083481.001]
  • [Cites] Neuroradiology. 1982;23 (4):207-9 [7121811.001]
  • [Cites] Cell Biol Int. 2006 Sep;30(9):704-13 [16829143.001]
  • [Cites] Am J Clin Oncol. 2003 Aug;26(4):S98-102 [12902865.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):639-48 [8334619.001]
  • [Cites] Histopathology. 2006 Aug;49(2):178-87 [16879395.001]
  • [Cites] Neurol Med Chir (Tokyo). 1992 Feb;32(2):65-71 [1376862.001]
  • [Cites] Pathol Int. 2005 Jan;55(1):1-7 [15660696.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Jun;60(6):628-36 [11398839.001]
  • [Cites] BMC Cancer. 2006 Apr 19;6:97 [16623952.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22-39 [13406590.001]
  • [Cites] J Biochem Mol Biol. 2006 Sep 30;39(5):469-78 [17002866.001]
  • [Cites] J Cell Biol. 2006 Dec 18;175(6):1017-28 [17158951.001]
  • [Cites] Clinics (Sao Paulo). 2005 Jun;60(3):201-6 [15962080.001]
  • [Cites] Biochem Biophys Res Commun. 2005 May 6;330(2):489-97 [15796909.001]
  • [Cites] Virchows Arch. 1998 Feb;432(2):163-7 [9504862.001]
  • [Cites] J Neuropathol Exp Neurol. 2000 Oct;59(10):872-9 [11079777.001]
  • [Cites] Br J Neurosurg. 1995;9(1):47-50 [7786426.001]
  • [Cites] Lung Cancer. 2006 Jul;53(1):91-6 [16697074.001]
  • [Cites] Neuropathol Appl Neurobiol. 2004 Apr;30(2):118-25 [15043709.001]
  • [Cites] Trends Immunol. 2006 Mar;27(3):146-53 [16423560.001]
  • [Cites] J Histochem Cytochem. 1998 May;46(5):585-94 [9606106.001]
  • [Cites] J Cereb Blood Flow Metab. 2007 Mar;27(3):460-8 [16788715.001]
  • [Cites] J Clin Neurosci. 2007 Apr;14(4):359-63 [17236775.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):29-37 [15015767.001]
  • [Cites] Acta Neurochir (Wien). 2004 Jan;146(1):37-44; discussion 44 [14740263.001]
  • [Cites] J Neurosurg. 2002 Nov;97(5):1078-82 [12450029.001]
  • [Cites] Pathol Res Pract. 2006;202(5):365-72 [16563650.001]
  • [Cites] Childs Nerv Syst. 1995 Nov;11(11):661-3 [8608584.001]
  • [Cites] J Neurooncol. 2005 Jul;73(3):219-23 [15980972.001]
  • [Cites] Histopathology. 2006 Jun;48(7):836-45 [16722933.001]
  • [Cites] J Neurooncol. 2002 Nov;60(2):159-64 [12635663.001]
  • [Cites] Int J Biochem Cell Biol. 2004 Jun;36(6):1046-69 [15094120.001]
  • [Cites] Lancet. 2004 May 8;363(9420):1535-43 [15135603.001]
  • [Cites] J Neurooncol. 2005 Aug;74(1):19-30 [16078103.001]
  • [Cites] Curr Opin Neurol. 2004 Dec;17(6):687-92 [15542977.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):183-202 [15674477.001]
  • [Cites] Matrix Biol. 2007 Jan;26(1):58-68 [17055233.001]
  • [Cites] Cancer Res. 2006 Nov 1;66(21):10233-7 [17079438.001]
  • [Cites] Cancer. 1999 Feb 15;85(4):936-44 [10091773.001]
  • [Cites] Stroke. 2006 Jun;37(6):1399-406 [16690896.001]
  • [Cites] Int J Cancer. 2003 Feb 10;103(4):483-8 [12478663.001]
  • [Cites] J Neurooncol. 2004 Dec;70(3):349-57 [15662977.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):3962-5 [12124327.001]
  • [Cites] Clin Mol Pathol. 1996 Jun;49(3):M140-6 [16696062.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Jan 15;140(2):99-106 [12645646.001]
  • [Cites] J Appl Genet. 2006;47(1):39-48 [16424607.001]
  • [Cites] Hum Mol Genet. 2000 Jul 1;9(11):1567-74 [10861283.001]
  • [Cites] J Neurosurg. 1985 Jan;62(1):18-24 [3964853.001]
  • [Cites] Epilepsy Res. 2000 Jan;38(1):45-52 [10604605.001]
  • [Cites] Neurosurgery. 1992 Jul;31(1):2-12 [1641106.001]
  • [Cites] J Neurooncol. 2007 Jan;81(2):131-7 [16850103.001]
  • [Cites] Lancet Neurol. 2006 Dec;5(12):1045-54 [17110285.001]
  • (PMID = 18418552.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / Eicosanoids; 0 / Fatty Acids; 0 / Ki-67 Antigen; 0 / Neoplasm Proteins; 0 / Proliferating Cell Nuclear Antigen; EC 1.14.99.1 / Cyclooxygenase 2; EC 1.14.99.1 / PTGS2 protein, human
  •  go-up   go-down


16. Simon SL, Moonis G, Judkins AR, Scobie J, Burnett MG, Riina HA, Judy KD: Intracranial capillary hemangioma: case report and review of the literature. Surg Neurol; 2005 Aug;64(2):154-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Capillary hemangiomas are benign vascular lesions that commonly present at birth or in early infancy on the face, scalp, back, or chest.
  • The authors present an exceedingly rare case of an intracranial capillary hemangioma arising in an adult.
  • The patient underwent a resection of her tumor, which was diagnosed as a capillary hemangioma by histopathologic examination.
  • The patient required 2 further resections after the lesion exhibited a rapid regrowth from residual tumor in the left transverse sinus.
  • [MeSH-major] Brain Neoplasms / surgery. Hemangioma, Capillary / surgery. Neoplasm Recurrence, Local / surgery. Pregnancy Complications, Neoplastic / surgery
  • [MeSH-minor] Adult. Female. Humans. Pregnancy. Treatment Outcome


17. Monleón D, Morales JM, Gonzalez-Darder J, Talamantes F, Cortés O, Gil-Benso R, López-Ginés C, Cerdá-Nicolás M, Celda B: Benign and atypical meningioma metabolic signatures by high-resolution magic-angle spinning molecular profiling. J Proteome Res; 2008 Jul;7(7):2882-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign and atypical meningioma metabolic signatures by high-resolution magic-angle spinning molecular profiling.
  • Meningiomas are neoplasms that arise from the leptomeningeal covering of the brain and spinal cord, accounting for 15%-20% of CNS tumors.
  • The WHO classifies meningiomas into three histological grades: benign, atypical, and anaplasic in accordance with the clinical prognosis.
  • Sometimes, meningiomas with histological diagnosis of benign meningioma show clinical characteristics of atypical meningioma.
  • In this context, high-resolution magic-angle spinning (HR-MAS) spectroscopy of intact tissue from brain tumor biopsies has shown great potential as a support diagnostic tool.
  • In this work, we show differences between benign and atypical meningiomas in HR-MAS molecular profiles of meningioma biopsies.
  • Glutamine and glutamate, which are related to glutathione metabolism and have been associated with tumor recurrence, are also increased in atypical meningiomas.
  • Other metabolites associated with tumor malignancy that show statistically significant differences between benign and atypical meningiomas include phosphocholine and phosphoethanolamine.
  • Overall, this work suggests that the additional information obtained by NMR metabolomics applied to biopsies of human meningiomas may be useful for assessing tumor grade and determining optimum treatment strategies.
  • [MeSH-major] Meningeal Neoplasms / metabolism. Meningioma / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / metabolism. Female. Gene Expression Profiling. Humans. Magnetic Resonance Spectroscopy. Male. Middle Aged. Principal Component Analysis

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18507434.001).
  • [ISSN] 1535-3893
  • [Journal-full-title] Journal of proteome research
  • [ISO-abbreviation] J. Proteome Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


18. Amoli FA, Mehrabani PM, Tari AS: Aggressive orbital optic nerve meningioma with benign microscopic features: a case report. Orbit; 2007 Dec;26(4):271-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aggressive orbital optic nerve meningioma with benign microscopic features: a case report.
  • Primary optic nerve meningiomas occur at lower ages than meningiomas arising from the coverings of the brain and spinal cord.
  • The patient had a history of orbital meningioma from 10 years ago and several surgical resections due to tumor recurrence during these 10 years.
  • Fine-needle aspiration cytology of the mass confirmed tumor recurrence.
  • The patient first received radiotherapy due to the inoperable mass, and the tumor was resected 1.5 month later.
  • The interesting aspect of this case was the aggressive behavior of the tumor with intraocular invasion, despite its benign histopathological features, which led to wide exenteration of the eye together with resection of the upper and lower lids.
  • [MeSH-major] Meningioma / pathology. Optic Nerve Neoplasms / pathology
  • [MeSH-minor] Adult. Combined Modality Therapy. Female. Humans. Magnetic Resonance Imaging. Neoplasm Invasiveness. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Meningioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18097966.001).
  • [ISSN] 0167-6830
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


19. Mahfouz S, Aziz AA, Gabal SM, el-Sheikh S: Immunohistochemical study of CD99 and EMA expression in ependymomas. Medscape J Med; 2008;10(2):41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumors of the central nervous system (CNS) represent a unique, heterogeneous population of neoplasms and include both benign and malignant tumors.
  • EMA expression and pattern of distribution, on the other hand, cannot be employed to determine the type of variant or the degree of tumor aggressiveness, and hence cannot predict the behavior of ependymal neoplasms.
  • [MeSH-major] Antigens, CD / analysis. Biomarkers, Tumor / analysis. Brain Neoplasms / diagnosis. Brain Neoplasms / metabolism. Cell Adhesion Molecules / analysis. Ependymoma / diagnosis. Ependymoma / metabolism. Mucin-1 / analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Gene Expression Profiling. Humans. Infant. Infant, Newborn. Male. Middle Aged. Neoplasm Proteins / analysis. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Appl Immunohistochem Mol Morphol. 2000 Mar;8(1):25-31 [10937045.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2001 Jun;9(2):125-9 [11396629.001]
  • [Cites] Diagn Cytopathol. 2002 Apr;26(4):247-50 [11933271.001]
  • [Cites] J Neurooncol. 2002 May;58(1):13-9 [12160136.001]
  • [Cites] Exp Mol Med. 2002 Jul 31;34(3):177-83 [12216109.001]
  • [Cites] Acta Neuropathol. 2003 Oct;106(4):385-8 [12898159.001]
  • [Cites] Mod Pathol. 2003 Oct;16(10):980-91 [14559980.001]
  • [Cites] Am J Pathol. 2003 Nov;163(5):1721-7 [14578171.001]
  • [Cites] Curr Treat Options Oncol. 2003 Dec;4(6):517-23 [14585232.001]
  • [Cites] Cancer. 2004 Mar 15;100(6):1230-7 [15022291.001]
  • [Cites] J Neuropathol Exp Neurol. 2004 Mar;63(3):185-92 [15055442.001]
  • [Cites] Neuropathol Appl Neurobiol. 1988 May-Jun;14(3):197-205 [3405393.001]
  • [Cites] Cancer Res. 1988 Nov 1;48(21):6127-31 [2844401.001]
  • [Cites] Acta Neuropathol. 1989;78(3):325-8 [2763805.001]
  • [Cites] Virchows Arch A Pathol Anat Histopathol. 1990;417(2):97-103 [1695040.001]
  • [Cites] Arch Pathol Lab Med. 1990 Sep;114(9):956-60 [2390011.001]
  • [Cites] Cancer. 1991 Apr 1;67(7):1886-93 [1848471.001]
  • [Cites] Acta Neuropathol. 1991;82(3):208-16 [1718129.001]
  • [Cites] Am J Surg Pathol. 1994 May;18(5):486-94 [7513503.001]
  • [Cites] J Neurooncol. 2005 Jan;71(2):189-93 [15690137.001]
  • [Cites] Brain Tumor Pathol. 2004;21(1):17-21 [15696964.001]
  • [Cites] Cancer. 2005 Jun 15;103(12):2598-605 [15861411.001]
  • [Cites] Histopathology. 2007 Feb;50(3):365-70 [17257132.001]
  • [Cites] J Neurooncol. 2002 Jul;58(3):255-70 [12187959.001]
  • [Cites] Acta Neuropathol. 1997 Mar;93(3):310-6 [9083565.001]
  • [Cites] Neuropathology. 2004 Dec;24(4):330-5 [15641594.001]
  • [Cites] Pathol Res Pract. 2004;200(10):717-25 [15648610.001]
  • (PMID = 18382710.001).
  • [ISSN] 1934-1997
  • [Journal-full-title] Medscape journal of medicine
  • [ISO-abbreviation] Medscape J Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor; 0 / CD99 protein, human; 0 / Cell Adhesion Molecules; 0 / Mucin-1; 0 / Neoplasm Proteins
  • [Other-IDs] NLM/ PMC2270873
  •  go-up   go-down


20. Zhou Y, Liu F, Xu Q, Wang X: Analysis of the expression profile of Dickkopf-1 gene in human glioma and the association with tumor malignancy. J Exp Clin Cancer Res; 2010;29:138
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Analysis of the expression profile of Dickkopf-1 gene in human glioma and the association with tumor malignancy.
  • BACKGROUND: Gliomas represent the most common primary malignant brain tumors, yet little is known about the molecular pathogenesis of these tumors.
  • The aim of this study was to examine the expression profile of DKK-1 gene in human glioma and its association with tumor malignancy.
  • A total of 47 tumor biopsy specimens and 11 normal brain tissue samples from patients with cerebral trauma internal decompression were embedded in paraffin blocks and used for immunostaining.
  • Twenty-six primary tumors and 7 corresponding brain samples were stored in liquid nitrogen and used for RT-PCR.
  • RESULTS: DKK-1 could only be detected in 12 human glioblastoma cell lines, not in a panel of other tumor and normal cell lines.
  • Kendall's tau-c association analysis also revealed the increased DKK-1 protein expression in tumor tissues of higher pathologic classification.
  • The levels of cerebral fluid DKK-1 protein were significantly higher in glioma patients than in healthy donors or in neuronal benign tumor patients, suggesting that the DKK-1 molecule in cerebral fluids can be applicable to detect the presence of glioma and be developed as a novel prognostic treatment.
  • [MeSH-major] Biomarkers, Tumor / analysis. Brain Neoplasms / genetics. Gene Expression Profiling. Glioma / genetics. Intercellular Signaling Peptides and Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Enzyme-Linked Immunosorbent Assay. Female. Gene Expression. Humans. Immunohistochemistry. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction. Young Adult

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gene. 1999 Oct 1;238(2):301-13 [10570958.001]
  • [Cites] Cancer Res. 2007 Mar 15;67(6):2517-25 [17363569.001]
  • [Cites] Cytogenet Cell Genet. 2000;89(3-4):220-4 [10965128.001]
  • [Cites] Curr Biol. 2000 Dec 14-28;10(24):1611-4 [11137016.001]
  • [Cites] Nature. 2001 May 17;411(6835):321-5 [11357136.001]
  • [Cites] Nat Cell Biol. 2001 Jul;3(7):683-6 [11433302.001]
  • [Cites] Curr Biol. 2001 Jun 26;11(12):951-61 [11448771.001]
  • [Cites] Curr Biol. 2001 Aug 7;11(15):R592-5 [11516963.001]
  • [Cites] Dev Cell. 2001 Sep;1(3):423-34 [11702953.001]
  • [Cites] Genome Biol. 2002;3(1):REVIEWS3001 [11806834.001]
  • [Cites] Oncogene. 2002 Jan 31;21(6):878-89 [11840333.001]
  • [Cites] N Engl J Med. 2002 May 16;346(20):1513-21 [12015390.001]
  • [Cites] Nature. 2002 Jun 6;417(6889):664-7 [12050670.001]
  • [Cites] Nat Cell Biol. 2002 Jul;4(7):E172-3 [12105428.001]
  • [Cites] Curr Opin Genet Dev. 2003 Feb;13(1):28-33 [12573432.001]
  • [Cites] Lab Invest. 2003 Mar;83(3):429-34 [12649343.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 Apr;129(4):199-221 [12707770.001]
  • [Cites] J Cell Sci. 2003 Jul 1;116(Pt 13):2627-34 [12775774.001]
  • [Cites] Biochim Biophys Acta. 2003 Jun 5;1653(1):1-24 [12781368.001]
  • [Cites] Genes Dev. 2003 Jul 15;17(14):1709-13 [12865297.001]
  • [Cites] J Biol Chem. 2003 Jul 25;278(30):28067-78 [12740383.001]
  • [Cites] Dev Cell. 2003 Sep;5(3):367-77 [12967557.001]
  • [Cites] J Pathol. 2003 Oct;201(2):204-12 [14517837.001]
  • [Cites] Carcinogenesis. 2004 Jan;25(1):47-59 [14555616.001]
  • [Cites] N Engl J Med. 2003 Dec 25;349(26):2483-94 [14695408.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):266-71 [14695885.001]
  • [Cites] Science. 2004 Mar 5;303(5663):1483-7 [15001769.001]
  • [Cites] Nat Genet. 2004 Apr;36(4):417-22 [15034581.001]
  • [Cites] Biochem Biophys Res Commun. 2004 May 21;318(1):259-64 [15110782.001]
  • [Cites] Cancer Res. 2004 Jul 15;64(14):4717-20 [15256437.001]
  • [Cites] Oncogene. 2004 Aug 26;23(39):6672-6 [15221014.001]
  • [Cites] Nature. 1998 Jan 22;391(6665):357-62 [9450748.001]
  • [Cites] Int J Cancer. 1998 Sep 25;78(1):95-9 [9724099.001]
  • [Cites] Oncogene. 2005 Feb 3;24(6):1098-103 [15592505.001]
  • [Cites] Int J Cancer. 2006 Oct 1;119(7):1728-31 [16646053.001]
  • [Cites] Neuro Oncol. 2007 Apr;9(2):135-44 [17329407.001]
  • [Cites] Oncogene. 2000 Mar 30;19(14):1843-8 [10777218.001]
  • (PMID = 21029453.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DKK1 protein, human; 0 / Intercellular Signaling Peptides and Proteins
  • [Other-IDs] NLM/ PMC2990739
  •  go-up   go-down


21. Stewart DR, Sloan JL, Yao L, Mannes AJ, Moshyedi A, Lee CC, Sciot R, De Smet L, Mautner VF, Legius E: Diagnosis, management, and complications of glomus tumours of the digits in neurofibromatosis type 1. J Med Genet; 2010 Aug;47(8):525-32
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Glomus tumours are benign painful tumours of the glomus body, a thermoregulatory shunt in the digits.
  • [MeSH-major] Fingers / pathology. Glomus Tumor / complications. Glomus Tumor / diagnosis. Neurofibromatosis 1 / complications. Toes / pathology
  • [MeSH-minor] Adult. Belgium. Child. Demography. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Nails / pathology

  • Genetic Alliance. consumer health - Neurofibromatosis.
  • Genetic Alliance. consumer health - Neurofibromatosis type 1.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Orthop Belg. 2000 Apr;66(2):169-73 [10842878.001]
  • [Cites] J Dermatol. 2000 Jun;27(6):418-9 [10920593.001]
  • [Cites] J Hand Surg Br. 2002 Jun;27(3):229-31 [12074607.001]
  • [Cites] J Med Genet. 2002 Aug;39(8):e45 [12161612.001]
  • [Cites] N Engl J Med. 2002 Sep 12;347(11):854-5; author reply 854-5 [12226162.001]
  • [Cites] Hand Clin. 2002 Nov;18(4):655-70; discussion 671 [12516980.001]
  • [Cites] Brain. 2004 Sep;127(Pt 9):1993-2009 [15289270.001]
  • [Cites] Plast Reconstr Surg. 2004 Nov;114(6):1486-9 [15509936.001]
  • [Cites] J Am Acad Dermatol. 1995 Feb;32(2 Pt 1):277-8 [7829715.001]
  • [Cites] Radiology. 1995 May;195(2):507-15 [7724775.001]
  • [Cites] J Hand Surg Br. 1996 Apr;21(2):257-60 [8732413.001]
  • [Cites] Int Angiol. 1995 Sep;14(3):226-8 [8919238.001]
  • [Cites] Int J Dermatol. 1997 Dec;36(12):894-900 [9466193.001]
  • [Cites] Brain. 1999 Mar;122 ( Pt 3):473-81 [10094256.001]
  • [Cites] J Dermatol. 1999 Aug;26(8):535-7 [10487011.001]
  • [Cites] J Med Genet. 2004 Nov;41(11):837-41 [15520408.001]
  • [Cites] J Hand Surg Br. 2005 Oct;30(5):535-40 [16085343.001]
  • [Cites] J Hand Surg Am. 2006 Oct;31(8):1397-400 [17027805.001]
  • [Cites] J Med Genet. 2007 Feb;44(2):81-8 [17105749.001]
  • [Cites] Arch Pathol Lab Med. 2008 Sep;132(9):1448-52 [18788860.001]
  • [Cites] Sheng Li Xue Bao. 2008 Oct 25;60(5):581-3 [18958364.001]
  • [Cites] Clin Med. 2008 Dec;8(6):611-7 [19149284.001]
  • [Cites] Pain Pract. 2009 Mar-Apr;9(2):86-99 [19215592.001]
  • [Cites] Cancer Res. 2009 Sep 15;69(18):7393-401 [19738042.001]
  • (PMID = 20530151.001).
  • [ISSN] 1468-6244
  • [Journal-full-title] Journal of medical genetics
  • [ISO-abbreviation] J. Med. Genet.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / / ZIA CP010144-13
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS387951; NLM/ PMC3412429
  •  go-up   go-down


22. Sun FH, Piao YS, Wang W, Chen L, Wei LF, Yang H, Lu DH: [Brain tumors in patients with intractable epilepsy: a clinicopathologic study of 35 cases]. Zhonghua Bing Li Xue Za Zhi; 2009 Mar;38(3):153-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Brain tumors in patients with intractable epilepsy: a clinicopathologic study of 35 cases].
  • OBJECTIVE: To study the clinicopathologic features of brain tumors occurring in patients with medically intractable epilepsy.
  • METHODS: The clinical, radiologic and pathologic features of brain tumors occurring in 35 patients with intractable epilepsy encountered during the period from January, 2005 to April, 2008 in Xuanwu Hospital were retrospectively reviewed.
  • The histologic types of brain tumors included ganglioglioma (13/35, WHO grade I and 6/35, WHO grade II), dysembryoplastic neuroepithelial tumor (3/35, WHO grade I), pleomorphic xanthoastrocytoma (3/35, WHO grade II), diffuse astrocytoma (1/35, WHO grade II), oligoastrocytoma (1/35, WHO grade II), angiocentric glioma (1/35, WHO grade I) and meningioangiomatosis (1/35).
  • The 6 remaining cases showed features seen in between glioneuronal hamartoma and mixed neuronal-glial tumor.
  • CONCLUSIONS: Brain tumors in patients with medically intractable epilepsy are almost always benign and located in the temporal lobe.
  • Most of them represent mixed neuronal-glial tumors and some show transitional features in-between glioneuronal hamartoma and mixed neuronal-glial neoplasm.
  • The similar morphologic pattern and biological behavior of glioneuronal hamartoma and mixed neuronal-glial tumor may suggest a common pathogenetic mechanism.
  • [MeSH-major] Brain Neoplasms / complications. Epilepsy / etiology. Glioma / complications
  • [MeSH-minor] Adolescent. Adult. Antigens, CD34 / metabolism. Astrocytoma / complications. Astrocytoma / metabolism. Astrocytoma / pathology. Brain Diseases / complications. Brain Diseases / metabolism. Brain Diseases / pathology. Child. Child, Preschool. Female. Ganglioglioma / complications. Ganglioglioma / metabolism. Ganglioglioma / pathology. Hamartoma / complications. Hamartoma / metabolism. Hamartoma / pathology. Humans. Infant. Magnetic Resonance Imaging. Male. Oligodendroglioma / complications. Oligodendroglioma / metabolism. Oligodendroglioma / pathology. Retrospective Studies. Temporal Lobe / pathology. Young Adult

  • Genetic Alliance. consumer health - Epilepsy.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - Epilepsy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19575848.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, CD34
  •  go-up   go-down


23. Wang F, Wang Z, Yao W, Xie H, Xu J, Tian L: Role of 99mTc-octreotide acetate scintigraphy in suspected lung cancer compared with 18F-FDG dual-head coincidence imaging. J Nucl Med; 2007 Sep;48(9):1442-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Forty-four consecutive patients with suspected pulmonary neoplasms underwent tomographic (99m)Tc-octreotide scintigraphy and (18)F-FDG coincidence imaging using the same gantry.
  • The tumor-to-normal tissue tracer values for both (99m)Tc-octreotide and (18)F-FDG were determined using region of interests and expressed as T/N(r) and T/N(m), respectively.
  • Thirteen of the 44 patients had benign lung lesions.
  • Thirteen patients with 39 distant sites of abnormal uptake visualized (imaging stage IV) with (99m)Tc-octreotide included 2 patients with brain metastases, 6 patients with pleural invasion and multiple bone metastasis, 2 patients with contralateral internal lung metastasis and pleural invasion, and 3 patients with only multiple bone metastasis.
  • [MeSH-major] Fluorodeoxyglucose F18. Lung Neoplasms / radionuclide imaging. Octreotide / analogs & derivatives. Organotechnetium Compounds. Radiopharmaceuticals
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Neoplasm Metastasis

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17704242.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 99mTc-octreotide; 0 / Organotechnetium Compounds; 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18; RWM8CCW8GP / Octreotide
  •  go-up   go-down


24. Pastel DA, Mamourian AC, Duhaime AC: Internal structure in pineal cysts on high-resolution magnetic resonance imaging: not a sign of malignancy. J Neurosurg Pediatr; 2009 Jul;4(1):81-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECT: In this paper, the authors' goal was to determine whether benign pineal cysts have smooth walls or internal structure on high-resolution MR imaging and to evaluate their imaging characteristics on FLAIR images.
  • CONCLUSIONS: Although the presence of a thin wall supports the diagnosis of a benign pineal cyst, fine internal septations or small internal cysts are common on high-resolution MR imaging and this finding should not be considered evidence of an underlying tumor.
  • [MeSH-major] Brain Neoplasms / pathology. Cysts / pathology. Magnetic Resonance Imaging. Pineal Gland / pathology. Pinealoma / pathology
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Image Processing, Computer-Assisted. Male. Middle Aged. Retrospective Studies. Young Adult


25. Kim DW, Jung SA, Kim CG, Park SA: The efficacy of dual time point F-18 FDG PET imaging for grading of brain tumors. Clin Nucl Med; 2010 Jun;35(6):400-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The efficacy of dual time point F-18 FDG PET imaging for grading of brain tumors.
  • PURPOSE: Several studies have explored the usefulness of dual time point F-18 FDG positron emission tomography imaging (DTPI) in improving detection of brain metastases and tumors outside the brain, distinguishing malignant from benign.
  • In the same manner, DTPI may show better performance to grade of brain tumors.
  • METHODS: Twenty-two lesions of 18 consecutive patients with primary or metastatic brain tumor were included prospectively.
  • CONCLUSION: DTPI may be a better imaging method to grade the brain tumor than early imaging only.
  • [MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Positron-Emission Tomography
  • [MeSH-minor] Adult. Aged. Biological Transport. Female. Humans. Male. Middle Aged. Time Factors. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20479584.001).
  • [ISSN] 1536-0229
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


26. Schoch B, Hogan A, Gizewski ER, Timmann D, Konczak J: Balance control in sitting and standing in children and young adults with benign cerebellar tumors. Cerebellum; 2010 Sep;9(3):324-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Balance control in sitting and standing in children and young adults with benign cerebellar tumors.
  • Balance control was assessed in 16 patients after surgery of a benign cerebellar tumor in chronic state and healthy age- and gender-matched control subjects.
  • [MeSH-major] Cerebellar Neoplasms / surgery. Neurosurgical Procedures / adverse effects. Postoperative Complications / physiopathology. Postural Balance
  • [MeSH-minor] Adolescent. Adult. Biomechanical Phenomena. Cerebellum / pathology. Cerebellum / physiopathology. Cerebellum / surgery. Child. Female. Humans. Male. Posture. Young Adult

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2001 Dec 15;92(12):3155-64 [11753995.001]
  • [Cites] AMA Arch Neurol Psychiatry. 1955 Dec;74(6):653-80 [13268132.001]
  • [Cites] Nat Rev Neurosci. 2004 Oct;5(10):813-9 [15378041.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 2002 Sep;73(3):310-2 [12185166.001]
  • [Cites] Ann Neurol. 1998 Oct;44(4):601-10 [9778258.001]
  • [Cites] Prog Brain Res. 2004;143:353-66 [14653179.001]
  • [Cites] Neuropediatrics. 2006 Dec;37(6):350-8 [17357037.001]
  • [Cites] Neuroscientist. 2004 Jun;10(3):247-59 [15155063.001]
  • [Cites] J Neurophysiol. 2003 Apr;89(4):1844-56 [12612041.001]
  • [Cites] Cereb Cortex. 2004 Oct;14(10):1164-72 [15142954.001]
  • [Cites] Cerebellum. 2008;7(4):602-6 [18949530.001]
  • [Cites] Arch Neurol. 1999 Apr;56(4):421-5 [10199329.001]
  • [Cites] Neuroimage. 2006 Mar;30(1):36-51 [16253526.001]
  • [Cites] Annu Rev Neurosci. 1992;15:403-42 [1575449.001]
  • [Cites] Brain. 2005 Jun;128(Pt 6):1428-41 [15659424.001]
  • [Cites] J Neurol Sci. 1997 Feb 12;145(2):205-11 [9094050.001]
  • [Cites] J Comp Neurol. 1955 Aug;103(1):105-29 [13263445.001]
  • [Cites] Neuroimage. 2002 Sep;17(1):240-55 [12482081.001]
  • [Cites] Neuroimage. 2001 Aug;14(2):486-500 [11467921.001]
  • [Cites] Mov Disord. 1998 Nov;13(6):958-64 [9827622.001]
  • [Cites] Brain. 2008 Nov;131(Pt 11):2913-27 [18835866.001]
  • [Cites] Mov Disord. 2005 Aug;20(8):1006-13 [15838852.001]
  • [Cites] Magn Reson Med. 1998 Jul;40(1):143-51 [9660564.001]
  • (PMID = 20352395.001).
  • [ISSN] 1473-4230
  • [Journal-full-title] Cerebellum (London, England)
  • [ISO-abbreviation] Cerebellum
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Kwon JY, Chung KW, Park EK, Park SW, Choi BO: Charcot-Marie-Tooth 1A concurrent with schwannomas of the spinal cord and median nerve. J Korean Med Sci; 2009 Aug;24(4):763-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A schwannoma is a benign encapsulated tumor originating from a Schwann cell.
  • [MeSH-major] Charcot-Marie-Tooth Disease / diagnosis. Median Neuropathy / diagnosis. Neurilemmoma / diagnosis. Peripheral Nervous System Neoplasms / diagnosis. Spinal Cord Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Chromosomes, Human, Pair 17. Female. Genetic Predisposition to Disease. Humans. Magnetic Resonance Imaging. Male. Myelin Proteins / genetics. Pedigree

  • MedlinePlus Health Information. consumer health - Charcot-Marie-Tooth Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Neurol. 2002 Dec;15(6):679-84 [12447105.001]
  • [Cites] Mol Cell Neurosci. 2002 May;20(1):93-109 [12056842.001]
  • [Cites] Brain. 1980 Jun;103(2):259-80 [7397478.001]
  • [Cites] Cell. 1991 Jul 26;66(2):219-32 [1677316.001]
  • [Cites] Cell. 1993 Jan 15;72(1):143-51 [8422677.001]
  • [Cites] Lancet Neurol. 2007 Apr;6(4):340-51 [17362838.001]
  • [Cites] J Neurosurg. 1995 Oct;83(4):621-6 [7674010.001]
  • [Cites] Neurology. 1997 Feb;48(2):450-2 [9040737.001]
  • [Cites] Neurology. 1997 Feb;48(2):489-93 [9040744.001]
  • [Cites] Genet Med. 2006 Feb;8(2):86-92 [16481890.001]
  • [Cites] Muscle Nerve. 2007 Jan;35(1):122-4 [16969831.001]
  • [Cites] Neurology. 1994 Dec;44(12):2250-2 [7991107.001]
  • (PMID = 19654968.001).
  • [ISSN] 1598-6357
  • [Journal-full-title] Journal of Korean medical science
  • [ISO-abbreviation] J. Korean Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Myelin Proteins; 0 / PMP22 protein, human
  • [Other-IDs] NLM/ PMC2719205
  • [Keywords] NOTNLM ; Charcot-Marie-Tooth Disease / Neurilemmoma / PMP22 Duplication
  •  go-up   go-down


28. Viapiano MS, Bi WL, Piepmeier J, Hockfield S, Matthews RT: Novel tumor-specific isoforms of BEHAB/brevican identified in human malignant gliomas. Cancer Res; 2005 Aug 1;65(15):6726-33
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel tumor-specific isoforms of BEHAB/brevican identified in human malignant gliomas.
  • Malignant gliomas are deadly brain tumors characterized by diffuse invasion into the surrounding brain tissue.
  • Here we describe for the first time the expression of BEHAB/brevican in human brain and characterize two novel glioma-specific isoforms, B/b(sia) and B/b(Deltag), which are generated by differential glycosylation and are absent from normal adult brain and other neuropathologies.
  • In addition, its absence from benign gliomas prompts its use as a diagnostic marker to distinguish primary brain tumors of similar histology but different pathologic course.
  • [MeSH-major] Brain Neoplasms / metabolism. Carrier Proteins / metabolism. Glioma / metabolism. Nerve Tissue Proteins / metabolism
  • [MeSH-minor] Adolescent. Adult. Animals. Brevican. Cell Membrane / metabolism. Chondroitin Sulfate Proteoglycans. Female. Glycosylation. Humans. Lectins, C-Type. Male. Middle Aged. Protein Isoforms. Rats. Transfection

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16061654.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / R01/NS35228
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BCAN protein, human; 0 / Brevican; 0 / Carrier Proteins; 0 / Chondroitin Sulfate Proteoglycans; 0 / Lectins, C-Type; 0 / Nerve Tissue Proteins; 0 / Protein Isoforms
  •  go-up   go-down


29. Quintana LG, da Silva FP, Pieczarka JC, Nagamachi CY, Anselmo NP, de Oliveira EH: Correlation between argyrophilic nucleolar organizer region staining and brain tumor classification and grading. Cancer Invest; 2010 Jun;28(5):459-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation between argyrophilic nucleolar organizer region staining and brain tumor classification and grading.
  • Distinctions between benign and malignant tumors are less evident in the central nervous system than in other tissues.
  • Since the level of cell proliferation is an important feature in tumor grading, we applied AgNOR in 50 cases of brain tumors with different grades and histological origins in order to check its efficiency in discriminating between benign and malignant cases.
  • [MeSH-major] Brain Neoplasms / pathology. Nucleolus Organizer Region / pathology. Silver Staining
  • [MeSH-minor] Adult. Age Factors. Chromosomal Proteins, Non-Histone / metabolism. Humans. Middle Aged. Prognosis

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20014945.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chromosomal Proteins, Non-Histone
  •  go-up   go-down


30. Szabó PM, Wiener Z, Tömböl Z, Kovács A, Pócza P, Horányi J, Kulka J, Riesz P, Tóth M, Patócs A, Gaillard RC, Falus A, Rácz K, Igaz P: Differences in the expression of histamine-related genes and proteins in normal human adrenal cortex and adrenocortical tumors. Virchows Arch; 2009 Aug;455(2):133-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In this study, we examined the expression of histamine-related genes and proteins and histamine content in normal adrenal cortex, benign adrenocortical adenomas, and malignant adrenocortical cancer (ACC).
  • HDC expression and histamine content was highest in the normal tissues and lower in benign tumors, whereas it was significantly less in ACCs.
  • Adrenocortical tumorigenesis might, thus, be characterized by reduced histamine biosynthesis; furthermore, different adrenocortical tumor subtypes may show unique histamine receptor expression profiles.
  • [MeSH-major] Adrenal Cortex / metabolism. Adrenal Cortex Neoplasms / metabolism. Adrenocortical Adenoma / metabolism. Histamine / metabolism. Histidine Decarboxylase / metabolism. Receptors, Histamine / metabolism
  • [MeSH-minor] Adult. Aged. Female. Gene Expression Profiling. Humans. Male. Middle Aged. Receptors, G-Protein-Coupled / genetics. Receptors, G-Protein-Coupled / metabolism. Receptors, Histamine H1 / genetics. Receptors, Histamine H1 / metabolism. Receptors, Histamine H2 / genetics. Receptors, Histamine H2 / metabolism. Receptors, Histamine H3 / genetics. Receptors, Histamine H3 / metabolism

  • Hazardous Substances Data Bank. HISTAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Brain Res. 1985 Jul 29;339(2):393-6 [3896403.001]
  • [Cites] Am J Pathol. 1993 Apr;142(4):965-74 [7682764.001]
  • [Cites] Cancer Lett. 1995 Feb 10;89(1):23-8 [7882298.001]
  • [Cites] Histol Histopathol. 1997 Oct;12(4):1081-9 [9302569.001]
  • [Cites] Endocr Relat Cancer. 2007 Mar;14(1):13-28 [17395972.001]
  • [Cites] Digestion. 1999 Nov-Dec;60(6):522-7 [10545721.001]
  • [Cites] Arch Pathol Lab Med. 1985 Apr;109(4):357-60 [3157360.001]
  • [Cites] Br J Pharmacol. 1991 Dec;104(4):839-46 [1725765.001]
  • [Cites] J Steroid Biochem Mol Biol. 1991;40(1-3):381-9 [1659878.001]
  • [Cites] Trends Pharmacol Sci. 2005 Sep;26(9):462-9 [16054239.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Br J Clin Pharmacol. 1992 Oct;34(4):322-7 [1457266.001]
  • [Cites] Oncologist. 2008 May;13(5):548-61 [18515740.001]
  • [Cites] Cancer Biol Ther. 2008 Jan;7(1):28-35 [17932461.001]
  • [Cites] Eur J Endocrinol. 2005 Aug;153(2):307-15 [16061838.001]
  • [Cites] J Pharmacol Sci. 2005 Jan;97(1):116-23 [15655289.001]
  • [Cites] J Physiol. 1922 Dec 22;57(1-2):82-99 [16993603.001]
  • [Cites] Biochem Biophys Res Commun. 1995 Jun 15;211(2):570-7 [7794271.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Mar;87(3):1211-6 [11889190.001]
  • [Cites] Eur J Cell Biol. 2008 Apr;87(4):227-36 [18258331.001]
  • [Cites] Jpn J Pharmacol. 1997 Oct;75(2):115-21 [9414025.001]
  • [Cites] Am J Physiol Endocrinol Metab. 2005 Dec;289(6):E1058-63 [16076876.001]
  • [Cites] Int Immunol. 2007 Jan;19(1):51-8 [17118966.001]
  • [Cites] Inflamm Res. 1995 Apr;44 Suppl 1:S48-9 [8520996.001]
  • [Cites] Methods Mol Biol. 2006;315:13-34 [16110146.001]
  • [Cites] Neuroscience. 1992;47(4):999-1007 [1374544.001]
  • [Cites] Inflammopharmacology. 2005;13(1-3):281-9 [16259747.001]
  • [Cites] Eur J Pharmacol. 2006 Mar 8;533(1-3):69-76 [16448645.001]
  • [Cites] Horm Res. 2009 Jan;71 Suppl 1:99-104 [19153517.001]
  • [Cites] Pathol Int. 2004 Jun;54(6):408-12 [15144399.001]
  • [Cites] J Steroid Biochem Mol Biol. 2006 Oct;101(2-3):87-96 [16891114.001]
  • [Cites] Methods Mol Biol. 2006;315:63-76 [16110149.001]
  • [Cites] Pharmacol Ther. 2003 Apr;98(1):1-34 [12667886.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Dec;87(12):5367-84 [12466322.001]
  • [Cites] Mod Pathol. 2003 Jun;16(6):591-7 [12808065.001]
  • [Cites] J Clin Endocrinol Metab. 2007 Jan;92(1):148-54 [17062775.001]
  • [Cites] Cancer Res. 2008 Mar 15;68(6):1997-2005 [18339882.001]
  • [Cites] Rheumatol Int. 2005 Dec;26(2):173-8 [15986084.001]
  • [Cites] Inflamm Res. 1997 Mar;46 Suppl 1:S57-8 [9098764.001]
  • [Cites] J Clin Endocrinol Metab. 2006 May;91(5):1943-9 [16464939.001]
  • [Cites] Mod Pathol. 2003 Jan;16(1):72-8 [12527716.001]
  • [Cites] Nat Med. 1995 Dec;1(12):1243-4 [7489398.001]
  • [Cites] J Pharmacol Sci. 2003 Nov;93(3):321-30 [14646250.001]
  • [Cites] Curr Allergy Asthma Rep. 2008 Mar;8(1):21-7 [18377770.001]
  • [Cites] Trends Immunol. 2001 Dec;22(12):648-52 [11738976.001]
  • (PMID = 19568768.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / HRH4 protein, human; 0 / Receptors, G-Protein-Coupled; 0 / Receptors, Histamine; 0 / Receptors, Histamine H1; 0 / Receptors, Histamine H2; 0 / Receptors, Histamine H3; 820484N8I3 / Histamine; EC 4.1.1.22 / Histidine Decarboxylase
  •  go-up   go-down


31. Stüer C, Vilz B, Majores M, Becker A, Schramm J, Simon M: Frequent recurrence and progression in pilocytic astrocytoma in adults. Cancer; 2007 Dec 15;110(12):2799-808
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Most pilocytic astrocytomas (piloA) are benign growths (World Health Organization [WHO] grade 1) of the deep midline structures, the brainstem, and the cerebellum.
  • RESULTS: There were 20 patients (45%) with supratentorial lobar piloA (including 10 temporal/temporomesial tumors, 5 parietal tumors, 3 insular tumors, 1 frontal tumor, and 1 occipital tumors), 12 patients with cerebellar piloA, 7 patients with brainstem piloA, 2 patients with opticochiasmatic PiloA, 1 patient with intramedullary piloA, and 2 patients with piloA of the basal ganglia.
  • All but 1 patient with a lobar tumor presented with epilepsy.
  • Tumor recurrence or disease progression was observed in 13 of 44 patients (30%).
  • CONCLUSIONS: PiloA in adult patients, surprisingly, often was not a benign disease.
  • [MeSH-major] Astrocytoma / pathology. Astrocytoma / radiography. Brain Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Disease Progression. Female. Humans. Male. Middle Aged. Prognosis. Recurrence. Treatment Outcome

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Nat Clin Pract Neurol. 2008 Jun;4(6):296-7 [18414467.001]
  • (PMID = 17973253.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


32. Samaila MO, Mbibu HN, Oluwole OP: Human mycetoma. Surg Infect (Larchmt); 2007 Oct;8(5):519-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • However, the disease may present without these characteristic features, thus causing diagnostic difficulty with other chronic granulomatous infections such as tuberculosis or benign skin lesions.
  • The range of clinical misdiagnoses included skin tuberculosis, fibroma, amelanotic melanoma, basal-cell carcinoma, and brain tumor.
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Humans. Male. Middle Aged

  • Genetic Alliance. consumer health - Mycetoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17999585.001).
  • [ISSN] 1096-2964
  • [Journal-full-title] Surgical infections
  • [ISO-abbreviation] Surg Infect (Larchmt)
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Lönnrot K, Terho M, Kähärä V, Haapasalo H, Helén P: Desmoplastic infantile ganglioglioma: novel aspects in clinical presentation and genetics. Surg Neurol; 2007 Sep;68(3):304-8; discussion 308
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Desmoplastic infantile ganglioglioma is a rare tumor occurring mainly in infants and young children.
  • Both radiological and histopathological appearances may resemble malignancy, although its clinical course is mainly benign.
  • In 4 cases, there was a histopathologically verified single cystic tumor.
  • There were no recurrences in any of the patients after tumor resection.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / etiology. Ganglioglioma / diagnosis. Ganglioglioma / etiology
  • [MeSH-minor] Adult. Aged. Child. Child, Preschool. Epilepsy / etiology. Follow-Up Studies. Humans. Male. Neoplasm Proteins / metabolism. Nerve Tissue Proteins / metabolism. Oncogenes / physiology. Retrospective Studies. Treatment Outcome


34. Ceyssens S, Van Laere K, de Groot T, Goffin J, Bormans G, Mortelmans L: [11C]methionine PET, histopathology, and survival in primary brain tumors and recurrence. AJNR Am J Neuroradiol; 2006 Aug;27(7):1432-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [11C]methionine PET, histopathology, and survival in primary brain tumors and recurrence.
  • BACKGROUND AND PURPOSE: [(11)C]Methionine (MET) PET imaging is a sensitive technique for visualizing primary brain tumors and recurrence/progression after therapy.
  • METHODS: Cerebral uptake of MET was determined in 52 patients: in 26 patients for primary staging (group A) and 26 patients with suspected brain tumor recurrence/progression after therapy (group B).
  • Semiquantitative methionine uptake indices (UI) defined by the tumor (maximum)-to-background ratio was correlated with tumor grade and final outcome.
  • Although a weak linear correlation between MET uptake and grading was observed (R = 0.38, P = .028), analysis of variance showed no significant differences in MET UI between tumor grades for either group A or B.
  • Benign and grade I lesions showed significant difference in MET uptake in comparison with higher grade lesions (P = .006).
  • Moreover, there is no significant prognostic value in studying maximal methionine UI in brain tumors.
  • [MeSH-major] Brain Neoplasms / radionuclide imaging. Carbon Radioisotopes. Glioma / radionuclide imaging. Methionine. Neoplasm Recurrence, Local / pathology. Positron-Emission Tomography / methods. Radiopharmaceuticals
  • [MeSH-minor] Adolescent. Adult. Aged. Astrocytoma / pathology. Astrocytoma / radionuclide imaging. Astrocytoma / therapy. Brain / metabolism. Child. Child, Preschool. Disease Progression. Female. Forecasting. Humans. Male. Middle Aged. Neoplasm Staging. Oligodendroglioma / pathology. Oligodendroglioma / radionuclide imaging. Oligodendroglioma / therapy. Prognosis. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • Hazardous Substances Data Bank. (L)-Methionine .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16908552.001).
  • [ISSN] 0195-6108
  • [Journal-full-title] AJNR. American journal of neuroradiology
  • [ISO-abbreviation] AJNR Am J Neuroradiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Carbon Radioisotopes; 0 / Radiopharmaceuticals; AE28F7PNPL / Methionine
  •  go-up   go-down


35. Sentürk S, Oğuz KK, Cila A: Dynamic contrast-enhanced susceptibility-weighted perfusion imaging of intracranial tumors: a study using a 3T MR scanner. Diagn Interv Radiol; 2009 Mar;15(1):3-12
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To determine whether there are statistically significant differences in cerebral blood volume (CBV) and cerebral blood flow (CBF) of brain tumors of different histopathologic types including primary and secondary benign and malignant lesions.
  • To determine whether these measurements relate to tumor grade.
  • MATERIALS AND METHODS: Forty-five patients with brain tumors, age 2 to 79 years, underwent dynamic contrast-enhanced susceptibility- weighted echo-planar perfusion magnetic resonance imaging (MRI) using a 3T MR scanner.
  • The Mann-Whitney U test was used to compare rCBV and rCBF measurements of tumor groups -- 13 low-grade and 13 high-grade neuroepithelial (NE) tumors, five metastases, 10 meningiomas, and four others.
  • CONCLUSION: CBV and CBF measurements provided by 3T perfusion MRI can help to predict NE tumor grading preoperatively, and differentiate between primary brain tumors and metastases.
  • [MeSH-major] Brain / blood supply. Brain Neoplasms / blood supply. Brain Neoplasms / pathology. Cerebrovascular Circulation. Image Enhancement / methods. Magnetic Resonance Imaging
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Female. Humans. Male. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19263367.001).
  • [ISSN] 1305-3612
  • [Journal-full-title] Diagnostic and interventional radiology (Ankara, Turkey)
  • [ISO-abbreviation] Diagn Interv Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


36. Huang CF, Tu HT, Liu WS, Lin LY: Gamma Knife surgery for trigeminal pain caused by benign brain tumors. J Neurosurg; 2008 Dec;109 Suppl:154-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gamma Knife surgery for trigeminal pain caused by benign brain tumors.
  • OBJECT: The authors report the effects of Gamma Knife surgery (GKS) on benign tumor-related trigeminal pain in patients who underwent follow-up for a mean 57.8 months.
  • METHODS: From 1999 to 2004, 21 patients with benign tumor-related trigeminal pain (12 meningiomas and 9 schwannomas) underwent GKS as a primary or repeated treatment.
  • For meningiomas, the mean radiosurgical treatment volume was 8.2 ml (range 1.1-21 ml), and the mean radiosurgical tumor margin dose was 12.7 Gy (range 12-15 Gy); for schwannomas, the mean volume was 5.6 ml (range 2-9.2 ml), and the mean marginal dose was 13 Gy (range 11.5-16 Gy).
  • For all 21 patients (100%), control of tumor growth was documented at a mean of 46 months after GKS.
  • CONCLUSIONS: Gamma Knife surgery appears to be an effective tool to treat benign tumor-related trigeminal pain and control tumor growth.
  • [MeSH-major] Brain Neoplasms / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery. Neurilemmoma / surgery. Radiosurgery. Trigeminal Neuralgia / prevention & control
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Pain, Intractable / etiology. Pain, Intractable / prevention & control. Retrospective Studies. Time Factors. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Trigeminal Neuralgia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19123903.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


37. Keita M, Kampo MI, Timbo SK, Traoré CB, Diallo M, Doumbia-Singaré K, Ag Mohamed A: [Morbidity of the tumours of the sphere head and neck in Bamako]. Mali Med; 2009;24(3):1-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Where excluded from the study the patients whose file were not completed and those that have had eye and brain tumours From the data base of the department, a total of 60 cases of tumours were monitored and 25 others cases were excluded according to the criteria.
  • Among the 60 cases, 24 tumours (40%) were malign and 36 were benign.
  • Goiter was the most found benign tumor according to the results of the hystology analysis.
  • [MeSH-major] Head and Neck Neoplasms
  • [MeSH-minor] Adolescent. Adult. Child. Female. Humans. Male. Mali. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20093222.001).
  • [ISSN] 1993-0836
  • [Journal-full-title] Le Mali médical
  • [ISO-abbreviation] Mali Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Mali
  •  go-up   go-down


38. Del Valle L, White MK, Enam S, Piña Oviedo S, Bromer MQ, Thomas RM, Parkman HP, Khalili K: Detection of JC virus DNA sequences and expression of viral T antigen and agnoprotein in esophageal carcinoma. Cancer; 2005 Feb 1;103(3):516-27
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • JCV is oncogenic in experimental animals and is associated with human brain tumors.
  • Using immunohistochemistry, JCV T antigen was detected in 10 of 19 carcinomas (53%), agnoprotein was detected in 8 carcinomas (42%), p53 tumor suppressor was detected in 11 carcinomas (58%), and beta-catenin was detected in 4 carcinomas (21%).
  • Zero of 51 normal, benign, and premalignant esophageal samples expressed viral proteins.
  • [MeSH-major] Antigens, Viral, Tumor / analysis. Esophageal Neoplasms / virology. JC Virus / isolation & purification. Polyomavirus Infections / diagnosis. Tumor Virus Infections / diagnosis. Viral Proteins / analysis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. DNA, Viral / isolation & purification. Esophagus / virology. Female. Fluorescent Antibody Technique. Gene Expression Regulation. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Lasers. Male. Microdissection / methods. Middle Aged. Polymerase Chain Reaction. Viral Regulatory and Accessory Proteins

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2004 American Cancer Society
  • (PMID = 15630684.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Viral, Tumor; 0 / DNA, Viral; 0 / Viral Proteins; 0 / Viral Regulatory and Accessory Proteins; 0 / agnoprotein, polyomavirus
  •  go-up   go-down


39. Wöhrer A, Waldhör T, Heinzl H, Hackl M, Feichtinger J, Gruber-Mösenbacher U, Kiefer A, Maier H, Motz R, Reiner-Concin A, Richling B, Idriceanu C, Scarpatetti M, Sedivy R, Bankl HC, Stiglbauer W, Preusser M, Rössler K, Hainfellner JA: The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry. J Neurooncol; 2009 Dec;95(3):401-411
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Austrian Brain Tumour Registry: a cooperative way to establish a population-based brain tumour registry.
  • In Austria, registration of malignant brain tumours is legally mandatory, whereas benign and borderline tumours are not reported.
  • The Austrian Brain Tumour Registry (ABTR) was initiated under the auspices of the Austrian Society of Neuropathology for the registration of malignant and non-malignant brain tumours.
  • All Austrian neuropathology units involved in brain tumour diagnostics contribute data on primary brain tumours.
  • In 2005, we registered a total of 1,688 newly diagnosed primary brain tumours in a population of 8.2 million inhabitants with an overall age-adjusted incidence rate of 18.1/100,000 person-years.
  • Comparison with the Central Brain Tumor Registry of the United States (CBTRUS) database showed high congruency of findings.
  • The ABTR model led by neuropathologists in collaboration with epidemiologists and the Austrian National Cancer Registry presents a cooperative way to establish a population-based brain tumour registry with high quality data.
  • The continued operation of ABTR will aid in monitoring changes in incidence and in identifying regional disease clusters or geographic variations in brain tumour morbidity/mortality.
  • [MeSH-major] Brain Neoplasms / epidemiology. Glioblastoma / epidemiology. Registries / standards. Registries / statistics & numerical data
  • [MeSH-minor] Adenoma / epidemiology. Adenoma / pathology. Adolescent. Adult. Age Distribution. Aged. Aged, 80 and over. Austria / epidemiology. Child. Child, Preschool. Ependymoma / epidemiology. Ependymoma / pathology. Female. Geographic Information Systems. Humans. Incidence. Male. Meningeal Neoplasms / epidemiology. Meningeal Neoplasms / pathology. Middle Aged. Oligodendroglioma / epidemiology. Oligodendroglioma / pathology. Reproducibility of Results. Sex Distribution. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2004 Jan 20;108(3):450-5 [14648713.001]
  • [Cites] J Neurooncol. 1999 May;42(3):195-204 [10433103.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(2):348-57 [10637249.001]
  • [Cites] Br J Cancer. 2005 Oct 3;93(7):842-8 [16136046.001]
  • [Cites] Epidemiology. 2004 Nov;15(6):653-9 [15475713.001]
  • [Cites] Neuro Oncol. 2002 Oct;4(4):278-99 [12356358.001]
  • [Cites] J Clin Oncol. 2007 Sep 10;25(26):4104-9 [17827460.001]
  • [Cites] Neurol Clin. 2007 Nov;25(4):925-46, viii [17964021.001]
  • [Cites] AIDS Read. 2000 Aug;10(8):486-91 [10967810.001]
  • [Cites] Dis Nerv Syst. 1967 Feb;28(2):89-93 [5336568.001]
  • [Cites] Neurosurgery. 1987 Jul;21(1):21-6 [3039398.001]
  • [Cites] Neurosurgery. 1994 Jan;34(1):68-78 [8121571.001]
  • [Cites] Neurosurg Focus. 2005 Apr 15;18(4):e12 [15844864.001]
  • [Cites] J Natl Cancer Inst. 1998 Oct 7;90(19):1473-9 [9776413.001]
  • [Cites] J Epidemiol Biostat. 2000;5(2):99-107 [10890281.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] J Neurooncol. 2007 Sep;84(2):189-99 [17431547.001]
  • [Cites] J Neurooncol. 1994;18(1):69-81 [8057137.001]
  • [Cites] J Neurooncol. 2002 Oct;60(1):61-9 [12416547.001]
  • [Cites] Int J Oncol. 2008 May;32(5):1097-103 [18425337.001]
  • [Cites] Surg Neurol. 2006 Sep;66(3):258-63; discussion 263 [16935629.001]
  • [Cites] Neuro Oncol. 2006 Jan;8(1):27-37 [16443945.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):484-9 [18349266.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):997-1003 [15758010.001]
  • [Cites] Neuroepidemiology. 2006;27(1):22-7 [16770081.001]
  • [Cites] Int J Clin Oncol. 2008 Apr;13(2):90-6 [18463950.001]
  • [Cites] Radiat Res. 2005 Apr;163(4):424-32 [15799699.001]
  • [Cites] N Engl J Med. 2005 Mar 10;352(10 ):987-96 [15758009.001]
  • [Cites] N Engl J Med. 2001 Jan 11;344(2):79-86 [11150357.001]
  • (PMID = 19562257.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


40. Rachinger W, Goetz C, Pöpperl G, Gildehaus FJ, Kreth FW, Holtmannspötter M, Herms J, Koch W, Tatsch K, Tonn JC: Positron emission tomography with O-(2-[18F]fluoroethyl)-l-tyrosine versus magnetic resonance imaging in the diagnosis of recurrent gliomas. Neurosurgery; 2005 Sep;57(3):505-11; discussion 505-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Differentiation between tumor- and therapy-associated contrast enhancement on MRI scans after treatment may be difficult.
  • The aim of this study was to analyze the diagnostic value of O-(2-[F]fluoroethyl)-l-tyrosine (FET)-positron emission tomography (PET) and MRI in the detection of tumor recurrence in patients with glioma after radiotherapy, radiosurgery, or multimodal treatment.
  • METHODS: The study included 36 patients with gliomas and neuroradiological diagnosis of tumor recurrence and 9 patients who had undergone radioimmunotherapy.
  • RESULTS: Tumor recurrence was documented in 31 of 45 patients, and 14 of 45 patients were tumor free.
  • Specificity of FET-PET was 92.9%, and sensitivity was 100% (in patients suspected of having recurrent tumor as revealed by MRI).
  • CONCLUSION: For patients with gliomas undergoing multimodal treatment or various forms of irradiation, conventional follow-up with MRI is insufficient to distinguish between benign side effects of therapy and tumor recurrence.
  • [MeSH-major] Brain Neoplasms / diagnosis. Fluorine Radioisotopes. Fluorodeoxyglucose F18. Glioma / diagnosis. Magnetic Resonance Imaging / methods. Positron-Emission Tomography / methods
  • [MeSH-minor] Adult. Aged. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Image Processing, Computer-Assisted. Male. Middle Aged. Recurrence. Retrospective Studies. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16145529.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fluorine Radioisotopes; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


41. Carvalho LH, Smirnov I, Baia GS, Modrusan Z, Smith JS, Jun P, Costello JF, McDermott MW, Vandenberg SR, Lal A: Molecular signatures define two main classes of meningiomas. Mol Cancer; 2007;6:64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Meningiomas are common brain tumors that are classified into three World Health Organization grades (benign, atypical and malignant) and are molecularly ill-defined tumors.
  • While all benign meningiomas fall into the low-proliferative group and all malignant meningiomas fall into the high-proliferative group, atypical meningiomas distribute into either one of these groups.
  • We have identified genes that distinguish benign low-proliferative meningiomas from malignant high-proliferative meningiomas and have found that gain of cell-proliferation markers and loss of components of the transforming growth factor-beta signaling pathway were the major molecular mechanisms that distinguish these two groups.
  • CONCLUSION: Collectively, our data suggests that atypical meningiomas are not a molecularly distinct group but are similar to either benign or malignant meningiomas.
  • [MeSH-major] Chromosome Aberrations. Meningeal Neoplasms / classification. Meningeal Neoplasms / genetics. Meningioma / classification. Meningioma / genetics. Nucleic Acid Hybridization / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chromosome Deletion. Female. Gene Expression Profiling / methods. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neuropathol Exp Neurol. 2000 Oct;59(10):872-9 [11079777.001]
  • [Cites] J Neurooncol. 2001 Dec;55(3):149-58 [11859969.001]
  • [Cites] J Neuropathol Exp Neurol. 2006 May;65(5):445-54 [16772868.001]
  • [Cites] J Neurooncol. 2006 Jun;78(2):113-21 [16554968.001]
  • [Cites] Cancer Cell. 2006 Mar;9(3):157-73 [16530701.001]
  • [Cites] Neurosurgery. 2005 Sep;57(3):538-50; discussion 538-50 [16145534.001]
  • [Cites] Cancer Res. 2005 Jun 15;65(12):5070-5 [15958550.001]
  • [Cites] Clin Cancer Res. 2005 Apr 15;11(8):2907-18 [15837741.001]
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1678-86 [15753362.001]
  • [Cites] J Neurooncol. 2004 Nov;70(2):183-202 [15674477.001]
  • [Cites] Int J Cancer. 2005 Mar 20;114(2):249-56 [15540215.001]
  • [Cites] Cancer. 1999 May 1;85(9):2046-56 [10223247.001]
  • [Cites] Cancer. 1998 Jun 1;82(11):2262-9 [9610708.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Dec 23;94(26):14719-24 [9405679.001]
  • [Cites] Nat Genet. 1994 Feb;6(2):180-4 [8162072.001]
  • [Cites] Lab Invest. 1992 Sep;67(3):360-8 [1328762.001]
  • [Cites] Am J Pathol. 1992 Sep;141(3):633-42 [1325741.001]
  • [Cites] Biostatistics. 2004 Oct;5(4):557-72 [15475419.001]
  • [Cites] J Clin Pathol. 2004 Oct;57(10):1033-7 [15452155.001]
  • [Cites] Nat Rev Neurosci. 2004 Oct;5(10):782-92 [15378038.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):9-16 [15015765.001]
  • [Cites] Surg Neurol. 2003 Oct;60(4):298-305; discussion 305 [14505844.001]
  • [Cites] Biostatistics. 2003 Apr;4(2):249-64 [12925520.001]
  • [Cites] Cancer Control. 2003 Mar-Apr;10(2):148-58 [12712009.001]
  • [Cites] Genome Biol. 2003;4(1):R7 [12540299.001]
  • [Cites] Am J Pathol. 2002 Aug;161(2):665-72 [12163391.001]
  • [Cites] Nat Genet. 2002 May;31(1):19-20 [11984561.001]
  • [Cites] Brain Pathol. 2002 Apr;12(2):183-90 [11958372.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):661-9 [11485924.001]
  • [Cites] Genome Res. 2002 Feb;12(2):325-32 [11827952.001]
  • [Cites] Lancet Neurol. 2006 Dec;5(12):1045-54 [17110285.001]
  • (PMID = 17937814.001).
  • [ISSN] 1476-4598
  • [Journal-full-title] Molecular cancer
  • [ISO-abbreviation] Mol. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2173907
  •  go-up   go-down


42. Rush SZ, Abel TW, Valadez JG, Pearson M, Cooper MK: Activation of the Hedgehog pathway in pilocytic astrocytomas. Neuro Oncol; 2010 Aug;12(8):790-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pilocytic astrocytoma is commonly viewed as a benign lesion.
  • Expression levels of the Hh pathway transcriptional target PTCH were elevated in 45% of tumor specimens analyzed (ages 1-22 years) and correlated inversely with patient age.
  • Taken together, these findings suggest that Hh pathway activation is common in pediatric pilocytic astrocytomas and may be associated with younger age at diagnosis and tumor growth.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • COS Scholar Universe. author profiles.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2009 May 21;28(20):2119-23 [19363522.001]
  • [Cites] Acta Neuropathol. 2009 Jun;117(6):657-65 [19271226.001]
  • [Cites] Mol Carcinog. 2009 Aug;48(8):703-12 [19142899.001]
  • [Cites] Pediatr Blood Cancer. 2009 Sep;53(3):417-23 [19479971.001]
  • [Cites] J Clin Oncol. 2009 Aug 1;27(22):3691-7 [19581535.001]
  • [Cites] N Engl J Med. 2009 Sep 17;361(12):1173-8 [19726761.001]
  • [Cites] Oncogene. 2009 Oct 1;28(39):3468-76 [19617900.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Jan;27(1):44-51 [10564585.001]
  • [Cites] Cancer. 2000 Oct 1;89(7):1569-76 [11013373.001]
  • [Cites] Pediatr Neurosurg. 2001 Dec;35(6):311-7 [11786699.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Mar;61(3):215-25; discussion 226-9 [11895036.001]
  • [Cites] Curr Treat Options Oncol. 2001 Dec;2(6):529-36 [12057098.001]
  • [Cites] Nat Genet. 2002 Jul;31(3):306-10 [12068298.001]
  • [Cites] Science. 2002 Aug 30;297(5586):1559-61 [12202832.001]
  • [Cites] J Neurooncol. 2002 Sep;59(2):107-15 [12241103.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14071-6 [12391318.001]
  • [Cites] J Neurosurg. 2003 Jun;98(6):1170-4 [12816259.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2968-73 [12885817.001]
  • [Cites] Neurosurgery. 2003 Sep;53(3):544-53; discussion 554-5 [12943571.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):846-51 [14520411.001]
  • [Cites] Neurology. 2004 Apr 27;62(8):1311-6 [15111667.001]
  • [Cites] Nature. 2004 Oct 7;431(7009):707-12 [15361885.001]
  • [Cites] J Neurosurg. 1988 Jan;68(1):41-7 [3335911.001]
  • [Cites] J Neurosurg. 1988 Aug;69(2):171-6 [3392563.001]
  • [Cites] Neurosurgery. 1992 Sep;31(3):413-8; discussion 419 [1407423.001]
  • [Cites] Science. 1996 Jun 14;272(5268):1668-71 [8658145.001]
  • [Cites] Cell. 1996 Jun 14;85(6):841-51 [8681379.001]
  • [Cites] Cancer Res. 1997 Mar 1;57(5):842-5 [9041183.001]
  • [Cites] Cancer Res. 1997 Jun 1;57(11):2085-8 [9187099.001]
  • [Cites] Cancer Res. 1997 Jul 1;57(13):2581-5 [9205058.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2792-9 [9256121.001]
  • [Cites] J Neurooncol. 1998 Mar;37(1):9-16 [9525833.001]
  • [Cites] J Neurosurg. 1999 Feb;90(2):265-73 [9950497.001]
  • [Cites] Oncogene. 1999 Jan 21;18(3):833-6 [9989836.001]
  • [Cites] Neuropathol Appl Neurobiol. 1999 Apr;25(2):134-42 [10216001.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5198-204 [16051961.001]
  • [Cites] Cancer Res. 2006 Jan 15;66(2):839-45 [16424016.001]
  • [Cites] Dev Cell. 2006 Feb;10(2):187-97 [16459298.001]
  • [Cites] Curr Biol. 2007 Jan 23;17(2):165-72 [17196391.001]
  • [Cites] Childs Nerv Syst. 2007 May;23(5):543-7 [17226033.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] Oncogene. 2007 Aug 23;26(39):5752-61 [17353902.001]
  • [Cites] Stem Cells. 2007 Oct;25(10):2524-33 [17628016.001]
  • [Cites] J Clin Invest. 2008 May;118(5):1739-49 [18398503.001]
  • [Cites] Pediatr Blood Cancer. 2008 Aug;51(2):245-50 [18386785.001]
  • [Cites] J Neuropathol Exp Neurol. 2008 Sep;67(9):878-87 [18716556.001]
  • [Cites] Cancer Res. 2008 Nov 1;68(21):8673-7 [18974108.001]
  • [Cites] Cancer Res. 2009 Feb 15;69(4):1284-92 [19190345.001]
  • [Cites] Trends Pharmacol Sci. 2009 Jun;30(6):303-12 [19443052.001]
  • (PMID = 20223881.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P30 CA068485; United States / NINDS NIH HHS / NS / K02NS053614
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Chemical-registry-number] 0 / GLI1 protein, human; 0 / Hedgehog Proteins; 0 / RNA, Messenger; 0 / Receptors, Cell Surface; 0 / Transcription Factors; 0 / patched receptors
  • [Other-IDs] NLM/ PMC2940682
  •  go-up   go-down


43. Rourke T, Davies S, Samandouras G: Serial LPS without serial imaging in idiopathic intracranial hypertension: a lesson learned. Headache; 2008 Apr;48(4):630-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • With obscure etiology, confusing terminology, and controversial management, idiopathic intracranial hypertension (IIH), most commonly known as benign intracranial hypertension, remains a common and challenging clinical problem of the general and neurological practice.
  • The authors present a case of a patient who was diagnosed with IIH and treated with serial lumbar punctures for 4 years prior to her final diagnosis of a large intracranial tumor.
  • [MeSH-major] Brain Neoplasms / diagnosis. Ependymoma / diagnosis. Medical Errors. Pseudotumor Cerebri / pathology. Spinal Puncture
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Intracranial Hypertension.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18298581.001).
  • [ISSN] 0017-8748
  • [Journal-full-title] Headache
  • [ISO-abbreviation] Headache
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


44. Nakaya K, Niranjan A, Kondziolka D, Kano H, Khan AA, Nettel B, Koebbe C, Pirris S, Flickinger JC, Lunsford LD: Gamma knife radiosurgery for benign tumors with symptoms from brainstem compression. Int J Radiat Oncol Biol Phys; 2010 Jul 15;77(4):988-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gamma knife radiosurgery for benign tumors with symptoms from brainstem compression.
  • PURPOSE: This study evaluated the role of radiosurgery in the management of symptomatic patients with brainstem compression from benign basal tumors.
  • METHODS AND MATERIALS: Over a 17-year, period 246 patients (202 vestibular schwannomas and 44 meningiomas) with brainstem compression from benign skull-base tumors were managed with Gamma Knife radiosurgery.
  • Median tumor volumes were 3.9 cm(3) (range, 0.8-39.0 mL) and 6.6 mL (range, 1.6-25.1 mL) for vestibular schwannomas and meningiomas, respectively.
  • Patients were categorized into four groups on the basis of the tumor-brainstem relationship on neuroimaging.
  • The tumor control rate was 100 % for meningioma and 97% for vestibular schwannomas (although 5% required an additional procedure such as a ventriculoperitoneal shunt).
  • Balance improved significantly in patients who had less tumor compression (p = 0.0357) after radiosurgery.
  • CONCLUSION: Radiosurgery is a minimally invasive option for patients with benign basal tumors that indent or distort the brainstem.
  • A high tumor growth control rate and satisfactory rate of neurological preservation and symptom control can be obtained with radiosurgery.
  • [MeSH-major] Brain Stem. Meningeal Neoplasms / surgery. Meningioma / surgery. Neuroma, Acoustic / surgery. Radiosurgery / methods. Skull Base Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Analysis of Variance. Constriction, Pathologic / surgery. Female. Humans. Male. Middle Aged. Statistics, Nonparametric. Young Adult

  • MedlinePlus Health Information. consumer health - Acoustic Neuroma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20381265.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


45. Zhang QF, Liu DL, Yang ZQ: [Surgical treatment of tumors in anterior and middle skull base by modified maxillary bone disassembly procedures]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2006 Nov;41(11):840-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Ten tumors in the anterior and middle skull base were resected according to the pathology, size and site of the skull base tumors including 9 benign tumors and 1 malignant tumor.
  • The patients with benign tumors showed no recurrence .
  • One patient with melanoma died of brain metastase.
  • According to the location of the tumor, the modified maxillary bone disassembly is the nearest and harmless approach, through which the tumors can be completely excised with minimal invasiveness.
  • [MeSH-major] Maxilla / surgery. Skull Base Neoplasms / surgery. Surgery, Oral / methods
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17283538.001).
  • [ISSN] 1673-0860
  • [Journal-full-title] Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


46. Laxton AW, Shannon P, Nag S, Farb RI, Bernstein M: Rapid expansion of a previously asymptomatic subependymoma. Case report. J Neurosurg; 2005 Dec;103(6):1084-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One month after his initial presentation, he was admitted to the hospital with significant tumor expansion and clinical deterioration.
  • Histopathological analysis of this tumor showed central necrosis with associated edema in an otherwise typical and benign-appearing subependymoma.
  • [MeSH-major] Cerebral Ventricle Neoplasms / diagnosis. Glioma, Subependymal / diagnosis. Magnetic Resonance Imaging
  • [MeSH-minor] Adult. Brain Edema / etiology. Cranial Fossa, Posterior. Craniotomy. Disease Progression. Headache / etiology. Humans. Male. Necrosis. Time Factors

  • Genetic Alliance. consumer health - Subependymoma.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16381197.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


47. Chen CL, Shen CC, Wang J, Lu CH, Lee HT: Central neurocytoma: a clinical, radiological and pathological study of nine cases. Clin Neurol Neurosurg; 2008 Feb;110(2):129-36
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Central neurocytoma is a rare intraventricular brain tumor that affects young adults and presents with increased intracranial pressure secondary to obstructive hydrocephalus.
  • Most patients received craniotomy with removal of the tumor through transcallosal or transcortical approach.
  • CONCLUSION: Although central neurocytoma is generally a benign neoplasm, some variant forms of recurrence are also present.
  • Histologic features such as tumor proliferation (MIB-1 labeling index), vascular proliferation, and synaptophysin expression are often prominent in the recurrent tumor.
  • We recommend that these histologic features be considered for tumor recurrence during treatment and follow-up of these patients.

  • Genetic Alliance. consumer health - Central Neurocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2000 Jan 1;88(1):169-74 [10618620.001]
  • [Cites] J Neurosurg. 2007 Jul;107(1):7-12 [17639866.001]
  • [Cites] Cancer. 2000 Sep 1;89(5):1111-20 [10964342.001]
  • [Cites] Surg Neurol. 2001 Feb;55(2):74-8 [11301084.001]
  • [Cites] J Neurosurg. 2001 Nov;95(5):879-82 [11702880.001]
  • [Cites] Neurosurgery. 2002 Jun;50(6):1365-7 [12015858.001]
  • [Cites] Br J Neurosurg. 2002 Apr;16(2):126-32 [12046730.001]
  • [Cites] Neurology. 2002 Oct 22;59(8):1268-70 [12391364.001]
  • [Cites] J Magn Reson Imaging. 2003 Feb;17(2):256-60 [12541233.001]
  • [Cites] J Neurooncol. 2003 Feb;61(3):255-9 [12675319.001]
  • [Cites] Surg Neurol. 2003 Dec;60(6):560-5 [14670681.001]
  • [Cites] J Neurooncol. 2004 Feb;66(3):377-84 [15015671.001]
  • [Cites] Acta Neuropathol. 1982;56(2):151-6 [7064664.001]
  • [Cites] Acta Neuropathol. 1990;79(5):473-9 [2109481.001]
  • [Cites] J Neurooncol. 1990 Dec;9(3):231-8 [2086738.001]
  • [Cites] Lab Invest. 1991 Apr;64(4):585-91 [1901927.001]
  • [Cites] Neuroradiology. 1991;33(2):143-8 [2046899.001]
  • [Cites] J Neurosurg. 1992 Jan;76(1):32-7 [1727166.001]
  • [Cites] Radiology. 1992 Mar;182(3):787-92 [1535895.001]
  • [Cites] Cancer. 1993 Aug 15;72(4):1350-5 [8339224.001]
  • [Cites] Acta Radiol. 1993 Sep;34(5):520-6 [8369193.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):297-306 [8293189.001]
  • [Cites] Surg Neurol. 1994 Oct;42(4):335-9 [7974132.001]
  • [Cites] Clin Neurol Neurosurg. 1995 Aug;97(3):219-28 [7586853.001]
  • [Cites] Surg Neurol. 1996 Jan;45(1):49-56 [9190699.001]
  • [Cites] J Neurosurg. 1996 May;84(5):742-7 [8622146.001]
  • [Cites] Cancer. 1997 Feb 15;79(4):790-5 [9024717.001]
  • [Cites] J Neurosurg. 1997 Mar;86(3):547-52 [9046315.001]
  • [Cites] J Neuropathol Exp Neurol. 1997 May;56(5):551-6 [9143268.001]
  • [Cites] Cancer. 1997 May 15;79(10):1995-2002 [9149028.001]
  • [Cites] J Neurooncol. 1997 Sep;34(3):279-83 [9258819.001]
  • [Cites] Surg Neurol. 1998 Feb;49(2):197-204 [9457271.001]
  • [Cites] Pathol Oncol Res. 1999;5(2):155-9 [10393370.001]
  • [Cites] J Neurosurg. 1999 Sep;91(3):506-9 [10470830.001]
  • [Cites] J Neurooncol. 2005 Jan;71(1):53-9 [15719276.001]
  • [Cites] Neurosurg Rev. 2005 Apr;28(2):96-103 [15580370.001]
  • [Cites] J Comput Assist Tomogr. 2005 Sep-Oct;29(5):683-8 [16163043.001]
  • [Cites] Strahlenther Onkol. 2006 Jul;182(7):415-8 [16826361.001]
  • [Cites] Neurosurg Rev. 2006 Oct;29(4):286-92; discussion 292 [16604374.001]
  • [Cites] Neurosurg Rev. 2006 Oct;29(4):270-85; discussion 285 [16941163.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):1145-54 [17187939.001]
  • [Cites] Neuroradiology. 2007 Jul;49(7):551-4 [17364196.001]
  • [Cites] Neurosurgery. 2000 Feb;46(2):329-33; discussion 333-4 [10690721.001]
  • (PMID = 18022760.001).
  • [ISSN] 0303-8467
  • [Journal-full-title] Clinical neurology and neurosurgery
  • [ISO-abbreviation] Clin Neurol Neurosurg
  • [Language] ENG
  • [Grant] United States / NINDS NIH HHS / NS / R01 NS039918-03; United States / NINDS NIH HHS / NS / R01 NS039918-02; United States / NINDS NIH HHS / NS / NS039918-02; United States / NINDS NIH HHS / NS / R01 NS039918-01; United States / NINDS NIH HHS / NS / NS039918-03; United States / NINDS NIH HHS / NS / NS039918-01
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ NIHMS39918; NLM/ PMC2702989
  •  go-up   go-down


48. Chen G, Liu XY, Wang Z, Liu FY: Vascular endothelial growth factor C: the predicator of early recurrence in patients with N2 non-small-cell lung cancer. Eur J Cardiothorac Surg; 2010 Mar;37(3):546-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Cancer tissue samples from 92 patients with pN2 non-small-cell lung cancer and benign lung disease tissues samples from 30 patients were examined by reverse transcription polymerase chain reaction (RT-PCR) and immunohistochemistry assays to detect VEGF-C expression.
  • RESULTS: VEGF-C mRNA expression was observed in 64 (70%) pN2 lung cancer tissues, but was not found in benign lung disease tissues.
  • The main pattern was distant recurrence, and the most frequent sites were the brain and lung.
  • About one-half of the patients with N2 non-small-cell lung cancer would develop recurrence disease within 1 year after surgery, frequently with mediastinal nodes, brain or lung metastases.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Carcinoma, Non-Small-Cell Lung / metabolism. Lung Neoplasms / metabolism. Vascular Endothelial Growth Factor C / biosynthesis
  • [MeSH-minor] Adult. Aged. Brain Neoplasms / secondary. Chemotherapy, Adjuvant. Epidemiologic Methods. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local. Prognosis. RNA, Messenger / genetics. RNA, Neoplasm / genetics. Radiotherapy, Adjuvant. Reverse Transcriptase Polymerase Chain Reaction / methods

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
  • (PMID = 19758816.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 0 / VEGFC protein, human; 0 / Vascular Endothelial Growth Factor C
  •  go-up   go-down


49. Altundag MB, Ertas G, Ucer AR, Durmus S, Abanuz H, Calikoğlu T, Ozbagi K, Demirkasimoglu A, Kaya B, Bakkal BH, Altundag K: Brain metastasis of cardiac myxoma: case report and review of the literature. J Neurooncol; 2005 Nov;75(2):181-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain metastasis of cardiac myxoma: case report and review of the literature.
  • Cardiac myxoma is the most common benign heart tumor.
  • Recurrence has been related to incomplete excision, multifocality, and embolism of tumor fragments.
  • We report a case with multiple brain metastases presumably due to tumor embolization from previously operated cardiac myxoma.
  • [MeSH-major] Brain Neoplasms / secondary. Heart Neoplasms / pathology. Myxoma / pathology
  • [MeSH-minor] Adult. Cerebellum / pathology. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Telencephalon / pathology. Time Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chest. 2003 May;123(5):1379-85 [12740251.001]
  • [Cites] Surg Neurol. 1979 Jun;11(6):461-9 [483155.001]
  • [Cites] Chest. 1995 Mar;107(3):674-9 [7874936.001]
  • [Cites] Int J Cardiol. 2004 Apr;94(2-3):325-6 [15094003.001]
  • [Cites] Radiographics. 2002 May-Jun;22(3):673-89 [12006696.001]
  • [Cites] Am J Surg Pathol. 1980 Aug;4(4):391-9 [7425205.001]
  • [Cites] J Thorac Cardiovasc Surg. 1986 Mar;91(3):389-96 [3951243.001]
  • [Cites] N Engl J Med. 1995 Dec 14;333(24):1610-7 [7477198.001]
  • [Cites] J Thorac Cardiovasc Surg. 1985 Feb;89(2):298-303 [3968914.001]
  • [Cites] Int J Cardiol. 2004 Sep;96(3):471-3 [15301902.001]
  • [Cites] Neuroradiology. 1987;29(2):218 [3587605.001]
  • [Cites] Am Heart J. 2000 Jul;140(1):134-8 [10874274.001]
  • [Cites] Ann Thorac Surg. 1998 Nov;66(5):1791-2 [9875791.001]
  • [Cites] Am J Cardiol. 2002 Sep 1;90(5):563-5 [12208428.001]
  • [Cites] J Clin Endocrinol Metab. 2001 Sep;86(9):4041-6 [11549623.001]
  • [Cites] Cardiology. 1991;78(1):72-7 [2021969.001]
  • [Cites] Chest. 1978 Oct;74(4):451-2 [699660.001]
  • [Cites] Heart. 2001 Feb;85(2):218-22 [11156679.001]
  • [Cites] Thorac Cardiovasc Surg. 2004 Oct;52(5):302-4 [15470613.001]
  • [Cites] Circ J. 2004 Dec;68(12):1230-2 [15564714.001]
  • [Cites] Neurochirurgie. 1987;33(6):487-9 [3444488.001]
  • [Cites] Am J Cardiol. 1968 Mar;21(3):315-27 [5688975.001]
  • [Cites] Tex Heart Inst J. 2001;28(1):3-7 [11330738.001]
  • [Cites] Am J Surg Pathol. 1994 Jan;18(1):107-11 [8279623.001]
  • [Cites] Am J Clin Pathol. 1993 Dec;100(6):671-80 [8249916.001]
  • [Cites] J Formos Med Assoc. 2001 Jan;100(1):63-5 [11265265.001]
  • [Cites] Am Heart J. 1986 Feb;111(2):409-13 [3946183.001]
  • [Cites] J Neurosurg. 1990 Feb;72 (2):295-8 [2404090.001]
  • [Cites] Am J Med Genet. 1998 Nov 2;80(2):183-5 [9805140.001]
  • [Cites] Br Heart J. 1992 Jan;67(1):89-91 [1531423.001]
  • [Cites] Int J Cardiol. 1994 Jun 15;45(2):144-6 [7960255.001]
  • [Cites] Arch Neurol. 1970 Dec;23(6):558-67 [5478277.001]
  • [Cites] Am Heart J. 1990 Mar;119(3 Pt 1):679-80 [2309613.001]
  • [Cites] Arch Pathol Lab Med. 1988 Feb;112(2):185-90 [3122705.001]
  • [Cites] Eur J Cardiothorac Surg. 2002 Dec;22(6):971-7 [12467822.001]
  • [Cites] Surg Neurol. 1992 May;37(5):374-9 [1631764.001]
  • (PMID = 16132507.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 38
  •  go-up   go-down


50. Vender JR, Laird MD, Dhandapani KM: Inhibition of NFkappaB reduces cellular viability in GH3 pituitary adenoma cells. Neurosurgery; 2008 May;62(5):1122-7; discussion 1027-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: Adenomas of the pituitary gland are among the most common types of tumors of the adult brain.
  • Although adenomas are histologically benign, they may be associated with significant morbidity and mortality, mostly because of their invasive growth pattern and hormone hypersecretion.
  • We investigated the possible role of the NFkappaB transcription factor in pituitary tumor cell growth.
  • Cells were treated with mechanistically diverse pharmacological NFkappaB pathway inhibitors or with molecular inhibitors that were overexpressed in tumor cells before the assessment of cellular viability.
  • Treatment with wedelolactone, an IkappaB kinase inhibitor, or overexpression of an IkappaB super-repressor reduced cell viability, further implicating NFkappaB in pituitary tumor cell growth.
  • [MeSH-major] NF-kappa B / metabolism. Pituitary Neoplasms / metabolism. Signal Transduction / physiology
  • [MeSH-minor] Animals. Cell Line, Tumor. Cell Proliferation / drug effects. Cell Survival / drug effects. Coumarins / pharmacology. Enzyme Inhibitors / pharmacology. Proto-Oncogene Proteins c-akt. Rats

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580810.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Coumarins; 0 / Enzyme Inhibitors; 0 / NF-kappa B; 524-12-9 / wedelolactone; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  •  go-up   go-down


51. Ketter R, Rahnenführer J, Henn W, Kim YJ, Feiden W, Steudel WI, Zang KD, Urbschat S: Correspondence of tumor localization with tumor recurrence and cytogenetic progression in meningiomas. Neurosurgery; 2008 Jan;62(1):61-9; discussion 69-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correspondence of tumor localization with tumor recurrence and cytogenetic progression in meningiomas.
  • OBJECTIVE: Meningiomas are mostly benign tumors that originate from the coverings of the brain and spinal cord.
  • METHODS: Statistical analyses were performed for the karyotypes of 661 meningiomas with respect to localization, progression, and recurrence of the tumor.
  • A mathematical mixture model estimates typical pathogenetic routes in terms of the accumulation of somatic chromosome changes in tumor cells.
  • The model generates a genetic progression score (GPS) that estimates the prognosis as related to the cytogenetic properties of a given tumor.
  • This corresponds to a total rate of recurrence of 8.0% after macroscopically complete tumor extirpation.
  • Higher GPS values were shown to be strongly correlated with tumor recurrence (P = 2.9 x 10(-7)).
  • High-risk tumors, both in terms of histology and cytogenetics, are localized much more frequently at the brain surface than at the cranial base (P = 1.2 x 10(-5) for World Health Organization grade and P = 3.3 x 10(-12) for GPS categorization).
  • [MeSH-major] Chromosome Aberrations. Meningeal Neoplasms / genetics. Meningeal Neoplasms / pathology. Meningioma / genetics. Meningioma / pathology
  • [MeSH-minor] Adult. Aged. Cytogenetics. Disease Progression. Female. Follow-Up Studies. Humans. Karyotyping. Male. Middle Aged. Models, Theoretical. Neoplasm Recurrence, Local. Proportional Hazards Models. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Neurosurgery. 2009 Jun;64(6):E1206; author reply E1206 [19487876.001]
  • (PMID = 18300892.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


52. Novak L, Molnar P, Lengyel Z, Tron L: Does increased 18FDG uptake reflect malignant transformation of a low-grade glioma? A diagnostic dilemma. Neurol India; 2005 Mar;53(1):112-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Benign gliomas of the brain show decreased uptake of 18F fluorodeoxyglucose (FDG) on positron emission tomography (PET).
  • In 1996, increased epileptic activity was accompanied by increased 18FDG uptake within the temporal part of the tumor.
  • Histological examination of the resected tumor showed no change in the pathology when compared with the first biopsy.
  • [MeSH-major] Brain Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Glioma / radionuclide imaging. Positron-Emission Tomography
  • [MeSH-minor] Adult. Disease Progression. Female. Humans. Severity of Illness Index

  • Genetic Alliance. consumer health - Glioma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15805670.001).
  • [ISSN] 0028-3886
  • [Journal-full-title] Neurology India
  • [ISO-abbreviation] Neurol India
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] India
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


53. Langevin CJ, Hanasono MM, Riina HA, Stieg PE, Spinelli HM: Lateral transzygomatic approach to sphenoid wing meningiomas. Neurosurgery; 2010 Dec;67(2 Suppl Operative):377-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Sphenoid wing meningiomas are slow-growing, well-circumscribed, and histologically benign lesions.
  • To achieve maximal exposure and minimal brain retraction, a lateral transzygomatic approach with osteotomies of the entire zygoma, which remains pedicled on the masseter muscle, was used.
  • CONCLUSION: The lateral transzygomatic approach to the sphenoid wing can be performed safely with minimal morbidity and facilitates complete resection of the tumor.
  • This approach belongs in the armamentarium of surgeons who are involved in the resection of skull base neoplasms.
  • [MeSH-major] Craniotomy / methods. Meningeal Neoplasms / surgery. Meningioma / surgery. Neurosurgical Procedures / methods. Skull / surgery. Zygoma / surgery
  • [MeSH-minor] Adult. Aged. Dissection / methods. Female. Humans. Male. Middle Aged. Prognosis. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21099561.001).
  • [ISSN] 1524-4040
  • [Journal-full-title] Neurosurgery
  • [ISO-abbreviation] Neurosurgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


54. Utermark T, Kaempchen K, Antoniadis G, Hanemann CO: Reduced apoptosis rates in human schwannomas. Brain Pathol; 2005 Jan;15(1):17-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Schwannomas, tumors originating from Schwann cells, represent a frequent neurological tumor and can occur both in a genetic disorder called neurofibromatosis type 2 (NF2) and sporadically.
  • In both cases the genetic background is identical as all schwannomas are caused by biallelic mutations in the tumor suppressor gene NF2 coding for merlin.
  • Here, we report in vivo and in vitro evidence that the basal apoptosis rate of primary human schwannoma cells is reduced in comparison to that of normal Schwann cells, supporting the idea that in this benign tumor type, apoptosis has a role in tumorigenesis.
  • [MeSH-minor] Adult. Cell Survival / physiology. Cells, Cultured. Humans. Immunohistochemistry. In Situ Nick-End Labeling. Middle Aged

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15779232.001).
  • [ISSN] 1015-6305
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


55. Budrukkar A, Jalali R, Dutta D, Sarin R, Devlekar R, Parab S, Kakde A: Prospective assessment of quality of life in adult patients with primary brain tumors in routine neurooncology practice. J Neurooncol; 2009 Dec;95(3):413-419
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prospective assessment of quality of life in adult patients with primary brain tumors in routine neurooncology practice.
  • The aim of this article is to evaluate and assess the impact of various factors on quality of life (QOL) in adult patients with primary brain tumors seen consecutively in routine neurooncology practice.
  • Two hundred and fifty-seven adult patients, after undergoing surgical intervention and histologically proven primary brain neoplasms were registered in the NeuroOncology Clinic at our centre during 1 full calendar year.
  • The study included detailed neurological assessment, evaluation of QOL using EORTC questionnaire (QLQ-30) and specific Brain Cancer module (BN 20).
  • In the present analysis, QOL scores before starting adjuvant treatment were measured and impact of patient and tumor related factors were analyzed.
  • Baseline global QOL data of all patients (available in 243) was relatively low including in all histological tumor types.
  • Patients with lower performance status (KPS < 70) had a lower global QOL (KPS >or= 80 vs. <or= 70; 37 vs. 67; p = 0.001) including in all histological types of high-grade gliomas (HGG) (p = 0.005), low-grade gliomas (LGG) (p = 0.04) and benign tumors (p = <0.001).
  • Tumor type is an important patient related factor that influences baseline global scores (LGG vs. HGG 62 and 52; p = 0.015).
  • Type of surgery (biopsy/complete excision) (p = 0.284) and site of tumor (p = 0.309) did not show any impact on QOL score.
  • Patients with primary brain tumours before starting adjuvant therapy have relatively low baseline quality of life scores, especially in lower economic and literacy strata.
  • [MeSH-major] Brain Neoplasms / physiopathology. Brain Neoplasms / therapy. Glioma / physiopathology. Glioma / therapy. Outpatient Clinics, Hospital. Quality of Life
  • [MeSH-minor] Adenoma / physiopathology. Adenoma / therapy. Adolescent. Adult. Educational Status. Female. Health Status. Humans. India. Karnofsky Performance Status. Male. Meningeal Neoplasms / physiopathology. Meningeal Neoplasms / therapy. Middle Aged. Pituitary Neoplasms / physiopathology. Pituitary Neoplasms / therapy. Prospective Studies. Surveys and Questionnaires. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Cancer. 2002 Sep;38(14):1824-31 [12204663.001]
  • [Cites] Lancet. 2002 Nov 2;360(9343):1361-8 [12423981.001]
  • [Cites] Qual Life Res. 1996 Feb;5(1):139-50 [8901377.001]
  • [Cites] J Neurooncol. 2009 Aug;94(1):103-10 [19255726.001]
  • [Cites] Lancet Oncol. 2005 Dec;6(12 ):937-44 [16321761.001]
  • [Cites] J Neurooncol. 2008 Mar;87(1):111-4 [18004503.001]
  • [Cites] Neuro Oncol. 2000 Oct;2(4):221-8 [11265231.001]
  • [Cites] J Neurooncol. 2006 Feb;76(3):283-91 [16163448.001]
  • [Cites] J Natl Cancer Inst. 1993 Mar 3;85(5):365-76 [8433390.001]
  • [Cites] J Cancer Res Ther. 2006 Oct-Dec;2(4):166-70 [17998699.001]
  • [Cites] J Clin Oncol. 1998 Jan;16(1):139-44 [9440735.001]
  • [Cites] J Neurooncol. 2008 Dec;90(3):321-8 [18704269.001]
  • [Cites] BMC Cancer. 2007 Jan 25;7:18 [17254350.001]
  • (PMID = 19548070.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


56. Nagesh V, Tsien CI, Chenevert TL, Ross BD, Lawrence TS, Junick L, Cao Y: Radiation-induced changes in normal-appearing white matter in patients with cerebral tumors: a diffusion tensor imaging study. Int J Radiat Oncol Biol Phys; 2008 Mar 15;70(4):1002-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To quantify the radiation-induced changes in normal-appearing white matter before, during, and after radiotherapy (RT) in cerebral tumor patients.
  • METHODS AND MATERIALS: Twenty-five patients with low-grade glioma, high-grade glioma, or benign tumor treated with RT were studied using diffusion tensor magnetic resonance imaging.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2005 Aug;236(2):647-52 [16040920.001]
  • [Cites] J Head Trauma Rehabil. 2003 Jul-Aug;18(4):307-16 [16222127.001]
  • [Cites] Magn Reson Med. 2006 Feb;55(2):302-8 [16408263.001]
  • [Cites] J Neurosci Res. 2006 Feb 15;83(3):392-402 [16397901.001]
  • [Cites] J Clin Oncol. 2006 Feb 20;24(6):884-90 [16484697.001]
  • [Cites] Ment Retard Dev Disabil Res Rev. 2006;12(3):174-83 [17061283.001]
  • [Cites] Eur J Neurol. 2007 May;14(5):540-7 [17437614.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):144-50 [17306935.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 1;46(1):51-5 [10656372.001]
  • [Cites] Neuropsychiatry Neuropsychol Behav Neurol. 2000 Apr;13(2):101-11 [10780628.001]
  • [Cites] Radiat Res. 2000 Apr;153(4):357-70 [10798963.001]
  • [Cites] Magn Reson Med. 2000 Aug;44(2):259-68 [10918325.001]
  • [Cites] J Med Primatol. 2001 Apr;30(2):81-7 [11491408.001]
  • [Cites] Arch Phys Med Rehabil. 2001 Oct;82(10):1461-71 [11588754.001]
  • [Cites] Radiology. 2001 Nov;221(2):349-58 [11687675.001]
  • [Cites] Radiother Oncol. 2002 Apr;63(1):107-20 [12065111.001]
  • [Cites] Neuroimage. 2002 Nov;17(3):1429-36 [12414282.001]
  • [Cites] Neuroimage. 2003 Nov;20(3):1714-22 [14642481.001]
  • [Cites] Acta Neuropathol. 1968 Nov 1;11(4):267-74 [5710040.001]
  • [Cites] Cancer. 1979 Oct;44(4):1256-72 [387205.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1980 Sep;6(9):1215-28 [7007303.001]
  • [Cites] Cancer. 1984 Nov 1;54(9):1966-72 [6478431.001]
  • [Cites] Cancer. 1986 Aug 1;58(3):635-40 [3731021.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Aug;15(2):319-30 [2841263.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Dec;15(6):1371-81 [2461919.001]
  • [Cites] Br J Radiol. 1988 Nov;61(731):1043-52 [3208008.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Jan;18(1):37-42 [2298633.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Apr;20(4):689-96 [2004945.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(5):1089-91; discussion 1093-4 [1639645.001]
  • [Cites] Radiother Oncol. 1993 Oct;29(1):60-8 [8295989.001]
  • [Cites] Cancer. 1994 Nov 15;74(10):2828-35 [7954244.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1093-112 [7677836.001]
  • [Cites] Brain Res. 1995 Feb 6;671(1):141-8 [7728526.001]
  • [Cites] AJNR Am J Neuroradiol. 1991 Jan;12(1):45-62 [7502957.001]
  • [Cites] Radiology. 1996 Dec;201(3):637-48 [8939209.001]
  • [Cites] Magn Reson Med. 1996 Dec;36(6):893-906 [8946355.001]
  • [Cites] Magn Reson Med. 1998 Jun;39(6):928-34 [9621916.001]
  • [Cites] J Neurol. 1998 Nov;245(11):695-708 [9808237.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1999 Apr;66(4):480-4 [10201420.001]
  • [Cites] Brookhaven Symp Biol. 1961 Nov;14:176-99 [14010110.001]
  • [Cites] J Neurol Sci. 2005 Mar 15;229-230:195-200 [15760639.001]
  • [Cites] Neuroimage. 2005 May 15;26(1):132-40 [15862213.001]
  • (PMID = 18313524.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA113699-02; United States / NCI NIH HHS / CA / R21 CA113699; United States / NCI NIH HHS / CA / R21 CA113699-02; United States / NCI NIH HHS / CA / P01 CA059827; United States / NCI NIH HHS / CA / 3P01 CA59827; United States / NCI NIH HHS / CA / CA059827-06A1; United States / NCI NIH HHS / CA / P01 CA085878-01A2; United States / NCI NIH HHS / CA / P02 CA85878; United States / NCI NIH HHS / CA / P01 CA059827-06A1; United States / NCI NIH HHS / CA / P01 CA085878; United States / NCI NIH HHS / CA / R21 CA11369901
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS42273; NLM/ PMC2376211
  •  go-up   go-down


57. Yu T, Zeng C, Zhao JZ: [Intracranial subependymoma: clinical features and surgical management of 22 cases]. Zhonghua Yi Xue Za Zhi; 2010 Mar 23;90(11):756-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • One tumor was located in temporal lobe, mesencephalon, thalamus and pons.
  • CONCLUSION: Intracranial subependymoma is a rare benign tumor.
  • The prognosis is excellent and there is a rare tumor recurrence.
  • [MeSH-major] Brain Neoplasms. Glioma, Subependymal
  • [MeSH-minor] Adolescent. Adult. Child. Female. Humans. Male. Microsurgery. Middle Aged. Young Adult


58. Fukaya R, Yoshida K, Ohira T, Kawase T: Trigeminal schwannomas: experience with 57 cases and a review of the literature. Neurosurg Rev; 2010 Apr;34(2):159-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Trigeminal schwannoma is a mostly benign tumor that can be cured by complete resection.
  • Since 1990, all such patients have been treated using three main types of middle fossa skull base approaches, which minimize the exposure of the brain: the anterior transpetrosal approach, subtemporal interdural approach (Dolenc), or a combination of these approaches.
  • Before 1990, total tumor removal was achieved in only three of eight patients (38%).
  • However, total surgical removal after surgery and Gamma knife surgery was very difficult because of dense adhesions to the brain stem and cranial nerves.
  • A correct anatomical knowledge is critical for minimizing brain exposure and avoiding surgical complications.
  • [MeSH-major] Cranial Nerve Neoplasms / surgery. Neurilemmoma / surgery. Trigeminal Nerve Diseases / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Cranial Fossa, Middle / surgery. Dura Mater / surgery. Female. Follow-Up Studies. Humans. Karnofsky Performance Status. Male. Middle Aged. Neoplasm Recurrence, Local. Neurosurgical Procedures / methods. Radiosurgery. Retrospective Studies. Skull Base / surgery. Temporal Bone / surgery. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Neurochir (Wien). 1986;82(3-4):118-22 [3491493.001]
  • [Cites] Acta Neurochir (Wien). 1994;130(1-4):55-65 [7725943.001]
  • [Cites] Acta Neurochir (Wien). 1996;138(9):1027-35 [8911538.001]
  • [Cites] J Neurosurg. 1995 May;82(5):719-25 [7714595.001]
  • [Cites] Chin Med J (Engl). 2005 Mar 5;118(5):436-40 [15780219.001]
  • [Cites] Surg Neurol. 2007 Dec;68(6):594-602 [18053854.001]
  • [Cites] J Neurosurg. 1988 Dec;69(6):850-60 [3057125.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):801-6 [12788188.001]
  • [Cites] J Neurosurg. 1999 Jul;91(1):44-50 [10389879.001]
  • [Cites] Neurosurg Focus. 2008;25(6):E6; discussion E6 [19035703.001]
  • [Cites] J Neurosurg. 2007 May;106(5):839-45 [17542528.001]
  • [Cites] Neurosurgery. 2003 Apr;52(4):783-90; discussion 790 [12657173.001]
  • [Cites] J Neurosurg. 2007 Jan;106(1):18-23 [17236483.001]
  • [Cites] J Neurosurg. 1989 Oct;71(4):506-11 [2795170.001]
  • [Cites] Neurol Med Chir (Tokyo). 2005 Oct;45(10):526-9 [16247239.001]
  • [Cites] Clin Neurosurg. 1953;1:11-54 [14379464.001]
  • [Cites] Neurosurgery. 2006 Oct;59(4 Suppl 2):ONS270-7; discussion ONS277-8 [17041497.001]
  • [Cites] J Neurosurg. 2007 Oct;107(4):752-7 [17937219.001]
  • [Cites] Acta Neurochir (Wien). 1999;141(7):711-9 [10481782.001]
  • [Cites] Neurosurg Rev. 2007 Oct;30(4):329-37; discussion 337 [17676346.001]
  • [Cites] Acta Neurochir (Wien). 1994;129(3-4):113-20 [7847150.001]
  • [Cites] Surg Neurol. 2004 Nov;62(5):435-44; discussion 444-6 [15518853.001]
  • [Cites] Am J Otolaryngol. 1984 Sep-Oct;5(5):301-33 [6437262.001]
  • [Cites] J Neurosurg. 1989 May;70(5):737-45 [2709114.001]
  • [Cites] Surg Neurol. 1988 Dec;30(6):452-6 [3222724.001]
  • [Cites] Pediatr Neurosci. 1987;13(4):198-201 [3331430.001]
  • [Cites] J Neurosurg Sci. 1995 Sep;39(3):165-70 [8965124.001]
  • [Cites] Neurosurgery. 2003 Oct;53(4):815-21; discussion 821-2 [14519213.001]
  • [Cites] J Neurosurg. 1999 Aug;91(2):202-11 [10433308.001]
  • [Cites] Br J Neurosurg. 1988;2(1):67-71 [3268164.001]
  • [Cites] Surg Neurol. 1975 Dec;4(6):497-503 [1188585.001]
  • [Cites] Surg Neurol. 1983 Apr;19(4):351-3 [6836494.001]
  • [Cites] Neurosurgery. 1998 Feb;42(2):233-40; discussion 240-1 [9482173.001]
  • [Cites] J Clin Neurosci. 2008 Jul;15(7):738-43 [18396403.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Mar 15;52(4):1002-7 [11958895.001]
  • [Cites] Neurosurgery. 1991 Jun;28(6):869-75; discussion 875-6 [2067611.001]
  • [Cites] J Neurosurg. 2009 Mar;110(3):553-8 [19301456.001]
  • [Cites] J Neurosurg. 2002 Mar;96(3):453-63 [11883829.001]
  • [Cites] J Neurosurg. 2007 Oct;107(4):727-32 [17937215.001]
  • [Cites] J Neurosurg. 1995 May;82(5):711-8 [7714594.001]
  • [Cites] Neurosurgery. 1996 Sep;39(3):527-34; discussion 534-6 [8875483.001]
  • [Cites] J Neurosurg. 2005 Jan;102(s_supplement):220-224 [28306474.001]
  • [Cites] Acta Neurochir (Wien). 2007 Nov;149(11):1133-7; discussion 1137 [17728994.001]
  • [Cites] Acta Neurochir Suppl. 2004;91:89-102 [15707030.001]
  • (PMID = 20963463.001).
  • [ISSN] 1437-2320
  • [Journal-full-title] Neurosurgical review
  • [ISO-abbreviation] Neurosurg Rev
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


59. Zheng X, Liu W, Yang X, Gong J, Shen F, Shen G, Shen H, Zheng X, Fu W: Endoscope-assisted supraorbital keyhole approach for the resection of benign tumors of the sellar region. Minim Invasive Ther Allied Technol; 2007;16(6):363-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscope-assisted supraorbital keyhole approach for the resection of benign tumors of the sellar region.
  • The objective of the study was to evaluate the effectiveness of the supraorbital "keyhole" approach with endoscope assistance in surgical treatment of benign tumors around the sellar region.
  • There was no patient with evidence of residual or recurrent tumor during the follow-up period.
  • The supraorbital "keyhole" approach with endoscopic assistance in the surgical treatment of benign tumors around the sellar region is an ideal pattern.
  • [MeSH-major] Endoscopy. Neoplasms / surgery. Pituitary Neoplasms / surgery. Treatment Outcome
  • [MeSH-minor] Adolescent. Adult. Aged. Brain Neoplasms / surgery. Female. Humans. Length of Stay. Male. Middle Aged. Prospective Studies

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17852733.001).
  • [ISSN] 1364-5706
  • [Journal-full-title] Minimally invasive therapy & allied technologies : MITAT : official journal of the Society for Minimally Invasive Therapy
  • [ISO-abbreviation] Minim Invasive Ther Allied Technol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


60. Fassett DR, Pingree J, Kestle JR: The high incidence of tumor dissemination in myxopapillary ependymoma in pediatric patients. Report of five cases and review of the literature. J Neurosurg; 2005 Jan;102(1 Suppl):59-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The high incidence of tumor dissemination in myxopapillary ependymoma in pediatric patients. Report of five cases and review of the literature.
  • Myxopapillary ependymomas (MPEs) have historically been thought to be benign tumors occurring most frequently in adults.
  • Only 8 to 20% of these tumors occur in the first two decades of life, making this tumor a rarity in pediatric neurosurgery.
  • Four (80%) of these five patients suffered from disseminated disease of the central nervous system (CNS) at the time of presentation; this incidence is much higher than that reported in the combined adult and pediatric literature.
  • In those cases in which patients underwent screening for CNS tumor dissemination, however, the incidence of disseminated disease was 58% (seven of 12 patients).
  • In pediatric patients MPEs may spread throughout the CNS via cerebrospinal fluid pathways; therefore, MR imaging of the entire CNS axis is recommended at both presentation and follow-up review to detect tumor dissemination.
  • [MeSH-major] Brain Neoplasms / secondary. Ependymoma / pathology. Ependymoma / secondary. Neoplasm Metastasis. Spinal Cord Neoplasms / pathology


61. Abe T, Inoue R, Isono M, Ishii K, Fujiki M, Kamida T, Kobayashi H, Kashima K, Kusakabe T, Nakazato Y: Benign pleomorphic astrocytoma in the hypothalamus--case report. Neurol Med Chir (Tokyo); 2006 Feb;46(2):101-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Benign pleomorphic astrocytoma in the hypothalamus--case report.
  • A 41-year-old woman presented with an unusual case of benign astrocytoma with marked pleomorphism manifesting as consciousness disturbance due to intraventricular hemorrhage.
  • Despite partial resection of the tumor without additional therapy, there have been no signs of tumor regrowth for 6 years.
  • The histological findings revealed solid proliferation of tumor cells with marked pleomorphism, contrary to the benign clinical course.
  • Immunohistochemical staining indicated the glial origin of the tumor.
  • The tumor was similar to pleomorphic xanthoastrocytoma, but the histological findings were not exactly identical, indicating a new histological entity.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Hypothalamus / pathology
  • [MeSH-minor] Adult. Female. Humans. Magnetic Resonance Imaging. Neoplasm Invasiveness

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16498222.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


62. Roy S, Josephson SA, Fridlyand J, Karch J, Kadoch C, Karrim J, Damon L, Treseler P, Kunwar S, Shuman MA, Jones T, Becker CH, Schulman H, Rubenstein JL: Protein biomarker identification in the CSF of patients with CNS lymphoma. J Clin Oncol; 2008 Jan 1;26(1):96-105
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We tested the hypothesis that individual CSF proteins distinguish CNS lymphoma from benign focal brain lesions.
  • ATIII RNA transcripts were identified within CNS lymphomas, and ATIII protein was localized selectively to tumor neovasculature.
  • We propose that the discovery of CSF protein biomarkers will facilitate early and noninvasive diagnosis in patients with lesions not amenable to brain biopsy, as well as provide improved surrogates of prognosis and treatment response in CNS lymphoma and brain metastasis.
  • [MeSH-major] Biomarkers, Tumor / cerebrospinal fluid. Brain Neoplasms / cerebrospinal fluid. Lymphoma / cerebrospinal fluid. Neoplasm Proteins / cerebrospinal fluid
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antithrombin III / genetics. Antithrombin III / metabolism. Case-Control Studies. Chromatography, Liquid. Diagnosis, Differential. Enzyme-Linked Immunosorbent Assay. Female. Humans. Immunoblotting. Immunoenzyme Techniques. Leukemia, Myeloid / cerebrospinal fluid. Leukemia, Myeloid / pathology. Lymphoma, B-Cell / cerebrospinal fluid. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell, Marginal Zone / cerebrospinal fluid. Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, Large B-Cell, Diffuse / cerebrospinal fluid. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Non-Hodgkin / cerebrospinal fluid. Lymphoma, Non-Hodgkin / pathology. Male. Middle Aged. Proteomics. Sensitivity and Specificity. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization. Survival Rate

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Feb;17(2):554-60 [10080599.001]
  • [Cites] Bioinformatics. 2004 Dec 12;20(18):3575-82 [15284095.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5034-43 [15955902.001]
  • [Cites] Hematol Oncol Clin North Am. 2005 Aug;19(4):705-17, vii [16083831.001]
  • [Cites] Mol Cell Proteomics. 2005 Sep;4(9):1341-9 [15970584.001]
  • [Cites] Dis Markers. 2006;22(1-2):3-26 [16410649.001]
  • [Cites] Blood. 2006 May 1;107(9):3716-23 [16418334.001]
  • [Cites] J Biol Chem. 2006 Dec 8;281(49):37302-10 [17040907.001]
  • [Cites] Expert Rev Mol Med. 2006;8(31):1-19 [17156576.001]
  • [Cites] Cancer Cell. 2007 Jan;11(1):83-95 [17222792.001]
  • [Cites] Anal Chem. 2003 Sep 15;75(18):4818-26 [14674459.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):266-72 [12525518.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):2053-63 [12466122.001]
  • [Cites] Lancet. 2002 Feb 16;359(9306):572-7 [11867112.001]
  • [Cites] Curr Opin Neurol. 2000 Dec;13(6):641-8 [11148663.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):864-71 [9508167.001]
  • [Cites] Clin Chem. 1993 Apr;39(4):561-77 [8472349.001]
  • [Cites] Br J Haematol. 2004 Jul;126(2):202-8 [15238140.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):2922-7 [15131026.001]
  • [Cites] Bioinformatics. 2004 Mar 22;20(5):777-85 [14751995.001]
  • [Cites] J Neurosurg. 2007 Jan;106(1):72-5 [17236490.001]
  • [CommentIn] J Clin Oncol. 2009 May 1;27(13):2302-3; author reply 2303-4 [19332721.001]
  • (PMID = 18056677.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / K23 CA100291
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 9000-94-6 / Antithrombin III
  • [Other-IDs] NLM/ NIHMS612770; NLM/ PMC4134101
  •  go-up   go-down


63. Jensen RL, Caamano E, Jensen EM, Couldwell WT: Development of contrast enhancement after long-term observation of a dysembryoplastic neuroepithelial tumor. J Neurooncol; 2006 May;78(1):59-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Development of contrast enhancement after long-term observation of a dysembryoplastic neuroepithelial tumor.
  • Dysembryoplastic neuroepithelial tumors (DNET) are usually benign lesions that arise in cortical regions and are discovered after new onset of seizure.
  • This previously non-enhancing tumor evolved to become contrast enhanced on routine imaging without apparent tumor growth.
  • [MeSH-major] Brain Neoplasms / pathology. Neoplasms, Neuroepithelial / pathology. Radiographic Image Enhancement
  • [MeSH-minor] Adult. Biomarkers, Tumor / analysis. Contrast Media. Female. Gadolinium. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Middle Aged. Seizures / etiology

  • Genetic Alliance. consumer health - Dysembryoplastic Neuroepithelial Tumor.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GADOLINIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJNR Am J Neuroradiol. 2003 Feb;24(2):225-33 [12591638.001]
  • [Cites] Epilepsia. 2004 Jan;45(1):41-5 [14692906.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 May;24(5):829-34 [12748079.001]
  • [Cites] Brain Pathol. 1993 Jul;3(3):283-95 [8293188.001]
  • [Cites] AJNR Am J Neuroradiol. 1996 Mar;17(3):419-30 [8881234.001]
  • [Cites] Radiographics. 2002 Sep-Oct;22(5):1177-89 [12235346.001]
  • (PMID = 16314940.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Contrast Media; AU0V1LM3JT / Gadolinium
  •  go-up   go-down


64. Li NY, Zhou XJ, Jin XZ, Meng K, Ma HH, Zheng XG, Jiang SJ, Sun GQ: [A clinicopathologic study of dysembryoplstic neuroepithelial tumor]. Zhonghua Bing Li Xue Za Zhi; 2005 Sep;34(9):561-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A clinicopathologic study of dysembryoplstic neuroepithelial tumor].
  • OBJECTIVE To study the clinicopathologic features, radiologic findings, treatment modalities and prognosis of dysembryoplastic neuroepithelial tumor (DNT).
  • On magnetic resonance imaging (MRI) study, the tumor was hypodense on T1 and hyperdense on T2.
  • None of the cases showed tumor recurrence after operation.
  • The tumor was formed by an admixture of oligodendrocyte-like cells, mature neurons and astrocytes, with obvious microcystic changes.
  • CONCLUSIONS: DNT is a benign tumor (corresponding to WHO grade I) that can be cured by surgical excision, despite sometimes incomplete tumor removal.
  • [MeSH-major] Brain Neoplasms / pathology. Cerebral Cortex / pathology. Neoplasms, Neuroepithelial / pathology. Oligodendroglia / pathology
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neurofilament Proteins / metabolism. S100 Proteins / metabolism. Survival Rate. Synaptophysin / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16468305.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Neurofilament Proteins; 0 / S100 Proteins; 0 / Synaptophysin
  •  go-up   go-down


65. Lu C, Ji Y, Shan F, Guo W, Ding J, Ge D: Solitary fibrous tumor of the pleura: an analysis of 13 cases. World J Surg; 2008 Aug;32(8):1663-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solitary fibrous tumor of the pleura: an analysis of 13 cases.
  • BACKGROUND: Solitary fibrous tumor of the pleura is a rare soft-tissue tumor.
  • Seven tumors were malignant and the other six were benign.
  • Among them, one patient experienced a recurrence and one patient died of brain metastasis.
  • We speculate that CD34-negative and nestin-positive might be a malignant marker for solitary fibrous tumor of pleura.
  • [MeSH-major] Neoplasms, Fibrous Tissue / diagnosis. Neoplasms, Fibrous Tissue / surgery. Pleural Neoplasms / diagnosis. Pleural Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Biopsy, Needle / methods. Female. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Metastasis. Radiography, Thoracic. Thoracic Surgery, Video-Assisted. Tomography, X-Ray Computed. Ultrasonography, Interventional

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Histopathology. 1998 May;32(5):423-32 [9639117.001]
  • [Cites] Am J Surg Pathol. 1989 Aug;13(8):640-58 [2665534.001]
  • [Cites] Semin Thorac Cardiovasc Surg. 2003 Jul;15(3):305-9 [12973709.001]
  • [Cites] Ann Thorac Surg. 2000 Dec;70(6):1808-12 [11156076.001]
  • [Cites] Ann Thorac Surg. 2002 Jul;74(1):285-93 [12118790.001]
  • [Cites] Eur J Cardiothorac Surg. 1998 Nov;14(5):453-9 [9860200.001]
  • [Cites] Am J Surg Pathol. 1994 Aug;18(8):814-20 [7518652.001]
  • [Cites] Ultrastruct Pathol. 1991 Jul-Oct;15(4-5):489-92 [1755106.001]
  • [Cites] J Comput Assist Tomogr. 2002 Mar-Apr;26(2):174-9 [11884769.001]
  • [Cites] Cancer. 1981 Jun 1;47(11):2678-89 [7260861.001]
  • [Cites] Jpn J Clin Oncol. 1998 Feb;28(2):86-91 [9544821.001]
  • [Cites] Cancer Control. 2006 Oct;13(4):264-9 [17075563.001]
  • [Cites] Differentiation. 1997 Feb;61(3):151-9 [9084133.001]
  • [Cites] Chest. 2000 Mar;117(3):897-900 [10713024.001]
  • [Cites] Hum Pathol. 1995 Apr;26(4):428-31 [7535740.001]
  • [Cites] Acta Neuropathol. 2001 Oct;102(4):349-54 [11603810.001]
  • [Cites] Eur J Cardiothorac Surg. 2002 Jun;21(6):1087-93 [12048090.001]
  • [Cites] Chest. 1997 Nov 5;112(5):1424-8 [9367487.001]
  • [Cites] Chest. 2004 Mar;125(3):1144-7 [15006980.001]
  • [Cites] Eur J Cardiothorac Surg. 1997 Dec;12 (6):928-30 [9489884.001]
  • (PMID = 18427887.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 20
  •  go-up   go-down


66. Chung HT, Kim DG, Paek SH, Jung HW: Development of dose-volume relation model for gamma knife surgery of non-skull base intracranial meningiomas. Int J Radiat Oncol Biol Phys; 2009 Jul 15;74(4):1027-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS AND MATERIALS: The radiologic outcomes of GKS of 82 imaging-defined benign meningiomas located at non-skull base areas were analyzed.
  • The mean patient age was 55.0 years (range, 26-78) and the mean tumor volume was 5.6 cm(3) (range, 0.5-16.8).
  • RESULTS: The actuarial tumor control rate was 91.6% at 5 years.
  • [MeSH-major] Brain Neoplasms / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery. Radiosurgery / methods
  • [MeSH-minor] Adult. Aged. Analysis of Variance. Female. Follow-Up Studies. Humans. Logistic Models. Male. Middle Aged. Probability. Prognosis. Radiotherapy Dosage. Tumor Burden

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19056186.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


67. Regelsberger J, Hagel C, Emami P, Ries T, Heese O, Westphal M: Secretory meningiomas: a benign subgroup causing life-threatening complications. Neuro Oncol; 2009 Dec;11(6):819-24
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secretory meningiomas: a benign subgroup causing life-threatening complications.
  • While meningiomas are known as slow-growing extracerebral neoplasms, the subgroup of secretory meningiomas with histologically benign characteristics tend to cause disproportional peritumoral edema, frequently leading to severe medical and neurological complications in postoperative management.
  • The clinical course, radiological appearance, and histopathological features were retrospectively analyzed to examine the specifics of these benign lesions.
  • A severe, nearly hemispheric perifocal edema disproportional to tumor size was seen on preoperative MR imaging in 18 (41%) patients.
  • An association between the extent of brain edema and number of periodic acid Schiff-positive pseudopsammomas was found (p < 0.02).
  • Mean MIB-1 (Ki-67 antigen) proliferation index was 3.0% (range, 0%-17%) and did not correlate with edema or tumor recurrence.
  • [MeSH-major] Brain Edema / etiology. Meningeal Neoplasms / complications. Meningeal Neoplasms / metabolism. Meningioma / complications. Meningioma / metabolism
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / metabolism. Carcinoembryonic Antigen / metabolism. Female. Follow-Up Studies. Humans. Immunoenzyme Techniques. Keratins / metabolism. Ki-67 Antigen / metabolism. Male. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / metabolism. Neoplasm Staging. Prognosis. Retrospective Studies. Tomography, X-Ray Computed

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Adv Clin Path. 1999 Jul;3(3):47-53 [10655573.001]
  • [Cites] Neurosurgery. 2001 Feb;48(2):297-301; discussion 301-2 [11220371.001]
  • [Cites] J Clin Neurosci. 2001 May;8 Suppl 1:19-21 [11386820.001]
  • [Cites] J Clin Neurosci. 2001 Jul;8(4):335-9 [11437574.001]
  • [Cites] Cancer. 2002 Feb 1;94(3):765-72 [11857311.001]
  • [Cites] Hum Pathol. 2002 Jun;33(6):590-8 [12152157.001]
  • [Cites] Appl Immunohistochem Mol Morphol. 2007 Sep;15(3):353-7 [17721284.001]
  • [Cites] Am J Surg Pathol. 1986 Feb;10(2):102-11 [2420220.001]
  • [Cites] Zhonghua Bing Li Xue Za Zhi. 1989 Dec;18(4):287-9 [2636960.001]
  • [Cites] Histopathology. 1992 Nov;21(5):475-7 [1452131.001]
  • [Cites] Cancer. 1997 May 15;79(10):2003-15 [9149029.001]
  • [Cites] Neurosurg Rev. 2006 Jan;29(1):41-8 [16010579.001]
  • [Cites] Sichuan Da Xue Xue Bao Yi Xue Ban. 2006 May;37(3):488-91 [16761441.001]
  • [Cites] J Neurooncol. 2003 May;62(3):233-41 [12777074.001]
  • (PMID = 19066343.001).
  • [ISSN] 1523-5866
  • [Journal-full-title] Neuro-oncology
  • [ISO-abbreviation] Neuro-oncology
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen; 0 / Ki-67 Antigen; 68238-35-7 / Keratins
  • [Other-IDs] NLM/ PMC2802401
  •  go-up   go-down


68. Suma HR, Prabhu K, Shenoy RP, Annaswamy R, Rao S, Rao A: Estimation of salivary protein thiols and total antioxidant power of saliva in brain tumor patients. J Cancer Res Ther; 2010 Jul-Sep;6(3):278-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estimation of salivary protein thiols and total antioxidant power of saliva in brain tumor patients.
  • Brain is considered abnormally sensitive to oxidative damage as brain tissue has high rate of oxygen consumption, high lipid content and relatively low antioxidant defenses, compared to other tissues.
  • RESULTS: The mean values of salivary flow rate and pH were significantly decreased among malignant and benign tumor patients whereas the salivary osmolality was significantly increased in both the groups of patients.
  • The mean values of salivary FRAP were significantly reduced among malignant and benign tumor patients.
  • CONCLUSION: Hence with these observations it can be concluded that in saliva, besides the physical characteristics, salivary FRAP and protein thiol levels are appropriate indicators of the antioxidant status in brain tumor patients.
  • [MeSH-major] Antioxidants / metabolism. Brain Neoplasms / metabolism. Salivary Proteins and Peptides / metabolism. Sulfhydryl Compounds / metabolism
  • [MeSH-minor] Adult. Case-Control Studies. Cross-Sectional Studies. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21119253.001).
  • [ISSN] 1998-4138
  • [Journal-full-title] Journal of cancer research and therapeutics
  • [ISO-abbreviation] J Cancer Res Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Salivary Proteins and Peptides; 0 / Sulfhydryl Compounds
  •  go-up   go-down


69. Hsu CC, Pai CY, Kao HW, Hsueh CJ, Hsu WL, Lo CP: Do aggressive imaging features correlate with advanced histopathological grade in meningiomas? J Clin Neurosci; 2010 May;17(5):584-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Atypical and malignant meningiomas are more likely to recur than benign meningiomas.
  • We aimed to distinguish atypical and malignant meningiomas from benign meningiomas based on imaging findings.
  • Histopathological grades were assigned as benign and atypical/malignant meningiomas according to the World Health Organization (WHO) classification.
  • (iv) extracranial tumor extension through the skull base foramina;.
  • (v) arterial encasement; and (vi) peritumoral brain edema.
  • There were 59 benign and 16 atypical/malignant meningiomas.
  • Only intratumoral cystic change and extracranial tumor extension through the skull base foramina were more prevalent in atypical/malignant meningiomas (p=0.001).
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningeal Neoplasms / radiography. Meningioma / pathology. Meningioma / radiography
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chi-Square Distribution. Female. Humans. Image Interpretation, Computer-Assisted. Magnetic Resonance Imaging. Male. Middle Aged. Patient Selection. Severity of Illness Index

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20219376.001).
  • [ISSN] 1532-2653
  • [Journal-full-title] Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia
  • [ISO-abbreviation] J Clin Neurosci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Scotland
  •  go-up   go-down


70. Ruge JR, Liu J: Use of 5-aminolevulinic acid for visualization and resection of a benign pediatric brain tumor. J Neurosurg Pediatr; 2009 Nov;4(5):484-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of 5-aminolevulinic acid for visualization and resection of a benign pediatric brain tumor.
  • 5-Aminolevulinic acid has been used successfully to facilitate resection of adult malignant gliomas.
  • Intraoperatively, the residual tumor fluoresced, allowing for better visualization.
  • [MeSH-major] Aminolevulinic Acid. Astrocytoma / diagnosis. Astrocytoma / surgery. Brain Neoplasms / diagnosis. Brain Neoplasms / surgery. Neurosurgical Procedures / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19877785.001).
  • [ISSN] 1933-0715
  • [Journal-full-title] Journal of neurosurgery. Pediatrics
  • [ISO-abbreviation] J Neurosurg Pediatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 88755TAZ87 / Aminolevulinic Acid
  •  go-up   go-down


71. Torlakovic E, Slipicevic A, Robinson C, DeCoteau JF, Alfsen GC, Vyberg M, Chibbar R, Flørenes VA: Pax-5 expression in nonhematopoietic tissues. Am J Clin Pathol; 2006 Nov;126(5):798-804
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We evaluated 123 formalin-fixed, paraffin-embedded samples, including neuroendocrine tumors, adult brain, mesonephric tissues, and from various other sites.
  • Our study describes for the first time distribution of Pax-5 in adult brain tissue, including periaqueductal gray matter of the midbrain, area postrema of the medulla oblongata, and occasional cells of the spinal trigeminal nucleus (caudal nucleus).
  • Pax-5 expression also was found readily in benign and malignant mesonephric tissues and focally in müllerian duct-derived tissues and tumors.
  • [MeSH-minor] Adult. Blotting, Western. Cell Line, Tumor. Female. Gastrointestinal Neoplasms / metabolism. Gastrointestinal Neoplasms / pathology. Humans. Immunohistochemistry. Lung Neoplasms / metabolism. Lung Neoplasms / pathology. Pancreatic Neoplasms / metabolism. Pancreatic Neoplasms / pathology. Uterine Cervical Neoplasms / metabolism. Uterine Cervical Neoplasms / pathology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17050077.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / PAX5 protein, human
  •  go-up   go-down


72. Huang CF, Chiou SY, Wu MF, Tu HT, Liu WS, Chuang JC: Apparent diffusion coefficients for evaluation of the response of brain tumors treated by Gamma Knife surgery. J Neurosurg; 2010 Dec;113 Suppl:97-104
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apparent diffusion coefficients for evaluation of the response of brain tumors treated by Gamma Knife surgery.
  • The authors hypothesized that loss of tumor cells after Gamma Knife surgery (GKS) may alter the ADC value and used diffusion weighted MR imaging (DW imaging) to evaluate cellular changes in brain tumors to detect their treatment response and the efficacy of GKS.
  • METHODS: In this paper the authors describe a prospective trial involving 86 patients harboring 38 solid or predominantly solid brain metastases, 30 meningiomas, and 24 acoustic neuromas that were treated by GKS.
  • Follow-up MR images and clinical outcomes were reviewed at 3-month intervals for metastatic lesions and at 6-month intervals for benign tumors.
  • Calcification (p = 0.006) and tumor recurrence (p = 0.025) significantly prevented a rise in the ADC level.The mean ADC value for all solid acoustic neuromas was 1.06 ± 0.17 × 10-3 mm2/sec before GKS.
  • At the last mean MR imaging follow-up there appeared to be tumor enlargement in 3 patients (12.5%); however, since the ADC values in these patients were significantly higher than the preradiosurgery values, the finding was considered to be a sign of radiation necrosis rather than tumor recurrence.
  • In some patients in whom imaging findings are equivocal, ADC values may also be used to distinguish radiation-induced necrosis from tumor recurrence.(DOI: 10.3171/2010.7.GKS10864)
  • [MeSH-major] Brain Neoplasms / pathology. Brain Neoplasms / surgery. Diffusion Magnetic Resonance Imaging / methods. Image Processing, Computer-Assisted / methods. Radiosurgery / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Echo-Planar Imaging. Female. Humans. Male. Meningioma / pathology. Meningioma / surgery. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology. Neuroma, Acoustic / pathology. Neuroma, Acoustic / surgery. Tomography, X-Ray Computed. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21222290.001).
  • [ISSN] 1933-0693
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


73. Naydenov E, Tzekov C, Minkin K, Nachev S, Marinov M: [Malignant progression of an anaplastic ganglioglioma into a glioblastoma multiforme--report on two cases and review of the literature]. Khirurgiia (Sofiia); 2009;(2-3):69-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Ganglioglioma is an uncommon type of primary brain tumors.
  • In most of the cases the tumor demonstrates benign clinical behaviour with long-term patients' survival.
  • The tumor was excised partially and the histological result was anaplastic ganglioglioma (World Health Organization - WHO. gr. III).
  • A local tumor recurrence was found and the patient underwent second operative intervention with gross total tumor resection.
  • MRI data for large, heterointense tumor lesion in the left frontal lobe was found.
  • A subtotal tumor removal was made.
  • Data for additional local tumor growth was found on control CT-scan one month later.
  • The tumor behaviour may vary between the patients in spite of the similar histological characteristics which indicates the possible presence of different tumor subtypes.
  • [MeSH-major] Brain Neoplasms / pathology. Ganglioglioma / pathology. Glioblastoma / pathology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adolescent. Adult. Female. Frontal Lobe / pathology. Frontal Lobe / radiography. Frontal Lobe / surgery. Humans


74. Rieske P, Zakrzewska M, Biernat W, Bartkowiak J, Zimmermann A, Liberski PP: Atypical molecular background of glioblastoma and meningioma developed in a patient with Li-Fraumeni syndrome. J Neurooncol; 2005 Jan;71(1):27-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We observed three neoplasms with completely different histologies: malignant fibrous histiocytoma (MFH), atypical meningioma (AM), and glioblastoma (GB), developing in a patient with Li-Fraumeni syndrome.
  • [MeSH-major] Germ-Line Mutation. Glioblastoma / genetics. Histiocytoma, Benign Fibrous / genetics. Li-Fraumeni Syndrome / genetics. Meningioma / genetics. Neoplasms, Multiple Primary / genetics. Tumor Suppressor Protein p53 / genetics
  • [MeSH-minor] Adult. Brain Neoplasms / genetics. Brain Neoplasms / therapy. Chromosomes, Human, Pair 1 / genetics. Chromosomes, Human, Pair 22 / genetics. DNA / analysis. Fatal Outcome. Genetic Testing. Humans. Loss of Heterozygosity. Male. Microsatellite Repeats. Skin Neoplasms / genetics. Skin Neoplasms / therapy


75. Pasha Q, Malik SA, Shaheen N, Shah MH: Comparison of trace elements in the scalp hair of malignant and benign breast lesions versus healthy women. Biol Trace Elem Res; 2010 May;134(2):160-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of trace elements in the scalp hair of malignant and benign breast lesions versus healthy women.
  • Trace elements including Al, Ca, Cd, Co, Cr, Cu, Fe, K, Mg, Mn, Na, Ni, Pb, Sb, Sr, and Zn were analyzed in the scalp hair samples of women with malignant breast lesions, women with benign breast lesions, and healthy donors using atomic absorption spectrophotometric method.
  • In the scalp hair of malignant-tumor patients, the highest average concentration was shown by Ca (1,187 microg/g), followed by Na (655 microg/g), Mg (478 microg/g), Zn (391 microg/g), Sr (152 microg/g), Fe (114 microg/g), and K (89.8), while in the case of benign-tumor patients, the average estimated element levels were 1,522, 1,093, 572, 457, 217, 80.4, and 74.7 microg/g, respectively.
  • Average levels of Na, Sr, K, Cd, Co, Pb, Mg, Ca, Zn, Ni, Sb, and Mn were revealed to be significantly higher in the hair of malignant and benign patients compared to the healthy women; however, Fe, Cu, Al, and Cr were not significantly different in the scalp hair of the three groups.
  • The quartile distributions of Ca, Cd, Co, Cr, K, Mg, Mn, Na, Ni, Pb, Sb, and Sr revealed maximum spread in the scalp hair of malignant and benign groups; nevertheless, Al, Cu, Fe, and Zn exhibited almost comparable quartile levels in the three groups.
  • Strong correlation coefficients were found between Fe and Cd, Al and Na, Mn and Sr, Co and Cr, Cd and Cr, Pb and K, Pb and Mn, Cu and Na, and Al and Fe in the scalp hair of malignant-tumor patients, while Fe and K, Cd and Co, Na and Co, and Cr and Pb showed strong correlations in the scalp hair of benign-tumor patients, both of which were significantly different compared with the healthy subjects.
  • Multivariate cluster analysis also revealed divergent clustering of the elements in the scalp hair of malignant and benign patients in comparison with the healthy women.
  • [MeSH-major] Brain Neoplasms / metabolism. Hair / chemistry. Scalp / chemistry. Trace Elements / analysis
  • [MeSH-minor] Adult. Female. Humans. Middle Aged. Multivariate Analysis. Women's Health

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19644659.001).
  • [ISSN] 1559-0720
  • [Journal-full-title] Biological trace element research
  • [ISO-abbreviation] Biol Trace Elem Res
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Trace Elements
  •  go-up   go-down


76. Ellert-Miklaszewska A, Grajkowska W, Gabrusiewicz K, Kaminska B, Konarska L: Distinctive pattern of cannabinoid receptor type II (CB2) expression in adult and pediatric brain tumors. Brain Res; 2007 Mar 16;1137(1):161-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinctive pattern of cannabinoid receptor type II (CB2) expression in adult and pediatric brain tumors.
  • The efficacy of cannabinoids against high-grade glioma in animal models, mediated by two specific receptors, CB1 and CB2, raised promises for targeted treatment of the most frequent and malignant primary brain tumors.
  • Unlike the abundantly expressed CB1, the CB2 receptor shows a restricted distribution in normal brain.
  • Although brain tumors constitute the second most common malignancy in children and the prevalence of histological types of brain tumors vary significantly between the adult and pediatric populations, cannabinoid receptor expression in pediatric tumors remains unknown.
  • In the present study, we compared the expression of the CB2 receptor in paraffin-embedded sections from primary brain tumors of adult and pediatric patients.
  • Most glioblastomas expressed very high levels of CB2 receptors and the expression correlated with tumor grade.
  • Interestingly, some benign pediatric astrocytic tumors, such as subependymal giant cell astrocytoma (SEGA), which may occasionally cause mortality owing to progressive growth, also displayed high CB2 immunoreactivity.
  • In contrast, all examined cases of embryonal tumors (medulloblastoma and S-PNET), the most frequently diagnosed malignant brain tumors in childhood, showed no or trace CB2 immunoreactivity.
  • Our results suggest that the CB2 receptor expression depends primarily on the histopathological origin of the brain tumor cells and differentiation state, reflecting the tumor grade.
  • [MeSH-major] Brain Neoplasms / metabolism. Gene Expression Regulation, Neoplastic / physiology. Receptor, Cannabinoid, CB2 / metabolism
  • [MeSH-minor] Adolescent. Adult. Age Factors. Astrocytoma / metabolism. Child. Glioblastoma / metabolism. Histocompatibility Antigens / metabolism. Humans. Immunohistochemistry. Reverse Transcriptase Polymerase Chain Reaction / methods

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17239827.001).
  • [ISSN] 0006-8993
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Histocompatibility Antigens; 0 / Receptor, Cannabinoid, CB2
  •  go-up   go-down


77. Lázaro BC, Landeiro JA: Tectal plate tumors. Arq Neuropsiquiatr; 2006 Jun;64(2B):432-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tectal plate is a rare location for a tumor.
  • Open surgery was performed in three cases (due to tumor enlargement or need for the exact diagnosis).
  • In our series, except in the metastatic tumor case and the cavernoma, the other types of lesion consisted of low grade gliomas.
  • These lesions represent a different type of brain stem tumor sharing a common good prognosis, with a benign behavior.
  • When a patient presents with a benign lesions in the tectal region, treating the main symptom--hydrocephalus--should be the first attempt in management of these lesions.
  • [MeSH-major] Brain Stem Neoplasms / diagnosis. Glioma / diagnosis. Tectum Mesencephali
  • [MeSH-minor] Adolescent. Adult. Aged. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Time Factors. Tomography, X-Ray Computed. Treatment Outcome. Ventriculostomy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16917614.001).
  • [ISSN] 0004-282X
  • [Journal-full-title] Arquivos de neuro-psiquiatria
  • [ISO-abbreviation] Arq Neuropsiquiatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Brazil
  •  go-up   go-down


78. Wada K, Maruno M, Suzuki T, Kagawa N, Hashiba T, Fujimoto Y, Hashimoto N, Izumoto S, Yoshimine T: Chromosomal and genetic abnormalities in benign and malignant meningiomas using DNA microarray. Neurol Res; 2005 Oct;27(7):747-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chromosomal and genetic abnormalities in benign and malignant meningiomas using DNA microarray.
  • BACKGROUND: Meningioma is the commonest brain tumor and many genetic abnormalities, such as the loss of chromosome 22q and the mutation of NF2, have been reported.
  • METHODS: These classical abnormalities were detected using Southern blot, PCR, fluorescence in situ hybridization and comparative genomic hybridization, but these methods examine only very limited regions or limited mapping resolution of the tumor genome.
  • [MeSH-major] Chromosome Aberrations. Meningeal Neoplasms / genetics. Meningioma / genetics. Oligonucleotide Array Sequence Analysis
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Chromosome Mapping. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16197812.001).
  • [ISSN] 0161-6412
  • [Journal-full-title] Neurological research
  • [ISO-abbreviation] Neurol. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


79. Kravets LIa, Trofimov AO: [Delayed surgical operations in benign supratentorial gliomas]. Zh Vopr Neirokhir Im N N Burdenko; 2009 Jan-Mar;(1):24-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Delayed surgical operations in benign supratentorial gliomas].
  • Benign gliomas are slowly growing primary brain tumors with prolonged natural course and tendency to malignization.
  • The paper describes results of treatment of 19 patients with benign supratentorial gliomas.
  • Aspects of volume evolution and surgical excision of tumor are highlighted.
  • [MeSH-major] Glioma / surgery. Neurosurgical Procedures / methods. Supratentorial Neoplasms / surgery
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Time Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19505027.001).
  • [ISSN] 0042-8817
  • [Journal-full-title] Zhurnal voprosy neĭrokhirurgii imeni N. N. Burdenko
  • [ISO-abbreviation] Zh Vopr Neirokhir Im N N Burdenko
  • [Language] rus
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


80. Floeth FW, Pauleit D, Sabel M, Reifenberger G, Stoffels G, Stummer W, Rommel F, Hamacher K, Langen KJ: 18F-FET PET differentiation of ring-enhancing brain lesions. J Nucl Med; 2006 May;47(5):776-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 18F-FET PET differentiation of ring-enhancing brain lesions.
  • In all patients, the main differential diagnosis after MRI was a malignant lesion, in particular glioblastoma multiforme, versus a benign lesion, in particular brain abscess.
  • A malignant tumor was suspected for lesions showing increased (18)F-FET uptake on PET images with a mean lesion-to-brain ratio of at least 1.6 ((18)F-FET PET positive).
  • A nonneoplastic lesion was suspected in cases of minimal or absent (18)F-FET uptake, with a mean lesion-to-brain ratio of less than 1.6 ((18)F-FET PET negative).
  • The findings of (18)F-FET PET were positive in all 5 glioma patients and in 3 of 9 patients with nonneoplastic lesions, including 2 patients with brain abscesses and 1 patient with a demyelinating lesion.
  • CONCLUSION: Although (18)F-FET PET has been shown to be valuable for the diagnostic evaluation of brain tumors, our data indicate that, like (18)F-FDG PET, (18)F-FET PET has limited specificity in distinguishing between neoplastic and nonneoplastic ring-enhancing intracerebral lesions.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18 / pharmacology. Positron-Emission Tomography / methods
  • [MeSH-minor] Adult. Aged. Biopsy. Female. Glioma / radionuclide imaging. Humans. Magnetic Resonance Imaging / methods. Male. Middle Aged. Radiopharmaceuticals / pharmacology. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16644747.001).
  • [ISSN] 0161-5505
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


81. Salemi M, Calogero AE, Vicari E, Migliore E, Zaccarello G, Cosentino A, Amore M, Tricoli D, Castiglione R, Bosco P, Rappazzo G: A high percentage of skin melanoma cells expresses SPANX proteins. Am J Dermatopathol; 2009 Apr;31(2):182-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The expression of SPANX proteins was evaluated by immunohistochemistry in normal skin (n = 12), melanomas (n = 21), and benign nevi (n = 10), using a polyclonal antibody raised in our laboratory.
  • Benign nevi had an intermediate number of cells expressing SPANX proteins (25% +/- 8.5%), which resulted significantly higher than normal skin cells and significantly lower than skin melanoma cells.
  • In melanoma cells, the labeling was mostly nuclear, sometimes incomplete or limited to the perinuclear wall, even if cytoplasmic staining was also seen in SPANX-positive tumor cells.
  • [MeSH-major] Melanoma / metabolism. Nuclear Proteins / metabolism. Skin / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Animals. Antibodies. Antibody Specificity. Biopsy. Epitopes / immunology. Epitopes / metabolism. Female. Humans. Immunohistochemistry. Male. Mice. Middle Aged. Multigene Family / physiology. Neoplasms / metabolism. Neoplasms / pathology. Nevus / metabolism. Nevus / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19318807.001).
  • [ISSN] 1533-0311
  • [Journal-full-title] The American Journal of dermatopathology
  • [ISO-abbreviation] Am J Dermatopathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies; 0 / Epitopes; 0 / Nuclear Proteins; 0 / SPANXA1 protein, human
  •  go-up   go-down


82. Nakamura M, Ishii K, Watanabe K, Tsuji T, Matsumoto M, Toyama Y, Chiba K: Long-term surgical outcomes for myxopapillary ependymomas of the cauda equina. Spine (Phila Pa 1976); 2009 Oct 1;34(21):E756-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Because of the rarity of this tumor, there is no consensus on its optimal treatment options and prognosis.
  • The effects of surgical margins at surgery and postoperative radiotherapy on tumor recurrence and prognosis were investigated.
  • RESULTS: In 15 patients, total resection achieved (6 cases of en bloc resection without postoperative radiation, and in 9 cases piecemeal resection) was followed by whole brain and spinal cord radiation or local irradiation.
  • Fourteen of these patients survived without tumor recurrence.
  • In 1 case of total resection without radiotherapy, the tumor capsule was violated intraoperatively and local recurrence occurred 2 years after surgery.
  • Of these, 2 patients who received radiation (24 Gy) only to the whole brain and spinal cord developed recurrence, and 2 who received whole brain and spinal cord radiation (24 Gy) supplemented with local radiation (46 Gy) developed no recurrence.
  • Although this tumor is histologically benign, CSF dissemination can occur once tumor capsule is violated, before or during surgery.
  • Therefore, early diagnosis is essential, and a therapeutic strategy including radiotherapy, on the assumption that this tumor is malignant, should be established.
  • [MeSH-major] Cauda Equina. Ependymoma / surgery. Neurosurgical Procedures. Peripheral Nervous System Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Incidence. Longitudinal Studies. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / prevention & control. Prognosis. Radiotherapy, Adjuvant / methods. Retrospective Studies. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19934795.001).
  • [ISSN] 1528-1159
  • [Journal-full-title] Spine
  • [ISO-abbreviation] Spine
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


83. Shingu T, Akiyama Y, Daisu M, Maruyama N, Matsumoto Y, Miyazaki T, Nagai H, Yamamoto Y, Yamasaki T, Yoshida M, Maruyama R, Moritake K: Symptomatic hemorrhage associated with recurrent pilocytic astrocytoma with granulation tissue--case report. Neurol Med Chir (Tokyo); 2007 May;47(5):222-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Computed tomography and T(2)*-weighted magnetic resonance imaging revealed hemorrhage in the tumor located in the right basal ganglia, thalamus, and hypothalamus.
  • Although neither symptomatic hemorrhage nor late benign recurrence is common, careful long-term follow up is necessary for patients with pilocytic astrocytoma.
  • [MeSH-major] Astrocytoma / pathology. Brain Neoplasms / pathology. Cerebral Hemorrhage / etiology. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Female. Granulation Tissue / pathology. Humans

  • Genetic Alliance. consumer health - Pilocytic astrocytoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17527050.001).
  • [ISSN] 0470-8105
  • [Journal-full-title] Neurologia medico-chirurgica
  • [ISO-abbreviation] Neurol. Med. Chir. (Tokyo)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


84. Burghaus S, Hölsken A, Buchfelder M, Fahlbusch R, Riederer BM, Hans V, Blümcke I, Buslei R: A tumor-specific cellular environment at the brain invasion border of adamantinomatous craniopharyngiomas. Virchows Arch; 2010 Mar;456(3):287-300
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A tumor-specific cellular environment at the brain invasion border of adamantinomatous craniopharyngiomas.
  • Craniopharyngiomas (CP) are benign epithelial tumors of the sellar region and can be clinicopathologically distinguished into adamantinomatous (adaCP) and papillary (papCP) variants.
  • Both subtypes are classified according to the World Health Organization grade I, but their irregular digitate brain infiltration makes any complete surgical resection difficult to obtain.
  • Herein, we characterized the cellular interface between the tumor and the surrounding brain tissue in 48 CP (41 adaCP and seven papCP) compared to non-neuroepithelial tumors, i.e., 12 cavernous hemangiomas, 10 meningiomas, and 14 metastases using antibodies directed against glial fibrillary acid protein (GFAP), vimentin, nestin, microtubule-associated protein 2 (MAP2) splice variants, and tenascin-C.
  • Furthermore, the outer tumor cell layer of adaCP showed a distinct expression of MAP2, a novel finding helpful in the differential diagnosis of epithelial tumors in the sellar region.
  • Our data support the hypothesis that adaCP, unlike other non-neuroepithelial tumors of the central nervous system, create a tumor-specific cellular environment at the tumor-brain junction.
  • [MeSH-major] Craniopharyngioma / pathology. Pituitary Neoplasms / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Biomarkers, Tumor / metabolism. Brain / metabolism. Child. Child, Preschool. Female. Gene Expression Regulation, Neoplastic. Glial Fibrillary Acidic Protein / metabolism. Humans. Intermediate Filament Proteins / metabolism. Male. Microtubule-Associated Proteins / metabolism. Middle Aged. Neoplasm Invasiveness / pathology. Neoplasm Invasiveness / physiopathology. Neoplasm Metastasis / pathology. Neoplasm Metastasis / physiopathology. Nerve Tissue Proteins / metabolism. Nestin. Tenascin / metabolism. Vimentin / metabolism

  • MedlinePlus Health Information. consumer health - Pituitary Tumors.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1595-603 [17122517.001]
  • [Cites] Am J Pathol. 2002 Dec;161(6):1997-2001 [12466115.001]
  • [Cites] Neuropathol Appl Neurobiol. 2002 Dec;28(6):480-8 [12445164.001]
  • [Cites] Endocr Rev. 2006 Jun;27(4):371-97 [16543382.001]
  • [Cites] J Pathol. 2004 Jul;203(3):814-21 [15221941.001]
  • [Cites] Expert Rev Anticancer Ther. 2007 May;7(5):675-87 [17492931.001]
  • [Cites] Nat Cell Biol. 2001 Sep;3(9):778-84 [11533656.001]
  • [Cites] Brain Res. 2002 Jul 12;943(2):174-80 [12101039.001]
  • [Cites] Acta Neurochir (Wien). 2008 Dec;150(12):1213-26 [19002375.001]
  • [Cites] Oncogene. 2005 Dec 8;24(55):8200-4 [16091738.001]
  • [Cites] Glia. 2000 Feb 1;29(3):233-45 [10642750.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3897-904 [8033113.001]
  • [Cites] Acta Neuropathol. 2004 Aug;108(2):89-96 [15146346.001]
  • [Cites] Acta Neuropathol. 2005 Jun;109(6):589-97 [15891929.001]
  • [Cites] Brain Res Dev Brain Res. 2002 Nov 15;139(1):9-17 [12414089.001]
  • [Cites] J Neurochem. 1999 Dec;73(6):2531-7 [10582615.001]
  • [Cites] Glia. 1997 Jan;19(1):35-46 [8989566.001]
  • [Cites] J Biol Chem. 1990 Nov 15;265(32):19679-84 [2174050.001]
  • [Cites] Neurosurgery. 2005 Apr;56(4):763-76 [15792515.001]
  • [Cites] Brain Res Dev Brain Res. 1992 Feb 21;65(2):259-67 [1373996.001]
  • [Cites] Acta Neuropathol. 1978 Sep 15;43(3):191-203 [696237.001]
  • [Cites] Brain Pathol. 2009 Jul;19(3):357-64 [18540944.001]
  • [Cites] Pediatr Neurosurg. 1996 Nov;25(5):240-6; discussion 247 [9309787.001]
  • [Cites] Brain Res Dev Brain Res. 1992 Jul 24;68(1):111-23 [1521317.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Nov 21;92(24):10894-8 [7479905.001]
  • [Cites] J Cell Sci. 1994 Nov;107 ( Pt 11):3115-25 [7699010.001]
  • [Cites] Cell Tissue Res. 2003 Dec;314(3):315-24 [14523640.001]
  • [Cites] Acta Neuropathol. 2007 Aug;114(2):97-109 [17618441.001]
  • [Cites] J Neurosurg. 2007 Jan;106(1 Suppl):3-12 [17233305.001]
  • [Cites] Matrix Biol. 2001 Feb;20(1):13-22 [11246000.001]
  • [Cites] J Neurosurg. 1999 Feb;90(2):237-50 [9950494.001]
  • [Cites] J Neurosurg. 1988 Aug;69(2):155-70 [3292716.001]
  • [Cites] Eur J Endocrinol. 2005 Apr;152(4):557-67 [15817911.001]
  • [Cites] J Neurosurg. 1990 Jul;73(1):12-7 [2352012.001]
  • [Cites] Horm Res. 2008;69(4):193-202 [18204266.001]
  • [Cites] Curr Drug Targets CNS Neurol Disord. 2005 Feb;4(1):85-92 [15723616.001]
  • [Cites] Lab Invest. 2002 Mar;82(3):345-51 [11896213.001]
  • [Cites] Clin Endocrinol (Oxf). 2005 Apr;62(4):397-409 [15807869.001]
  • [Cites] J Neuropathol Exp Neurol. 2001 Oct;60(10):984-93 [11589429.001]
  • [Cites] Annu Rev Cell Biol. 1989;5:71-92 [2480799.001]
  • [Cites] Curr Opin Pediatr. 2007 Aug;19(4):471-9 [17630614.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Sep;82(17):6006-9 [3898077.001]
  • [Cites] Cancer Res. 2006 Dec 15;66(24):11771-80 [17178873.001]
  • [Cites] Glia. 1995 Apr;13(4):233-54 [7615335.001]
  • [Cites] Dev Dyn. 2004 May;230(1):1-11 [15108304.001]
  • [Cites] Brain Tumor Pathol. 2005;22(2):75-8 [18095108.001]
  • [Cites] J Neurosurg. 1998 Oct;89(4):547-51 [9761047.001]
  • [Cites] Eur J Neurosci. 2005 Oct;22(8):1863-72 [16262626.001]
  • [Cites] Pituitary. 2005;8(2):75-9 [16195780.001]
  • [Cites] Neurosurgery. 1994 Dec;35(6):1001-10; discussion 1010-1 [7885544.001]
  • [Cites] Acta Neuropathol. 2007 May;113(5):585-90 [17221204.001]
  • [Cites] Brain Res Dev Brain Res. 2002 Mar 31;134(1-2):87-92 [11947939.001]
  • [Cites] Cell. 1990 Feb 23;60(4):585-95 [1689217.001]
  • [Cites] Exp Neurol. 1999 Dec;160(2):348-60 [10619552.001]
  • [Cites] Eur J Endocrinol. 2008 Dec;159 Suppl 1:S95-9 [18775978.001]
  • [Cites] J Pediatr Endocrinol Metab. 2006 Apr;19 Suppl 1:453-4 [16700324.001]
  • [Cites] Cancer. 2003 Dec 1;98(11):2430-9 [14635078.001]
  • [Cites] J Neurosurg. 1995 Aug;83(2):206-14 [7616262.001]
  • [Cites] Neuropathology. 2007 Feb;27(1):1-9 [17319278.001]
  • (PMID = 20069432.001).
  • [ISSN] 1432-2307
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Glial Fibrillary Acidic Protein; 0 / Intermediate Filament Proteins; 0 / Microtubule-Associated Proteins; 0 / NES protein, human; 0 / Nerve Tissue Proteins; 0 / Nestin; 0 / Tenascin; 0 / Vimentin
  •  go-up   go-down


85. Yen CP, Sheehan J, Patterson G, Steiner L: Gamma knife surgery for neurocytoma. J Neurosurg; 2007 Jul;107(1):7-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECT: Although considered benign tumors, neurocytomas have various biological behaviors, histological patterns, and clinical courses.
  • Three patients harbored five recurrent tumors after a gross-total resection, three had progression of previous partially resected tumors, and one had undergone a tumor biopsy only.
  • The mean tumor volume at the time of GKS ranged from 1.4 to 19.8 cm3 (mean 6.0 cm3).
  • A mean peripheral dose of 16 Gy was prescribed to the tumor margin with the median isodose configuration of 32.5%.
  • Because of secondary hemorrhage, an accurate tumor volume could not be determined in one.
  • Four patients were asymptomatic during the follow-up period, and the condition of the patient who had residual hemiparesis from a previous transcortical resection of the tumor was stable.
  • Additionally, the patient who experienced tumor hemorrhage required a shunt revision, and another patient died of sepsis due to a shunt infection.
  • It offers control over the tumor with the benefits of minimal invasiveness and low morbidity rates.
  • [MeSH-major] Brain Neoplasms / radiotherapy. Brain Neoplasms / surgery. Neurocytoma / radiotherapy. Neurocytoma / surgery. Radiosurgery
  • [MeSH-minor] Adolescent. Adult. Dose Fractionation. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Microsurgery. Neoplasm Recurrence, Local

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17639866.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Wang FL, Li XH, Gui QP, Liu L: [Clinicopathologic and radiologic features of dysembryoplastic neuroepithelial tumors]. Zhonghua Bing Li Xue Za Zhi; 2005 Sep;34(9):566-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To study the clinicopathologic features and radiologic findings of dysembryoplastic neuroepithelial tumor (DNT).
  • CONCLUSIONS: DNT is a benign tumor with excellent prognosis after surgical excision.
  • [MeSH-major] Brain Neoplasms / pathology. Cerebral Cortex / pathology. Neuroectodermal Tumors, Primitive / pathology
  • [MeSH-minor] Adolescent. Adult. Child. Child, Preschool. Epilepsies, Partial / etiology. Epilepsies, Partial / metabolism. Epilepsies, Partial / pathology. Epilepsies, Partial / surgery. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neurofilament Proteins / metabolism. Oligodendroglia / pathology. Oligodendroglia / ultrastructure. S100 Proteins / metabolism. Survival Rate. Synaptophysin / metabolism

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16468306.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Neurofilament Proteins; 0 / S100 Proteins; 0 / Synaptophysin
  •  go-up   go-down


87. Tabernero MD, Maillo A, Gil-Bellosta CJ, Castrillo A, Sousa P, Merino M, Orfao A: Gene expression profiles of meningiomas are associated with tumor cytogenetics and patient outcome. Brain Pathol; 2009 Jul;19(3):409-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiles of meningiomas are associated with tumor cytogenetics and patient outcome.
  • Cytogenetic analysis is a powerful tool for predicting recurrence in meningiomas, even among histologically benign/grade I tumors.
  • Despite this, no study has been reported in which the impact of tumor cytogenetics on the gene expression profiles (GEP) has been analyzed in meningiomas.
  • Accordingly, based on the expression of 85 genes (40 of which were coded in the altered chromosomes used for patient stratification) the cytogenetic class of the tumor could be predicted with an error of <1%, a clear association being found between the GEP and patient outcome (P = 0.03) but not tumor histopathology.
  • [MeSH-major] Cytogenetic Analysis. Gene Expression Profiling. Meningeal Neoplasms / genetics. Meningioma / genetics. Neoplasm Recurrence, Local / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. In Situ Hybridization, Fluorescence. Kaplan-Meier Estimate. Male. Middle Aged. Oligonucleotide Array Sequence Analysis. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18637901.001).
  • [ISSN] 1750-3639
  • [Journal-full-title] Brain pathology (Zurich, Switzerland)
  • [ISO-abbreviation] Brain Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  •  go-up   go-down


88. Ali Y, Rahme R, Moussa R, Abadjian G, Menassa-Moussa L, Samaha E: Multifocal meningeal melanocytoma: a new pathological entity or the result of leptomeningeal seeding? J Neurosurg; 2009 Sep;111(3):488-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Meningeal melanocytoma is a rare benign CNS tumor derived from the leptomeningeal melanocytes.
  • Although unusual, malignant transformation with leptomeningeal seeding into the brain or spinal cord may occur years after the initial diagnosis.
  • The authors report a unique case of multifocal benign meningeal melanocytoma involving both cerebellopontine angles and the thoracic spinal cord, with associated diffuse leptomeningeal hyperpigmentation.
  • [MeSH-major] Cerebellar Neoplasms / pathology. Cerebellopontine Angle. Melanocytes / pathology. Melanoma / pathology. Meningeal Neoplasms / pathology. Neoplasm Seeding. Spinal Cord Neoplasms / pathology
  • [MeSH-minor] Adult. Humans. Magnetic Resonance Imaging. Male

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19361258.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


89. Bullitt E, Zeng D, Gerig G, Aylward S, Joshi S, Smith JK, Lin W, Ewend MG: Vessel tortuosity and brain tumor malignancy: a blinded study. Acad Radiol; 2005 Oct;12(10):1232-40
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vessel tortuosity and brain tumor malignancy: a blinded study.
  • Characteristic vessel tortuosity abnormalities appear early during tumor development, affect initially healthy vessels, spread beyond the confines of tumor margins, and do not simply mirror tissue perfusion.
  • MATERIALS AND METHODS: The regional vasculature of 34 healthy subjects was compared with the tumor-associated vasculature of 30 brain tumors before surgical resection.
  • Vessels were segmented from an MRA of each subject, a region of interest was defined in each tumor patient and was mapped to all healthy controls, and a statistical analysis of vessel shape measures was then performed over the region of interest.
  • Many difficult cases were included, such as pinpoint, hemorrhagic, and irradiated tumors, as were hypervascular benign tumors.
  • Tumors were identified as benign or malignant on the basis of histological evaluation.
  • RESULTS: A discriminant analysis performed at the study's conclusion successfully classified all but one of the 30 tumors as benign or malignant on the basis of vessel tortuosity.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acad Radiol. 2003 Dec;10(12):1341-8 [14697002.001]
  • [Cites] Int J Mol Med. 2002 Mar;9(3):299-310 [11836637.001]
  • [Cites] Nat Med. 2001 Sep;7(9):987-9 [11533692.001]
  • [Cites] Neuroradiology. 2001 May;43(5):345-52 [11396737.001]
  • [Cites] Brain Tumor Pathol. 2000;17(3):111-20 [11310918.001]
  • [Cites] Cancer Res. 2000 Jul 15;60(14):3683-8 [10919633.001]
  • [Cites] Cancer Biother Radiopharm. 1999 Feb;14(1):31-6 [10850285.001]
  • [Cites] J Natl Cancer Inst. 2000 Jan 19;92(2):143-7 [10639516.001]
  • [Cites] J Natl Cancer Inst. 2000 Jan 19;92(2):94-5 [10639502.001]
  • [Cites] Nat Med. 2004 Feb;10(2):145-7 [14745444.001]
  • [Cites] IEEE Trans Med Imaging. 2003 Sep;22(9):1163-71 [12956271.001]
  • [Cites] AJNR Am J Neuroradiol. 2003 Nov-Dec;24(10):1989-98 [14625221.001]
  • [Cites] Clin Cancer Res. 2002 Apr;8(4):1284-91 [11948144.001]
  • [Cites] Semin Nucl Med. 2003 Apr;33(2):148-62 [12756647.001]
  • [Cites] Med Image Anal. 2005 Feb;9(1):39-49 [15581811.001]
  • [Cites] Technol Cancer Res Treat. 2004 Dec;3(6):585-90 [15560716.001]
  • [Cites] Technol Cancer Res Treat. 2004 Dec;3(6):577-84 [15560715.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1969 Apr;105(4):795-805 [4308528.001]
  • [Cites] IEEE Trans Med Imaging. 2002 Feb;21(2):61-75 [11929106.001]
  • (PMID = 16179200.001).
  • [ISSN] 1076-6332
  • [Journal-full-title] Academic radiology
  • [ISO-abbreviation] Acad Radiol
  • [Language] ENG
  • [Grant] United States / NIBIB NIH HHS / EB / EB000219-08A1; United States / NIBIB NIH HHS / EB / R01 EB000219-07; United States / NIBIB NIH HHS / EB / R01 EB000219-08A1; United States / NIBIB NIH HHS / EB / R01 EB000219; United States / NIBIB NIH HHS / EB / EB000219-07
  • [Publication-type] Controlled Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS53777; NLM/ PMC2517122
  •  go-up   go-down


90. Lah TT, Nanni I, Trinkaus M, Metellus P, Dussert C, De Ridder L, Rajcević U, Blejec A, Martin PM: Toward understanding recurrent meningioma: the potential role of lysosomal cysteine proteases and their inhibitors. J Neurosurg; 2010 May;112(5):940-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Primary meningioma cultured spheroids were "confronted" with embryonic chick heart spheroids in vitro, and cathepsin B was used as molecular marker to immunolabel the invasive tumor cells.
  • As to the second aim, the possible association of cathepsin B along with selected molecular markers, cathepsin L, and endogenous cysteine protease inhibitors (stefins A and B and cystatin C) with meningioma malignancy was determined using enzyme-linked immunosorbent assays in tumor homogenates.
  • RESULTS: The more invasive tumors, which characteristically overgrew the normal tissue, were identified even within a group of histologically benign meningiomas.
  • More intensive staining of cathepsin B in these tumors was not only found at the tumor front, but also in the invading pseudopodia of a single migrating tumor cells.
  • As expected, WHO grade, age, and Simpson grade (complete tumor resection) were prognostic, with Simpson grade only relevant in the short term (up to 90 months) but not in longer-term follow-up.
  • Of note, the known tumor invasiveness marker cathepsin B, measured in whole-tumor homogenates, was not prognostic, in contrast to its endogenous inhibitor stefin B, which was highly significant and the only independent prognostic factor to predict meningioma relapse in multivariate analysis and reported herein for the first time.
  • [MeSH-major] Brain Neoplasms / drug therapy. Brain Neoplasms / pathology. Cysteine Proteinase Inhibitors / pharmacology. Cysteine Proteinase Inhibitors / therapeutic use. Lysosomes / drug effects. Meningioma / drug therapy. Meningioma / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cathepsin B / genetics. Cystatin A / genetics. Cystatin B / genetics. Female. Gene Silencing. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Neurosurgical Procedures. World Health Organization. Young Adult


91. Gallina P, Buccoliero AM, Mariotti F, Mennonna P, Di Lorenzo N: Oncocytic meningiomas: Cases with benign histopathological features and a favorable clinical course. J Neurosurg; 2006 Nov;105(5):736-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Oncocytic meningiomas: Cases with benign histopathological features and a favorable clinical course.
  • OBJECT: Oncocytic meningioma has recently been recognized as a distinct morphological variant of intracranial meningothelial neoplasms, and only a few cases have been reported in the literature.
  • The first description of this lesion, which was based on data in six cases, revealed a potentially aggressive nature with a tendency to infiltrate the brain and to recur.
  • Mitosis was also absent or exceedingly rare, and no brain cortex infiltration was observed.
  • At the last follow-up evaluation, all patients were asymptomatic and magnetic resonance imaging examinations demonstrated no evidence of tumor recurrence.
  • In fact, the histological features as well as the long-term favorable clinical course may suggest benign behavior of such neoplasms, as in the common forms of meningiomas.
  • [MeSH-major] Meningeal Neoplasms / pathology. Meningeal Neoplasms / surgery. Meningioma / pathology. Meningioma / surgery. Oxyphil Cells / physiology
  • [MeSH-minor] Adult. Antibodies, Antinuclear / metabolism. Antibodies, Monoclonal / metabolism. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17121136.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Antinuclear; 0 / Antibodies, Monoclonal; 0 / MIB-1 antibody
  •  go-up   go-down


92. Ray WZ, Blackburn SL, Casavilca-Zambrano S, Barrionuevo C, Orrego JE, Heinicke H, Dowling JL, Perry A: Clinicopathologic features of recurrent dysembryoplastic neuroepithelial tumor and rare malignant transformation: a report of 5 cases and review of the literature. J Neurooncol; 2009 Sep;94(2):283-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic features of recurrent dysembryoplastic neuroepithelial tumor and rare malignant transformation: a report of 5 cases and review of the literature.
  • Dysembryoplastic neuroepithelial tumors (DNETs) have traditionally been viewed as benign "quasihamartomatous" tumors widely considered curable with surgery alone.
  • Although the radiology was often alarming (e.g., new ring enhancing mass), the pathology remained benign in most cases.
  • These findings suggest that these patients may need closer follow-up than initially suggested, lending further support to the notion that this tumor behaves more like a benign neoplasm, rather than a dysplastic or hamartomatous lesion.
  • [MeSH-major] Brain Neoplasms / pathology. Cell Transformation, Neoplastic / pathology. Neoplasm Recurrence, Local / diagnosis. Neoplasms, Neuroepithelial / pathology
  • [MeSH-minor] Adolescent. Adult. Child. Female. Humans. Magnetic Resonance Imaging. Male. Young Adult


93. Cohen-Gadol AA, Geryk B, Binder DK, Tubbs RS: Conquering the third ventricular chamber. J Neurosurg; 2009 Sep;111(3):590-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The authors have reviewed the previously undisclosed efforts of Cushing to approach the third ventricle through a direct review of his available patient records at the Cushing Brain Tumor Registry.
  • The authors compare these efforts to those of Dandy published in Dandy's pioneering work Benign Tumors in the Third Ventricle of the Brain: Diagnosis and Treatment.
  • [MeSH-minor] Adolescent. Adult. Child. Female. History, 20th Century. Humans. Male. Neurosurgical Procedures / history. United States

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Neurosurg. 2010 May;112(5):1156-61; author reply 1161 [20345221.001]
  • (PMID = 19361257.001).
  • [ISSN] 0022-3085
  • [Journal-full-title] Journal of neurosurgery
  • [ISO-abbreviation] J. Neurosurg.
  • [Language] eng
  • [Publication-type] Biography; Case Reports; Historical Article; Journal Article
  • [Publication-country] United States
  • [Personal-name-as-subject] Cushing H; Dandy W
  •  go-up   go-down


94. Hahn BM, Schrell UM, Sauer R, Fahlbusch R, Ganslandt O, Grabenbauer GG: Prolonged oral hydroxyurea and concurrent 3d-conformal radiation in patients with progressive or recurrent meningioma: results of a pilot study. J Neurooncol; 2005 Sep;74(2):157-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PATIENTS AND METHODS: Twenty-one patients with recurrent or progressive meningiomas (13 benign, 4 atypical and malignant, 4 with unproven histology) received treatment by fractionated 3d-conformal radiation (55.8-59.4 Gy) and concurrent HU, administered for a median time of three months with a daily dosage of 20 mg/kg.
  • Three pts had significant improvement of tumor associated neurological symptoms with imaging criteria of minor response.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hydroxyurea / therapeutic use. Meningioma / drug therapy. Meningioma / radiotherapy. Neoplasm Recurrence, Local / drug therapy. Neoplasm Recurrence, Local / radiotherapy
  • [MeSH-minor] Administration, Oral. Adult. Aged. Combined Modality Therapy. Disease Progression. Female. Follow-Up Studies. Humans. Male. Meningeal Neoplasms / drug therapy. Meningeal Neoplasms / radiotherapy. Middle Aged. Pilot Projects. Radiotherapy, Conformal. Remission Induction. Survival Rate

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurosurg. 1997 May;86(5):840-4 [9126900.001]
  • [Cites] J Neurosurg. 1994 Feb;80(2):191-4 [8283255.001]
  • [Cites] Brain Pathol. 2002 Apr;12(2):183-90 [11958372.001]
  • [Cites] J Neurooncol. 2002 Dec;60(3):269-75 [12510778.001]
  • [Cites] J Neurooncol. 2000 Jun;48(2):151-60 [11083080.001]
  • [Cites] J Neurosurg. 1997 May;86(5):793-800 [9126894.001]
  • [Cites] Cancer. 1993 Aug 1;72(3):639-48 [8334619.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Mar 15;55(4):1000-5 [12605979.001]
  • [Cites] J Neurosurg. 1999 Jul;91(1):44-50 [10389879.001]
  • [Cites] J Neurosurg. 1991 Jun;74(6):861-6 [2033444.001]
  • [Cites] Strahlenther Onkol. 1999 Feb;175(2):62-7 [10065140.001]
  • [Cites] Forum (Genova). 2003;13(1):76-89 [14732889.001]
  • [Cites] J Clin Neurosci. 2002 Mar;9(2):156-8 [11922703.001]
  • [Cites] Surg Neurol. 1986 May;25(5):436-40 [3961659.001]
  • [Cites] J Neurosurg. 1997 May;86(5):845-52 [9126901.001]
  • [Cites] Neurosurgery. 1993 Apr;32(4):643-57 [8474655.001]
  • [Cites] J Clin Oncol. 2001 Aug 1;19(15):3547-53 [11481362.001]
  • [Cites] J Neurooncol. 2000 Sep;49(2):165-70 [11206012.001]
  • [Cites] J Neurosurg. 1994 Feb;80(2):195-201 [8283256.001]
  • [Cites] J Neurosurg. 1996 May;84(5):733-6 [8622144.001]
  • [Cites] Strahlenther Onkol. 1998 Dec;174(12):624-8 [9879349.001]
  • [Cites] J Neurosurg. 2002 Aug;97(2):341-6 [12186462.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Apr 1;44(1):75-9 [10219797.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Apr;18(4):755-61 [2108937.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 1;46(1):57-61 [10656373.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1999 Jan 15;43(2):321-7 [10030256.001]
  • [Cites] J Neurooncol. 2004 Jan;66(1-2):241-9 [15015792.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Sep 1;39(2):427-36 [9308947.001]
  • [Cites] J Neurosurg. 1985 Jan;62(1):18-24 [3964853.001]
  • [Cites] Radiother Oncol. 2001 Oct;61(1):65-70 [11578730.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Aug;15(2):299-304 [3403313.001]
  • [Cites] Surg Neurol. 1986 Nov;26(5):461-9 [3764651.001]
  • [Cites] J Neurooncol. 2004 Mar-Apr;67(1-2):221-6 [15072471.001]
  • (PMID = 16193387.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; X6Q56QN5QC / Hydroxyurea
  • [Number-of-references] 36
  •  go-up   go-down


95. Stein PJ: A case of cerebellopontine angle meningioma presenting with neck and upper extremity pain. J Manipulative Physiol Ther; 2009 Nov-Dec;32(9):776-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTERVENTION AND OUTCOME: Magnetic resonance imaging studies of the neck and brain revealed a posterior fossa tumor, which was eventually diagnosed as a benign meningioma.
  • Partial surgical removal of the tumor mass was followed by radiation therapy.
  • CONCLUSION: Patients with brain lesions may present to chiropractic practices with predominantly musculoskeletal symptoms.
  • [MeSH-major] Cerebellar Neoplasms / pathology. Cerebellar Neoplasms / radiography. Cerebellopontine Angle / pathology. Cerebellopontine Angle / radiography. Meningioma / pathology. Meningioma / radiography. Neck / physiopathology. Pain / etiology. Pain / physiopathology. Upper Extremity / physiopathology
  • [MeSH-minor] Adult. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Meningioma.
  • MedlinePlus Health Information. consumer health - Pain.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20004806.001).
  • [ISSN] 1532-6586
  • [Journal-full-title] Journal of manipulative and physiological therapeutics
  • [ISO-abbreviation] J Manipulative Physiol Ther
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


96. Weitzner MA, Kanfer S, Booth-Jones M: Apathy and pituitary disease: it has nothing to do with depression. J Neuropsychiatry Clin Neurosci; 2005;17(2):159-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In many ways, these patients resemble patients with other malignant brain tumors.
  • Although the majority of pituitary adenomas are benign, the physical, emotional, and cognitive changes that these patients experience on their well-being is malignant.
  • There is a growing understanding that pituitary patients may experience these emotional problems as a result of long-term effects that the pituitary tumor itself, treatment, and/or hormonal changes have on the hypothalamic-pituitary-end organ axis.
  • [MeSH-minor] Adenoma / psychology. Adenoma / surgery. Adult. Humans. Male. Middle Aged. Pituitary Neoplasms / psychology. Pituitary Neoplasms / surgery. Prolactinoma / psychology. Prolactinoma / surgery

  • Genetic Alliance. consumer health - Depression.
  • MedlinePlus Health Information. consumer health - Depression.
  • MedlinePlus Health Information. consumer health - Pituitary Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15939968.001).
  • [ISSN] 0895-0172
  • [Journal-full-title] The Journal of neuropsychiatry and clinical neurosciences
  • [ISO-abbreviation] J Neuropsychiatry Clin Neurosci
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 41
  •  go-up   go-down


97. Qi ZH, Li CF, Li ZF, Zhang K, Wang Q, Yu DX: Preliminary study of 3T 1H MR spectroscopy in bone and soft tissue tumors. Chin Med J (Engl); 2009 Jan 5;122(1):39-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MRS provides the biochemistry information that may be used to diagnose tumors or differentiate the malignant tumor from benign.
  • The objective of this study is to investigate the benign and malignant bone and soft tissue tumors by 1H-MR spectroscopy ((1)H-MRS) on a 3 Tesla MR scanner, then to assess the usefulness of (1)H-MRS in diagnosing bone and soft tissue tumors and distinguishing benign from malignant tumors.
  • METHODS: Fifty-six patients with bone and soft tissue tumors proved clinically and pathologically were examined with (1)H-MRS. (1)H-MRS was performed to study malignant musculoskeletal tumors, benign tumors and normal muscle adjacent to lesions to analyze the characteristics, and single-voxel point-resolved spectroscopy sequence was used.
  • Proton brain exam-single voxel of (1)H-MRS which directly appeared in the spectrum, was observed to find the peak height of choline compounds (Cho) opposite to the creatine (Cr), and whether there was a Cho peak.
  • Then according to the results, it was judged whether there existed benign or malignant tumors.
  • RESULTS: (1)H-MRS spectra style of bone and soft tissue tumors was different from that of normal muscle, and differences also existed between benign and malignant tumors.
  • Choline level in malignant tumor was markedly higher than that in benign tumors.
  • Cho/Cr in malignant tumor was higher than in benign tumor significantly (P < 0.05).
  • The true positive rate of bone and soft tissue between benign and malignant tumors was 34/36, the true negative rate was 15/18, the false positive rate was 3/18 and the false negative rate was 2/36.
  • CONCLUSIONS: The increase of Cho level measured by (1)H-MRS is related to the bone and soft tissue malignant tumor.
  • Cho/Cr in malignant tumor was higher than in benign tumor, so they will play a vital role in the diagnosis and differential diagnosis of bone and soft tissue tumors.
  • [MeSH-major] Brain Neoplasms / diagnosis. Magnetic Resonance Spectroscopy / methods. Soft Tissue Neoplasms / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Choline / metabolism. Creatine / metabolism. Female. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • Hazardous Substances Data Bank. CREATINE .
  • Hazardous Substances Data Bank. CHOLINE CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19187615.001).
  • [ISSN] 0366-6999
  • [Journal-full-title] Chinese medical journal
  • [ISO-abbreviation] Chin. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] MU72812GK0 / Creatine; N91BDP6H0X / Choline
  •  go-up   go-down


98. Motta FJ, Valera ET, Lucio-Eterovic AK, Queiroz RG, Neder L, Scrideli CA, Machado HR, Carlotti-Junior CG, Marie SK, Tone LG: Differential expression of E-cadherin gene in human neuroepithelial tumors. Genet Mol Res; 2008;7(2):295-304
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This study aimed to evaluate the expression of E-cadherin and their correlation with clinical features in microdissected brain tumor samples from 81 patients, divided into 62 astrocytic tumors grades I to IV and 19 medulloblastomas, and from 5 white matter non-neoplasic brain tissue samples.
  • Non-neoplasic brain tissue showed a higher expression level of CDH1 gene than did neuroepithelial tumors.
  • Non-neoplasic brain tissue showed a higher expression level of CDH1 gene than grade I malignancy astrocytomas, considered as benign tumors (P = 0.0473).
  • [MeSH-major] Cadherins / genetics. Gene Expression Profiling. Neoplasms, Neuroepithelial / genetics
  • [MeSH-minor] Adolescent. Adult. Brain / metabolism. Gene Expression Regulation, Neoplastic. Humans. Middle Aged. RNA, Messenger / genetics. RNA, Messenger / metabolism. Reverse Transcriptase Polymerase Chain Reaction

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18551395.001).
  • [ISSN] 1676-5680
  • [Journal-full-title] Genetics and molecular research : GMR
  • [ISO-abbreviation] Genet. Mol. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Brazil
  • [Chemical-registry-number] 0 / Cadherins; 0 / RNA, Messenger
  •  go-up   go-down


99. Liu AL, Wang C, Sun S, Wang M, Liu P: Gamma knife radiosurgery for tumors involving the cavernous sinus. Stereotact Funct Neurosurg; 2005;83(1):45-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: A Hundred and forty-four (82.3%) patients were followed from 1 to 84 months (median 32.5 months); total tumor control rate was 94%.
  • Surgery was performed after radiosurgery in 3 patients because of tumor enlargement.
  • Metastatic tumor in the cavernous sinus was highly sensitive to irradiation.
  • CONCLUSION: With high tumor control rate and few complications, GK surgery could become a main option for small benign or residual tumors involving the cavernous sinus.
  • [MeSH-major] Brain Neoplasms / surgery. Cavernous Sinus / surgery. Meningeal Neoplasms / surgery. Meningioma / surgery. Neuroma / surgery. Radiosurgery
  • [MeSH-minor] Adenoma / pathology. Adenoma / surgery. Adolescent. Adult. Aged. Child. Chordoma / pathology. Chordoma / surgery. Female. Follow-Up Studies. Hemangioma, Cavernous / pathology. Hemangioma, Cavernous / surgery. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Pituitary Neoplasms / pathology. Pituitary Neoplasms / surgery. Reoperation. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15860936.001).
  • [ISSN] 1011-6125
  • [Journal-full-title] Stereotactic and functional neurosurgery
  • [ISO-abbreviation] Stereotact Funct Neurosurg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


100. Asano K, Takeda T, Nakano T, Ohkuma H: Correlation of MIB-1 staining index and (201)Tl-SPECT retention index in preoperative evaluation of malignancy of brain tumors. Brain Tumor Pathol; 2010 Apr;27(1):1-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation of MIB-1 staining index and (201)Tl-SPECT retention index in preoperative evaluation of malignancy of brain tumors.
  • MIB-1 staining provides a useful index of the malignancy of brain tumors.
  • However, because of the difficulty of evaluating malignancy based on the preoperative imaging findings, we investigated the correlation between the (201)Tl-SPECT retention index (RI) and MIB-1 staining index (MIB-1 SI) to determine the usefulness of RI for preoperative evaluation of the malignancy of brain tumors.
  • The subjects of this study were 47 patients who underwent tumor removal surgery at our hospital in 2006 and 2007.
  • The tumors consisted of 16 intraaxial tumors (all gliomas: 9 glioblastomas, 2 anaplastic astrocytomas, 2 anaplastic oligoastrocytomas, 1 oligodendroglioma, and 2 ependymomas), 8 other malignant brain tumors, and 23 extraaxial tumors (10 meningiomas, 7 pituitary adenomas, and 6 schwannomas).
  • RI values may also be useful for evaluating apparently benign extraaxial tumors for possible malignancy.
  • [MeSH-major] Biomarkers, Tumor / analysis. Brain Neoplasms / diagnosis. Brain Neoplasms / pathology. Ki-67 Antigen / analysis. Preoperative Period. Staining and Labeling. Tomography, Emission-Computed, Single-Photon
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Middle Aged. Radiopharmaceuticals. Thallium Radioisotopes. Young Adult

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20425041.001).
  • [ISSN] 1861-387X
  • [Journal-full-title] Brain tumor pathology
  • [ISO-abbreviation] Brain Tumor Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; 0 / Radiopharmaceuticals; 0 / Thallium Radioisotopes
  •  go-up   go-down






Advertisement